{"id":179,"date":"2016-05-24T16:59:37","date_gmt":"2016-05-24T15:59:37","guid":{"rendered":"http:\/\/ramoncacabelos.org\/web\/?page_id=179"},"modified":"2016-06-02T11:06:52","modified_gmt":"2016-06-02T10:06:52","slug":"publicaciones","status":"publish","type":"page","link":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/","title":{"rendered":"Publicaciones"},"content":{"rendered":"

[et_pb_section admin_label=\u00bbsection\u00bb transparent_background=\u00bboff\u00bb background_color=\u00bb#141414″ allow_player_pause=\u00bboff\u00bb inner_shadow=\u00bboff\u00bb parallax=\u00bboff\u00bb parallax_method=\u00bboff\u00bb padding_mobile=\u00bboff\u00bb make_fullwidth=\u00bboff\u00bb use_custom_width=\u00bboff\u00bb width_unit=\u00bbon\u00bb make_equal=\u00bboff\u00bb use_custom_gutter=\u00bboff\u00bb][et_pb_row admin_label=\u00bbrow\u00bb][et_pb_column type=\u00bb4_4″][et_pb_text admin_label=\u00bbTexto\u00bb background_layout=\u00bblight\u00bb text_orientation=\u00bbleft\u00bb text_font_size=\u00bb30″ text_text_color=\u00bb#e09900″ use_border_color=\u00bboff\u00bb border_color=\u00bb#ffffff\u00bb border_style=\u00bbsolid\u00bb]<\/p>\n

Publicaciones<\/p>\n

[\/et_pb_text][et_pb_image admin_label=\u00bbImagen\u00bb src=\u00bbhttp:\/\/ramoncacabelos.org\/web\/wp-content\/uploads\/2016\/05\/papers-cientificos-ramon-cacabelos.jpg\u00bb show_in_lightbox=\u00bboff\u00bb url_new_window=\u00bboff\u00bb use_overlay=\u00bboff\u00bb animation=\u00bbleft\u00bb sticky=\u00bboff\u00bb align=\u00bbleft\u00bb force_fullwidth=\u00bboff\u00bb always_center_on_mobile=\u00bbon\u00bb use_border_color=\u00bboff\u00bb border_color=\u00bb#ffffff\u00bb border_style=\u00bbsolid\u00bb \/][et_pb_text admin_label=\u00bbTexto\u00bb background_layout=\u00bbdark\u00bb text_orientation=\u00bbleft\u00bb text_font_size=\u00bb16″ use_border_color=\u00bboff\u00bb border_color=\u00bb#ffffff\u00bb border_style=\u00bbsolid\u00bb text_font=\u00bbLato Light||||\u00bb]<\/p>\n

Art\u00edculos y Trabajos Cient\u00edficos<\/span><\/h2>\n

Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Nishimura, T. Histamine within the hypothalamo-hypophyseal system after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:342-344.<\/p>\n

Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Tada, K., Takeda, M., Nishimura, T., Takagi, T., Sugita, T., Tanizawa, O. On the chronological changes in hypothalamic catecholamines and plasma ACTH after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:345-347.<\/p>\n

Cacabelos, R., Yamatodani, A., Watanabe, T., Takagi, T., Tanizawa, O., Hariguchi, S., Nishimura, T., Wada, H. Effects of alpha-fluoromethylhistidine on ACTH, vasopressin, and oxytocin in the hypothalamo-hypophyseal system and plasma. Bull. Japn. Neurochem. Soc., 23:403-405 (1984).<\/p>\n

Cacabelos, R. Histaminolog\u00eda. Med. Clin., 84:524-527 (1985).<\/p>\n

Cacabelos, R., Takagi, T., Otsuki, Y., Sugita, S., Hariguchi, S., Nishimura, T., Tanizawa, O. An\u00e1lisis cronobiol\u00f3gico de los efectos producidos por la adrenalectom\u00eda sobre los sistemas oxitocin\u00e9rgico y vasopresin\u00e9rgico. Endocrinolog\u00eda, 32:126-135 (1985).<\/p>\n

Cacabelos, R., Yamatodani, A., Fukui, H., Watanabe, T., Hariguchi, S., Nishimura, T., Wada, H. Age- and sex-related changes in histamine in the central nervous system. Bull. Jpn. Neurochem. Soc., 24:337-339 (1985).<\/p>\n

Cacabelos, R., Yamatodani, A., Fukui, H., Watanabe, T., Hariguchi, S., Nishimura, T., Wada, H. Nature of histaminergic neuromodulation of the corticotropinergic system. Biogenic Amines, 3:9-19 (1985).<\/p>\n

Nishimura, T., Takeda, M., Tada, K., Hariguchi, S., Cacabelos, R., Yamashita, T., Okabe, T. Experimental model of senile and vascular dementia. A biochemical hypothesis. Ronenkai-no-shogai-no-rinsho. Haseikiyo. Chiryo-ni-kansuru- kenkyu. Kenkyuseika-hokokusho, 59:15-23 (1985).<\/p>\n

Cacabelos, R., Niigawa, H., Hariguchi, S. Hypothalamo-hypophyseal system and brain function. J. Clin. Sci., 2:1108-1120 (1986).<\/p>\n

Niigawa, H., Cacabelos, R., Miyake, A., Tanaka, J., Murakoshi, K., Tada, K., Hariguchi, S., Nishimura, T. Study of the effects of histamine and histamine antagonists in the gonadotropinergic system. Implications for aging. Bull. Jpn. Neurochem. Soc., 25:298-300 (1986).<\/p>\n

Cacabelos, R., Yamatodani, A., Fukui, H., Takeda, M., Nishimura, T., Wada, H. Age-and sex-related changes in histamine and H-1 receptors in the central nervous system following a long-term castration. Bull. Jpn. Neurochem. Soc., 25:271-273 (1986).<\/p>\n

Cacabelos, R., Niigawa, H., Nishimura, T. Neuroendocrine system in aging. Gerontopsychiatry, 3:691-711 (1986).<\/p>\n

Nishimura, T., Yamashita, T., Tada, K., Cacabelos, R., Niigawa, H., Suzuki, H. Recent advances in biochemical studies of dementia in the elderly. Brain Nerve, 39:9-16 (1987).<\/p>\n

Cacabelos, R., Niigawa, H., Nishimura, T. Neuroendocrine function in psychiatric disorders and dementia. Jap. J. Neuropsychopharmacol., 9:13-49 (1987).<\/p>\n

Cacabelos, R., Niigawa, H., Nishimura, T. Neurochemistry of senile dementia. Changes in neuropeptides. Clin. Neurosci., 5:1111-1115 (1987).<\/p>\n

Cacabelos, R. Sistema vasopresin\u00e9rgico (I). Med. Clin., 88:160-168 (1987).<\/p>\n

Cacabelos, R. Sistema vasopresin\u00e9rgico (II). Med. Clin., 88:334-343 (1987).<\/p>\n

Cacabelos, R., Yamatodani, A., Niigawa, H., Harigmchi, S., Nishimura, T., Wada, H. Histaminergic neuromodulation of the release of vasopressin. Neuroendocrinology, 45:368-375 (1987).<\/p>\n

Cacabelos, R., Niigawa, H., Hariguchi, S., Nishimura, T. Influence of somatostatin and growth hormone-releasing factor on locomotion and learning in rats. OUCEM-86: A computerized system to study behavioral parameters in small mammals. Prog. Med., 7:763-773 (1987).<\/p>\n

Cacabelos, R., Yamatodani, A., Fukui, H., Niigawa, H., Miyake, A., Watanabe, T., Nishimura, T., Wada, H. Time- and dose-dependent responses of brain histamine to intracerebroventricular and intraperitoneal administrations of growth hormone-releasing factor (GRF1-44). Tohoku J. Exp. Med., 151:429-442 (1987).<\/p>\n

Cacabelos, R., Niigawa, H., Nishimura, T., Yamatodani, A., Wada, H. Somatostatin-induced histamine response in the rat central nervous system. Tohoku J. Exp. Med., 152:397-405 (1987).<\/p>\n

Cacabelos, R., Niigawa, H., Yamatodani, A., Fukui, H., Wada, H., Nishimura, T. Vasopressin-induced histamine response in the CNS. Bull. Jpn. Neurochem. Soc., 26:559-561 (1987).<\/p>\n

Niigawa, H., Yamatodani, A., Nishimura, T., Wada, H., Cacabelos, R. Effect of neurotoxic lesions in the mammillary bodies on the distribution of brain histamine. Bull. Jpn. Neurochem. Soc., 26:556-558 (1987).<\/p>\n

Cacabelos, R., Niigawa, H., Ikemura, T., Yanagi, Y., Tanaka, S., Rodr\u00edguez-Arnao, M.D., G\u00f3mez-Pan, A., Nishimura, T. GHRH- induced GH response in patients with senile dementia of the Alzheimer type. Acta Endocrinol. (Copenh.), 117:295-301 (1988).<\/p>\n

Cacabelos, R., Niigawa, H., Yamatodani, A., G\u00f3mez-Pan, A., Nishimura, T., Wada, H. Antagonistic effects of growth hormone-releasing factor and somatostatin on brain histamine. Endocrinology, 122:1269-1276 (1988).<\/p>\n

Cacabelos, R. Nuevas perspectivas en el abordaje cl\u00ednico de la enfermedad de Alzheimer. Rev. Esp. Geriat. Gerontol., 23:67-69 (1988).<\/p>\n

Cacabelos, R., Niigawa, H., Nishimura, T. Antagonistic effects of somatostatin and growth hormone-releasing factor on behavior. Jpn. J. Psychopharmacol., 8:235-236 (1988).<\/p>\n

Niigawa, H., Murakoshi, K., Nishimura, T., Cacabelos, R. Effects of chronic administration of L-histidine on behavior and learning. Jpn. J. Psychopharmacol., 8:169-170 (1988).<\/p>\n

Murakoshi, K., Niigawa, H., Nishimura, T., Cacabelos, R. Computerized analysis of the effects of L-histidine, histamine, and antihistaminics on behavioral parameters. Jpn. J. Psychopharmacol., 8:167-168 (1988).<\/p>\n

Niigawa, H., Cacabelos, R., Hariguchi, S. Functions of biogenic amines. Effects of aging. Clin. Neurosci., 6:522-524 (1988).<\/p>\n

Cacabelos, R., Niigawa, H., Rodr\u00edguez-Arnao, M.D., G\u00f3mez-Pan, A., Nishimura, T. Influence of somatostatin and growth hormone-releasing factor on behavior. Clinical and therapeutic implications in neuropsychiatric disorders. Horm. Res., 29:129-132 (1988).<\/p>\n

Niigawa, H., Yamatodani, A., Nishimura, T., Wada, H., Cacabelos, R. Effect of neurotoxic lesions in the mammillary bodies on the distribution of brain histamine. Brain Res., 459:183-186 (1988).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer: Alternativas cl\u00ednico-terap\u00e9uticas. Med. Clin., 91:454-474 (1988).<\/p>\n

Niigawa, H., Cacabelos, R., Hariguchi, S., Nishimura, T. Effects of lesions in the nucleus basalis of Meynert on stress-induced neuropeptide release. Bull. Jpn. Neurochem. Soc., 27:232-233 (1988).<\/p>\n

Cacabelos, R. Factor liberador de la hormona de crecimiento en la enfermedad de Alzheimer. Med. Clin., 92:299-301 (1989).<\/p>\n

Cacabelos, R. Neurobiolog\u00eda y utilizaci\u00f3n del GRF como marcador diagn\u00f3stico en trastornos mentales. Endocrinolog\u00eda, 36:71-77 (1989).<\/p>\n

Cacabelos, R., Yamatodani, A., Niigawa, H., Hariguchi, S., Tada, K., Nishimura, T., Wada, H., Brandeis, L., Pearson, J. Brain histamine in Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 11:353-360 (1989).<\/p>\n

Cacabelos, R. Growth hormone-releasing factor in mental disorders: A diagnostic marker and therapeutic alternative. Meth. Find. Exp. Clin. Pharmacol., 11:421-436 (1989).<\/p>\n

Cacabelos, R. Growth hormone-releasing factor in mental disorders. Drug News Perspect., 2:133-140 (1989).<\/p>\n

Cacabelos, R. Organizaci\u00f3n funcional y biolog\u00eda molecular del sistema neuroendocrino. Endocrinolog\u00eda, 36:332-344 (1989).<\/p>\n

Niigawa, H., Cacabelos, R., Hariguchi, S., Nishimura, T. Neurochemical and behavioral changes in rats with lesions in the mammillary bodies and basal forebrain. Bull. Jpn. Neurochem. Soc., 28:390-391 (1989).<\/p>\n

Cacabelos, R. Neuroinmunoendocrinolog\u00eda: neurorregulaci\u00f3n peptid\u00e9rgica de la respuesta inmune y acciones intersist\u00e9micas. Endocrinolog\u00eda, 36:418-425 (1989).<\/p>\n

Cacabelos, R. Recent advances in neuropsychopharmacology. Drug News & Perspectives, 2:439-442 (1989).<\/p>\n

Itowi, N., Yamatodani, A., Cacabelos, R., Goto, M., Wada, H. Effect of histamine depletion on circadian variations of corticotropin and corticosterone in rats. Neuroendocrinology, 50:187-192 (1989).<\/p>\n

Cacabelos, R. Acciones centrales de los neurop\u00e9ptidos hipofisiotropos. Endocrinolog\u00eda, 37:60-76 (1990).<\/p>\n

Cacabelos, R., Albarr\u00e1n, M., Di\u00e9guez, C., Fari\u00f1as, F., del Pino, J.L., Exp\u00f3sito, J., Mart\u00edn-Loeches, M., Rubia, F.J. GRF-induced GH response in attention-deficit hyperactivity disorder. Meth. Find. Exp. Clin. Pharmacol., 12:79-85 (1990).<\/p>\n

Mart\u00edn-Loeches, M., Gil Gregorio, P., Miguel Tobal, F., Exp\u00f3sito Torrej\u00f3n, F.J., Cacabelos Garc\u00eda, R., Rubia Vila, F.J. Relaci\u00f3n entre datos psicom\u00e9tricos y potenciales evocados tard\u00edos en la enfermedad de Alzheimer. Rev. Esp. Geriatr. Gerontol., 25:21-26 (1990).<\/p>\n

Cacabelos, R. Brain histamine in Alzheimer\u2019s disease. Parkinson\/Alzheimer Digest, 2:26-27 (1990).<\/p>\n

Cacabelos, R. Influencia de la gen\u00e9tica molecular en el futuro de la psiquiatr\u00eda. Anuario Psiqui\u00e1trico, 1:3-6 (1990).<\/p>\n

\u00c1lvarez, X.A., Couto, D.F., Fari\u00f1as, F., Fern\u00e1ndez, M., Otero, F., Cacabelos, R. Influencia del sistema somatotropin\u00e9rgico sobre la memoria de evocaci\u00f3n a corto plazo en sujetos j\u00f3venes sanos. Anuario Psiqui\u00e1trico, 1:259-269 (1990).<\/p>\n

Niigawa, H., Okado, T., Hariguchi, S., Nishimura, T., Cacabelos, R. Effect of scopolamine on behavioral parameters. A computerized analysis with the OUCEM-86 system. Anuario Psiqui\u00e1trico, 1:277-286 (1990).<\/p>\n

Niigawa, H., Nakamura, K., Hariguchi, S., Nishimura, T., Cacabelos, R. Effects of chronic administration of L-histidine on behaviour and learning. A computerized analysis with the OUCEM-86 system. Anuario Psiqui\u00e1trico, 1:287-298 (1990).<\/p>\n

Niigawa, H., Hariguchi, S., Nishimura, T., Cacabelos, R. Behavioral changes in rats with bilateral lesions in the nucleus basalis of Meynert. A computerized analysis with the OUCEM-86 system. Anuario Psiqui\u00e1trico, 1:299-305 (1990).<\/p>\n

Fern\u00e1ndez, M., Fari\u00f1as, F., Cornes, J.M., Borr\u00e1s, C.G., Rodr\u00edguez, A., Cacabelos, R. Respuesta de GH a GRF en pacientes con trastorno depresivo mayor. Anuario Psiqui\u00e1trico, 1:347-353 (1990).<\/p>\n

Otero, F., Tortajada, I., Alonso, J., Tabernero, J., Seoane, J., Agra, S., Cornes, J.M., Cacabelos, R Respuesta de GH a GRF(1-29)NH2 en pacientes con esquizofrenia. Anuario Psiqui\u00e1trico, 1:355-362 (1990).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Efectos extraespec\u00edficos de la administraci\u00f3n aguda de GRF(l-29)NH2 en sujetos j\u00f3venes sanos. Anuario Psiqui\u00e1trico, 1:363-372 (1990).<\/p>\n

Fari\u00f1as, F., Garc\u00eda-Alonso, L., Cacabelos, R. Respuesta de GH a GRF(1-29)NH2 en retrasos de crecimiento con patolog\u00eda neuropsiqui\u00e1trica asociada. Anuario Psiqui\u00e1trico, 1:383-388 (1990).<\/p>\n

Rubia, F.J., Mart\u00edn-Loeches, M., Exp\u00f3sito, F,J., Miguel, F., Cacabelos, R. Effects of growth hormone-releasing factor and somatostatin on brain bioelectrical activity and cognitive functions. Anuario Psiqui\u00e1trico, 1:389-399 (1990).<\/p>\n

del Pino, J.L., Mart\u00edn-Loeches, M., Exp\u00f3sito, J., Miguel, F., Cacabelos, R., Rubia, F.J. Mapas de actividad el\u00e9ctrica cerebral en la hipercinesia infantil. Anuario Psiqui\u00e1trico, 1:401-409 (1990).<\/p>\n

Mart\u00edn-Loeches, M., Gil, P., Exp\u00f3sito, F.J., Miguel, F., Cacabelos, R., Rubia, F.J. Mapas de actividad el\u00e9ctrica cerebral en la demencia senil de tipo Alzheimer durante tareas cognoscitivas. Anuario Psiqui\u00e1trico, 1:419-428 (1990).<\/p>\n

Fern\u00e1ndez, M., P\u00e9rez, A., Lois, J.M., Otero, F., Cacabelos, R. Evaluaci\u00f3n bioqu\u00edmica y estrategia terap\u00e9utica eficaz en un caso de depresi\u00f3n resistente. Anuario Psiqui\u00e1trico, 1:449-454 (1990).<\/p>\n

Cacabelos, R. Gen\u00e9tica de los trastornos neuropsiqui\u00e1tricos. Med. Cl\u00edn., 94:699-701 (1990).<\/p>\n

Cacabelos, R. Growth hormone-releasing factor in mental disorders: Diagnostic marker and therapeutic alternative. Psychiatry Digest, 3:20-21 (1990).<\/p>\n

Cacabelos, R. Histaminergic system: Neuroendocrine function of brain histamine. Meth. Find. Exp. Clin. Pharmacol., 12:341-376 (1990).<\/p>\n

Cacabelos, R., Niigawa, H., \u00c1lvarez, X.A., Mu\u00f1oz, M.D., Nishimura, T., Rubia, F.J. Antagonistic effects of growth hormone-releasing factor (GRF) and somatostatin on locomotor activity: GRF-induced hyperkinetic syndrome. Meth. Find. Exp. Clin. Pharmacol., 12:425-434 (1990).<\/p>\n

Cacabelos, R. Histamine research in Europe. Drug News Perspect., 3:441-443 (1990).<\/p>\n

Cacabelos, R. Neurobiolog\u00eda y gen\u00e9tica molecular de la enfermedad de Alzheimer: marcadores diagn\u00f3sticos y terap\u00e9utica. Med. Clin., 95:502-516 (1990).<\/p>\n

\u00c1lvarez, X.A., Cacabelos, R. Effects of GRF(1-29)NH2 on short-term memory: Neuroendocrine and neuropsychological assessment in healthy young subjects. Meth. Find. Exp. Clin. Pharmacol., 12:493-499 (1990).<\/p>\n

Cacabelos, R. Psiquiatr\u00eda. La Medicina Interna en 1990. Medicine Extra, 99-105 (1990).<\/p>\n

Cacabelos, R. Nuevas perspectivas en la enfermedad de Alzheimer. Rev. Cl\u00edn. Esp., 187:356-368 (1990).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Sistema psiconeuroendocrino y envejecimiento. Anal. Psicol., 6:115-146 (1990).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A. Histidine decarboxylase inhibition induced by alpha-fluoromethylhistidine provokes learning-related hypokinetic activity. Agents Actions, 33:131-134 (1991).<\/p>\n

Cacabelos, R. Demencia senil: Estrategias para una d\u00e9cada. Rev. Clin. Esp., 189:51-53 (1991).<\/p>\n

Cacabelos, R., Barquero, M., Garc\u00eda, P., \u00c1lvarez, X.A., Varela de Seijas, E. Cerebrospinal fluid interleukin-1\uf062 (IL-1\uf062) in Alzheimer\u2019s disease and neurological disorders. Meth. Find. Exp. Clin. Pharmacol., 13:455-458 (1991).<\/p>\n

Cacabelos, R., Franco-Maside, A., \u00c1lvarez, X.A. Interleukin-l in Alzheimer\u2019s disease and multi-infarct dementia: Neuropsychological correlations. Meth. Find. Exp. Clin. Pharmacol., 13:703-708 (1991).<\/p>\n

P\u00e9rez-Trull\u00e9n, J.M., V\u00e1zquez-Andr\u00e9, M.C., Cacabelos, R. Los potenciales evocados en la enfermedad de Alzheimer. La onda P300. Anuario Psiqui\u00e1trico, 2:77-97 (1991).<\/p>\n

Cacabelos, R. Funci\u00f3n neuroinmune en trastornos mentales. Anuario Psiqui\u00e1trico, 2:135-154 (1991).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Efectos de la somatotropina biosint\u00e9tica (r-hGH) y la somatoliberina [GRF(1-29)NH2] sobre la actividad psicomotriz. Anuario Psiqui\u00e1trico, 2:189-199 (1991).<\/p>\n

Cacabelos, R. Alteraciones neuroqu\u00edmicas en la enfermedad de Alzheimer: Neurotransmisores cl\u00e1sicos, sistemas enzim\u00e1ticos y factores de membrana. Geriatrika, X:39-53 (1991).<\/p>\n

\u00c1lvarez, X.A., Cacabelos, R. Age- and sex-related serum growth hormone (GH) levels in psychiatric patients and healthy control subjects. A correlation study between GH values and cognitive performance. Exp. Clin. Endocrinol. (Life Sci. Adv.), 10:245-257 (1991).<\/p>\n

Mart\u00edn-Loeches, M., Gil, P., Jim\u00e9nez, F., Exp\u00f3sito, F.J., Miguel, F., Cacabelos, R., Rubia, F.J. Topographic maps of brain electrical activity in primary degenerative dementia of the Alzheimer type and multiinfarct dementia. Biol. Psychiatry, 29:211-223 (1991).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Psiconeuroendocrinolog\u00eda geri\u00e1trica. Endocrinolog\u00eda, 39:135-145 (1992).<\/p>\n

Cacabelos, R., Niigawa, H., Yamatodani, A., Fukui, H., Nishimura, T., Wada, H. Vasopressin-induced changes in brain histamine and H-1 receptors. Exp. Clin. Endocrinol. (Life Sci. Adv.), 11:37-44 (1992).<\/p>\n

Cacabelos, R. Neurop\u00e9ptidos en psiquiatr\u00eda (I). Monogr. Psiquiatr\u00eda, 3:7-9 (1992).<\/p>\n

Franco, A., \u00c1lvarez, X.A., Cacabelos, R. Acciones centrales de los neurop\u00e9ptidos. Monogr. Psiquiatr\u00eda, 3:10-18 (1992).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Neurop\u00e9ptidos y envejecimiento. Monogr. Psiquiatr\u00eda, 3:19-28 (1992).<\/p>\n

Cacabelos, R. Alteraciones neuropeptid\u00e9rgicas en trastornos mentales. Monogr. Psiquiatr\u00eda, 4:3-12 (1992).<\/p>\n

Cacabelos, R. Disfunci\u00f3n neuropeptid\u00e9rgica en la enfermedad de Alzheimer. Monogr. Psiquiatr\u00eda, 4:13-21 (1992).<\/p>\n

Cacabelos, R. Factores neurotr\u00f3ficos: Neurobiolog\u00eda molecular y alteraciones en trastornos del sistema nervioso. Monogr. Psiquiatr\u00eda, 4:22-28 (1992).<\/p>\n

Cacabelos, R. Marcadores gen\u00e9ticos en trastornos neuropsiqui\u00e1tricos: Mapeo gen\u00e9tico y prospecciones diagn\u00f3sticas y terap\u00e9uticas. Med. Clin., 99:505-514 (1992).<\/p>\n

Cacabelos, R. Alzheimer\u2019s disease: News and prospects. Drug News Perspect., 5:501-506 (1992).<\/p>\n

Cacabelos, R. Prof. Hiroshi Wada or the art of teamwork. Ann. Psychiat., 3:V-VI (1992).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A. Neuroimmune function of brain histamine: implications for neurotrophic activity and neurotoxicity. Ann. Psychiat., 3:147-200 (1992).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Valle-Incl\u00e1n, F. Therapeutic effects of CDP-choline in Alzheimer\u2019s disease and multi-infarct dementia: psychometric assessment and immune function. Ann. Psychiat., 3:233-245 (1992).<\/p>\n

Caama\u00f1o, J., Valle-Incl\u00e1n, F., Cacabelos, R. Middle cerebral artery blood flow velocity in patients with vascular dementia: assessment by transcranial Doppler ultrasonography. Ann. Psychiat., 3:273-280 (1992).<\/p>\n

\u00c1lvarez, X.A., Cacabelos, R. Psychoneuroendocrinology and the aging brain. Ann. Psychiat., 3:281-299 (1992).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of anapsos on behavior and brain cytokines in rats. Ann. Psychiat., 3:329-341 (1992).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., P\u00e9rez-Trull\u00e9n, J.M., Franco-Maside, A., \u00c1lvarez, X.A. Serum histamine in Alzheimer\u2019s disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol., 14:711-715 (1992).<\/p>\n

Cacabelos, R. Marcadores gen\u00e9ticos en trastornos neuropsiqui\u00e1tricos: cartograf\u00eda gen\u00e9tica y prospecciones diagn\u00f3sticas y terap\u00e9uticas (II). Med. Clin., 100:28-36 (1993).<\/p>\n

Caama\u00f1o, J., G\u00f3mez, M.J., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia: Neuropsychological correlates. Meth. Find. Exp. Clin. Pharmacol., 15:193-199 (1993).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L. Dose- and time-dependent effects of histamine on hypothalamic levels of interleukin-1\uf062 in rats. Agents Actions, 38:C260- C262 (1993).<\/p>\n

Cacabelos, R., Hofman, A., Mullan, M., Ferris, S.M., Portera, A., Frey, H., Swaab, D F., de Leon, M., Terry, R., Masters, C.L., Iqbal, K., Wisniewski, H.M., Takeda, M., Giacobini, E., Nordberg, A., Winbald, B. Alzheimer\u2019s disease: Scientific progress for future trends. Drug News Perspect., 6:242-244 (1993).<\/p>\n

\u00c1lvarez, X.A., Cacabelos, R. Influence of growth hormone (GH) and GH-releasing factor on locomotor activity in rats. Peptides, 14:707-712 (1993).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J. Effect of CDP-choline on cognition and immune function in Alzheimer\u2019s disease and multi-infarct dementia. Ann. New York Acad. Sci., 695:321-323 (1993).<\/p>\n

Niimi, M., Mochizuki, T., Cacabelos, R., Yamatodani, A. Increase of histidine decarboxylase activity in mice hypothalamus after intracerebroventricular administration of lipopolysaccharide. Meth. Find. Exp. Clin. Pharmacol., 15:509-514 (1993).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of S 9977-2 on psychomotor activity, learning and brain interleukin-1\uf062 levels in rats. Meth. Find. Exp. Clin. Pharmacol., 15:587-595 (1993).<\/p>\n

Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Franco, A., Caama\u00f1o, J., Cacabelos, R. Histamine-induced interleukin-1 changes in the rat hypothalamus. Meth. Find. Exp. Clin. Pharmacol., 15:735-741 (1993).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J. Serum tumor necrosis factor (TNF) in Alzheimer\u2019s disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol., 16:29-35 (1994).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer: Disfunci\u00f3n neuroinmune y nuevas formas de intervenci\u00f3n terap\u00e9utica. Med. Clin., 102:420-422 (1994).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Franco, A., Mangues, R., Pellicer, A., Nishimura, T. Brain interleukin-1\uf062 in Alzheimer\u2019s disease and vascular dementia. Meth. Find. Exp. Clin. Pharmacol., 16:141-151 (1994).<\/p>\n

Caama\u00f1o, J., G\u00f3mez, M.J., Franco, A., Cacabelos, R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 16:211-218 (1994).<\/p>\n

Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Franco-Maside, A., Caama\u00f1o, J., Cacabelos, R. CDP-choline-induced blood histamine changes in Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 16:279-284 (1994).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Agents Actions, 41:C70-C72 (1994).<\/p>\n

Vinagre, D., Franco-Maside, A., G\u00f3mez, M.J., Caama\u00f1o, J., Cacabelos, R. Brain electrical activity mapping in cerebrovascular disorders and senile dementia. Drugs Today, 30:275-281 (1994).<\/p>\n

Caama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco-Maside, A., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia. Drugs Today, 30:283-293 (1994).<\/p>\n

Cacabelos, R., Nordberg, A., Caama\u00f1o, J., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., G\u00f3mez, M.J., \u00c1lvarez, X.A., Takeda, M., Prous, J. Jr. Nishimura, T., Winblad, B. Molecular strategies for the first generations of anti-dementia drugs (I): Tacrine and related compounds. Drugs Today, 30:295-337 (1994)<\/p>\n

Cacabelos, R., Winblad, B. Alzheimer\u2019s disease in a changing world. Ann. Psychiatry, 4:V-VI (1994).<\/p>\n

G\u00f3mez, M.J., Caama\u00f1o, J., Cacabelos, R. Alzheimer\u2019s disease assessment scale in senile dementia and in geriatric patients without cognitive impairment. Ann. Psychiatry, 4:69-81 (1994).<\/p>\n

Vinagre, D., Franco-Maside, A., G\u00f3mez, M.J., Caama\u00f1o, J., Cacabelos, R. Brain electrical activity mapping in cerebrovascular disorders and senile dementia. Ann. Psychiatry, 4:195-204 (1994).<\/p>\n

Caama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco, A., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia. Ann. Psychiatry, 4:205-219 (1994).<\/p>\n

Cacabelos, R., Nordberg, A., Caama\u00f1o, J., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., G\u00f3mez, M.J., \u00c1lvarez, X.A., Takeda, M., Prous, J., Nishimura, T., Winblad, B. Therapeutic strategies in Alzheimer\u2019s disease. Ann. Psychiatry, 4:221-279 (1994).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Franco, A. Enfermedad de Alzheimer. Bases moleculares, criterios diagn\u00f3sticos y normativa terap\u00e9utica. JANO Med. Hum., 1103:39-64 (1994).<\/p>\n

Cacabelos, R., Takeda, M., Nishimura, T. Tratamiento psicofarmacol\u00f3gico convencional para control de trastornos psiqui\u00e1tricos asociados a la enfermedad de Alzheimer. JANO Med. Hum., 1103:67-79 (1994).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Caama\u00f1o, J., Franco, A., Fern\u00e1ndez-Novoa, L., G\u00f3mez, M.J., Novo, B., Zas, R. Primeras generaciones de f\u00e1rmacos anti-demencia. JANO Med. Hum., 1104:25-59 (1994).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., Franco, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A. Agentes nootr\u00f3picos y f\u00e1rmacos polivalentes. JANO Med. Hum., 1105:25-55 (1994).<\/p>\n

Franco-Maside, A., Caama\u00f1o, J., G\u00f3mez, M.J., Cacabelos, R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 16:597-607 (1994).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of neurotoxic lesions in the posterior hypothalamic region on psychomotor activity and learning. Agents Actions, 43:21-23 (1994).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer; Bases etiopatog\u00e9nicas para nuevas estrategias terap\u00e9uticas. Cl\u00ednica, 7:31-53 (1994).<\/p>\n

Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A., Cacabelos, R. Effects of histamine and alpha-fluoromethylhistidine on brain tumor necrosis factor levels in rats. Immun. Res., 44:55-57 (1995).<\/p>\n

Cacabelos, R. From loyalty to efficacy. Ann. Psychiat., 5:1-111 (1995).<\/p>\n

Takeda, M., Cacabelos, R. Professor Nishimura and his work: Summary of a life devoted to Psychiatry. Ann. Psychiat., 5:1-13 (1995).<\/p>\n

G\u00f3mez, M.J., Caama\u00f1o, J., Vinagre, D., Franco-Maside, A., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Zas, R., Novo, R., Cacabelos, R. Non-cognitive impairment in senile dementia: A neuropsychological study. Ann. Psychiat., 5:31-40 (1995).<\/p>\n

Kudo, T., Takeda, M., Cacabelos, R., Nishimura, T. Biomarkers for Alzheimer\u2019s disease in cerebrovascular fluids. Ann. Psychiat., 5:41-52 (1995).<\/p>\n

Nakamura, Y., Cacabelos, R., Takeda, M. Impairment of axonal transport in Alzheimer\u2019s disease. Ann. Psychiat., 5:53-64 (1995).<\/p>\n

Fern\u00e1ndez-Novoa, L., Cacabelos, R. The histaminergic system in Alzheimer\u2019s disease. Ann. Psychiat., 5:127-158 (1995).<\/p>\n

Caama\u00f1o, J., Vinagre, D., G\u00f3mez, M.J., Novo, B., Zas, R., Franco, A., Cacabelos, R. Schizophrenic patients show lower peripheral resistances in the middle cerebral artery territory than healthy subjects: A preliminary transcranial Doppler study. Ann. Psychiat., 5:159-166 (1995).<\/p>\n

\u00c1lvarez, X.A., Zas, R., Lagares, R., Franco, A., Beyer, K., Polo, E., Garc\u00eda, M., Guez, D., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of S9977-2, a new cognition-enhancing drug, on behavior and brain neurotransmitters in rats. Ann. Psychiat., 5:247-265 (1995).<\/p>\n

\u00c1lvarez, X.A., Zas, R., Lagares, R., Franco, A., Maneiro, E., Miguel-Hidalgo, J.J., Lao, J.I., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Cacabelos, R. Neuroimmunomodulatory and neurotrophic activity of Anapsos: Studies with laboratory animals. Ann. Psychiat., 5:267-280 (1995).<\/p>\n

Franco-Maside, A., Vinagre, D., Caama\u00f1o, J., G\u00f3mez, M.J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Zas, R., Novo, B., Polo, E., Garc\u00eda, M., Castagn\u00e9, I., Newman, E., Guez, D., Cacabelos, R. Effects of S12024 on brain electrical activity parameters in patients with Alzheimer\u2019s disease. Ann. Psychiat., 5:281-294 (1995).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., G\u00f3mez, M.J., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., Vinagre, D., Novo, B., Zas, R., \u00c1lvarez, X.A. Treatment of Alzheimer\u2019s disease with CDP-choline: Effects on mental performance, brain electrical activity, cerebrovascular parameters and cytokine production. Ann. Psychiat., 5:295-315 (1995).<\/p>\n

Cacabelos, R. The multidisciplinary path to brain aging research and healthy environment for the elderly. Neurogerontol. Neurogeriat., 1:ix-x (1995).<\/p>\n

Cacabelos, R., Frey, H., Nishimura, T., Takeda, M., Winblad, B. Introduction to neurogerontology and psychogeriatrics. Neurogerontol. Neurogeriat., 1:1-4 (1994).<\/p>\n

Cacabelos, R. The aging process and theories of aging: Implications for neurogerontology. Neurogerontol. Neurogeriat., 1:5-20 (1995).<\/p>\n

\u00c1lvarez, X.A., Lagares, R., Zas, R., Fern\u00e1ndez-Novoa, L., Beyer, K., Maneiro, E., Franco-Maside, A., Lao, J.I., Miguel-Hidalgo, J.J., Cacabelos, R. Geriatric psychoneuroendocrinology. Neurogerontol. Neurogeriat., 1:61-83 (1995).<\/p>\n

G\u00f3mez, M.J., Caama\u00f1o, J., Vinagre, D., Franco, A., Cacabelos, R. Cognitive and non-cognitive profiles in cerebrovascular disorders and senile dementia: A neuropsychological study. Neurogerontol. Neurogeriat., 1:107-118 (1995).<\/p>\n

Franco-Maside, A., Vinagre, D., Caama\u00f1o, J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Novo, B., Zas, R., G\u00f3mez, M.J., Cacabelos, R. Brain mapping in neurogeriatrics. Neurogerontol. Neurogeriat., 1:119-139 (1995).<\/p>\n

Caama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Novo, B., Zas, R., Cacabelos, R. Transcranial Doppler ultrasonography in neurogeriatric disorders. Neurogerontol. Neurogeriat., 1:141-157 (1995).<\/p>\n

Cacabelos, R. Alzheimer\u2019s disease: Etiopathogenic factors. Neurogerontol. Neurogeriat., 1:299-328 (1995).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., \u00c1lvarez, X.A., G\u00f3mez, M.J., Franco-Maside, A., Vinagre, D., Fern\u00e1ndez-Novoa, L., Lao, J.I., Beyer, K., Recuero, M., Sastre, I., Bellido, M.J., Valdivieso, F., Vigo-Pelfrey, C. Diagnostic criteria and genotyping in Alzheimer\u2019s disease. Neurogerontol. Neurogeriat., 1:329-353 (1995).<\/p>\n

Caama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Novo, B., Zas, R., Cacabelos, R. Transcranial Doppler ultrasonography in neurogeriatric disorders. Meth. Find. Exp. Clin. Pharmacol., 17:135-148 (1995).<\/p>\n

Cacabelos, R. Tacrina: Primera generaci\u00f3n de f\u00e1rmacos antidemencia. Med. Clin., 105:105-115 (1995).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Parte I. Epidemiolog\u00eda y Etiopatogenia. FOMECO, 3:212-220 (1995).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Parte II. Diagn\u00f3stico y tratamiento. FOMECO, 3:268-281 (1995).<\/p>\n

Franco-Maside, A., Vinagre, D., Caama\u00f1o, J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Novo, B., Zas, R., G\u00f3mez, M.J., Cacabelos, R. Brain electrical activity in neurogerontology and psychogeriatric disorders. Meth. Find. Exp. Clin. Pharmacol., 17:207-224 (1995).<\/p>\n

Cacabelos, R., Lao, J.I., Beyer, K., \u00c1lvarez, X.A., Franco-Maside, A. Genetic testing in Alzheimer\u2019s disease: ApoE genotyping and etiopathogenic factors. Meth. Find. Exper. Clin. Pharmacol., 18(Suppl. A):161-179 (1996).<\/p>\n

Cacabelos, R. Clinical Neurosciences and Alzheimer\u2019s disease. Clin. Sci., 90:1 53-156 (1996).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., G\u00f3mez, M.J., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer\u2019s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. In: Neurobiology of Alzheimer\u2019s disease. Wurtman, R.J., Corkin, S., Growdon, J.H., Nitsch, R.M. (Eds.). Ann. New York Acad. Sci., 777:399-403 (1996).<\/p>\n

Cacabelos, R. Diagnosis of Alzheimer\u2019s disease: Defining genetic profiles (genotype vs. phenotype). Acta Neurol. Scand. Suppl., 165:72-84 (1996).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Informaciones Psiqui\u00e1tricas, 142:443-456 (1995).<\/p>\n

Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Det\u00f3lle-Sarbanch, S., Guez, D., Zas, R., Polo, E., Cacabelos, R. Effects of S-9977-2 on histamine levels in rats. Meth. Find. Exp. Clin. Pharmacol., 18;197-203 (1996).<\/p>\n

V\u00e1zquez, J., Fern\u00e1ndez-Shaw, C., Marina, A., Haas, C., Cacabelos, R., Valdivieso, F. Antibodies to human spectrin in Alzheimer\u2019s disease. J. Neuroimmunol., 68:39-44 (1996).<\/p>\n

Lombardi, V.R.M., Miguel-Hidalgo, J.J., Mancino, G., Maneiro, E., Poccia, F., Pl\u00e1cido, R., Lagares, R., Cacabelos, R. Apoptosis during HIV infection and in neurodegenerative disorders. Meth. Find. Exp. Clin. Pharmacol., 18:539-555 (1996).<\/p>\n

Maneiro, E., Lombardi, V.R.M., Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Meth. Find. Exp. Clin. Pharmacol., 18:615-645 (1996).<\/p>\n

Cacabelos, R. Progress in neuropsychiatric disorders and Alzheimer\u2019s disease. Ann. Psychiat., 6:XIII- XIV (1996).<\/p>\n

\u00c1lvarez, X.A., Ayuso-Guti\u00e9rrez, J.L., Cacabelos, R. Somatotropinergic system: neurobiology and effects on brain activity and mental functions. Ann. Psychiat., 6:73-104 (1996).<\/p>\n

Miguel-Hidalgo, J.J., Cacabelos, R. Hippocampal neurodegeneration: animal models for Alzheimer\u2019s disease. Ann. Psychiat., 6:147-157 (1996).<\/p>\n

\u00c1lvarez, X.A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., Beyer, K., Lao, J.I., Vecino, B., Cacabelos, R. Behavioral deficits in rats with hippocampal neurodegeneration induced by \uf062- amyloid implants. Ann. Psychiat., 6:159-171 (1996).<\/p>\n

Beyer, K., Lao, J.I., Cacabelos, R. Molecular genetics and genotyping in Alzheimer\u2019s disease. Ann. Psychiat., 6:173-187 (1996).<\/p>\n

Cacabelos, R., Rodr\u00edguez, B., Carrera, C., Beyer, K., Lao, J.I., Sellers, M.A. APOE-related dementia symptoms: Frequency and progression. Ann. Psyciat., 6:189-205 (1996).<\/p>\n

Lao, J.I., Beyer, K., Cacabelos, R. Genetic markers of mental retardation. Ann. Psychiat., 6:207-217 (1996).<\/p>\n

Maneiro, E., Lombardi, V.R.M., Cacabelos, R. Cytotoxic effects of beta amyloid, histamine, LPS and serum from Alzheimer\u2019s disease patients on cultured endothelial cells. A preliminary study. Ann. Psychiat., 6:231-239 (1996).<\/p>\n

Lombardi, V.R.M., Maneiro, E., Cacabelos, R. Neurologic manifestations linked to AIDS and HIV-l infection. Ann. Psychiat., 6:309-330 (1996).<\/p>\n

Maneiro, E., Lombardi, V.R.M., Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Ann. Psychiat., 6:331-365 (1996).<\/p>\n

Beyer, K., Lao, J.I., \u00c1lvarez, X.A., Cacabelos, R. Different implications of APOE-4 in Alzheimer\u2019s disease and vascular dementia in the Spanish population. Alzheimer\u2019s Res., 2:215-220 (1996).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Blood levels of histamine, IL-l\uf062, and TNF-\uf061 in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol., 29:237-252 (1996).<\/p>\n

Cacabelos, R., Rodr\u00edguez, B., Carrera, C., Caama\u00f1o, J., Beyer, K., Lao, J.I., Sellers, M.A. APOE-Related frequency of cognitive and noncognitive symptoms in dementia. Meth. Find. Exp. Clin. Pharmacol., 18:693-706 (1996).<\/p>\n

Lombardi, V.R.M., Maneiro, E., Cacabelos, R. Central nervous system damage during HIV infection. Meth. Find. Exp. Clin. Pharmacol., 18:707-722 (1996).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., Vinagre, D., Lao, J.I., Beyer, K., \u00c1lvarez, X.A. Brain mapping and transcranial Doppler ultrasonography in Alzheimer\u2019s disease drug monitoring. In: Alzheimer disease: From Molecular Biology to Therapy. R. Becker, E. Giacobini (Eds.). Birkh\u00e4user, Boston, pp. 469-473 (1996).<\/p>\n

\u00c1lvarez, X.A., Zas, R., Lagares, R., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., Miguel-Hidalgo, J.J., Cacabelos, R. Anapsos: New therapeutic strategies for neurodegeneration and brain aging with neuroimmunotrophic factors. In: Alzheimer disease: From Molecular Biology to Therapy. R. Becker, E. Giacobini (Eds.). Birkh\u00e4user, Boston, pp. 367-372 (1996).<\/p>\n

Beyer, K., Lao-Villad\u00f3niga, J.I., Vecino-Bilbao, B., Cacabelos, R., de la Fuente, R. A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia. J. Neurol. Neurosurg. Psychiat., 62:420-421 (1997).<\/p>\n

Miguel-Hidalgo, J.J., Cacabelos, R. Modeling neuronal degeneration in the rodent hippocampus: An approach for studying degenerative neuropathology in dementia. Meth. Find. Exp. Clin. Pharmacol., 19:133-142 (1997).<\/p>\n

Maneiro, E., Lombardi, V.R.M., Lagares, R., Cacabelos, R. An experimental model to study the cytotoxic effects induced by \uf062-amyloid, histamine, LPS and serum from Alzheimer patients on rat cultured endothelial cells. Meth. Find. Exp. Clin. Pharmacol., 19:5-12 (1997).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer: Diagn\u00f3stico molecular y futuro terap\u00e9utico. An. Med. Interna, 14(Supl. 1):72-74 (1997).<\/p>\n

\u00c1lvarez, X.A., Laredo, M., Corzo, D., Fern\u00e1ndez-Novoa, L., Mouzo, R., Perea, E., Daniele, D., Cacabelos, R. Citicoline improves memory performance in elderly subjects. Meth. Find. Exp. Clin. Pharmacol., 19:201-210 (1997).<\/p>\n

Beyer, K., Lao, J.I., \u00c1lvarez, X.A., Cacabelos, R. A general method for DNA polymorphism identification in genetic assessment and molecular diagnosis. Meth. Find. Exp. Clin. Pharmacol., 19:87-91 (1997).<\/p>\n

Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Sempere, J.M., Miguel-Hidalgo, J.J., D\u00edaz, J., Franco-Maside, A., Cacabelos, R. Effects of anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal degeneration. Meth. Find. Exp. Clin. Pharmacol., 19:99-106 (1997).<\/p>\n

\u00c1lvarez, X.A., Zas, R., Fern\u00e1ndez-Novoa, L., Garc\u00eda, M., Polo, E., Detolle-Sarbach, S., Guez, D., Cacabelos, R. Comparative effects of S9977-2 versus tacrine on passive avoidance learning and psychomotor activity. Hum. Psychopharmacol. Clin. Exp., 12:329-335 (1997).<\/p>\n

\u00c1lvarez, X.A., Franco-Maside, A., Zas, R., Sempere, J.M., D\u00edaz, J., Cacabelos, R. Anapsos reverses interleukin-1\uf062 overexpression and behavioral deficits in nbM-lesioned rats. Meth. Find. Exp. Clin. Pharmacol., 19:299-309 (1997).<\/p>\n

Sellers, M.A., P\u00e9rez, L., Cacabelos, R. Evaluaci\u00f3n neuropsicol\u00f3gica de la demencia senil en atenci\u00f3n primaria. Formaci\u00f3n M\u00e9dica Continuada en Atenci\u00f3n Primaria, 4:150-173 (1997).<\/p>\n

Cacabelos, R., Rodr\u00edguez, B., Carrera, C., Beyer, K., Lao, J.I., Sellers, M.A. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer\u2019s Dis. Assoc. Dis., 11(Suppl. 4):S27-S37 (1997).<\/p>\n

\u00c1lvarez, X.A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Sempere, J.M., Cacabelos, R. Anapsos: Neuroimmunotrophic treatment in Alzheimer\u2019s disease and neurodegenerative disorders. CNS Drug Rev., 3:181-206 (1997).<\/p>\n

Lao, J.I., Beyer, K., Cacabelos, R. La gen\u00e9tica molecular aplicada al diagn\u00f3stico de la enfermedad de Alzheimer. Informaciones Psiqui\u00e1tricas, 147:15-33 (1997).<\/p>\n

Fern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., \u00c1lvarez, X.A., Cacabelos, R. Global Deterioration Scale-related brain hemodynamics and histamine levels in Alzheimer\u2019s disease and vascular dementia. Ann. New York Acad. Sci., 826:396-400 (1997).<\/p>\n

\u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Corzo, L., Zas, R., Beyer, K., Lao, J.I., Cacabelos, R. Cerebrovascular changes associated with interleukin-1\uf062 (IL-1\uf062) and histamine levels in Alzheimer\u2019s disease. Ann. New York Acad. Sci., 826:375-378 (1997).<\/p>\n

Beyer, K., Lao, J.I., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Sellers, M.A., Cacabelos, R. APOE-\uf0654 allele frequency in Alzheimer\u2019s disease and vascular dementia in the Spanish population. Ann. New York Acad. Sci., 826:452-455 (1997).<\/p>\n

\u00c1lvarez, X.A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Intrahippocampal injections of the \uf062-amyloid 1-28 fragment induce behavioral deficits in rats. Meth. Find. Exp. Clin. Pharmacol., 19:471-479 (1997).<\/p>\n

\u00c1lvarez, X.A., Vecino, B., Perea, J.E., Daniele, D., Cacabelos, R. Citicoline antagonizes bromazepam-induced amnesia in rats. Hum. Psychopharmacol., 12:547-556 (1997).<\/p>\n

Cacabelos, R. Alzheimer\u2019s disease: Present and future. J. Autonomic Pharmacol., 17:282 (1997).<\/p>\n

Cacabelos, R. Etiopatogenia del deterioro cognitivo. Factores de riesgo de los trastornos de memoria. Prensa M\u00e9dica Argentina, 85:176-177 (1998).<\/p>\n

Cacabelos, R. Tratamiento del deterioro de la memoria y el d\u00e9ficit cognitivo. Prensa M\u00e9dica Argentina, 85:179-180 (1998).<\/p>\n

Cacabelos, R. Neuroimmune reactions and inflammatory mechanisms in Alzheimer\u2019s disease: gene-specific responses in therapeutics and prevention. Neurogerontol. Neurogeriat., 2:IX-XII (1998).<\/p>\n

Maneiro, E., Lombardi, V., Cacabelos, R. Neuroimmune dysfunction in Alzheimer\u2019s disease. Influence of \uf062-amyloid, interleukin-l\uf062, histamine, and APOE-related sera from patients with Alzheimer\u2019s disease on microglial cells. Neurogerontol. Neurogeriat., 2:77-104 (1998).<\/p>\n

Lombardi, V., Cacabelos, R. Apoptosis in neurodegenerative diseases: The neuroimmune network. Neurogerontol. Neurogeriat., 2:105-124 (1998).<\/p>\n

\u00c1lvarez, X.A., Miguel, J.J., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Sempere, J.M., Cacabelos, R. Therapeutic agents with potential amyloid scavenging activity: Neuroimmune-associated mechanisms. Neurogerontol. Neurogeriat., 2:141-163 (1998).<\/p>\n

Cacabelos, R., P\u00e9rez del T\u00edo, L., Sellers, A. Caregivers\u2019 perception on dementia-associated social, economic and health problems: Sociodemographic study in the Spanish population. Jap. J. Geriat. Psychiat., 9:133-139 (1998).<\/p>\n

Miguel-Hidalgo, J.J., \u00c1lvarez, A., Cacabelos, R. Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system. Cell Tiss. Res., 293:75-86 (1998).<\/p>\n

Miguel-Hidalgo, J.J., Cacabelos, R. \uf062-Amyloid (l-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol., 95:455-465 (1998).<\/p>\n

Miguel-Hidalgo, J.J., Vecino, B., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, A., Cacabelos, R. Neuroprotective role of S12024 against neurodegeneration in the rat dentate gyrus. Eur. Neuropsychopharmacol., 8:203-208 (1998).<\/p>\n

European Concerted Action on Pick\u2019s Disease (ECAPD) Consortium. \u00c1lvarez, X.A., Baker, S., Binetti, G., Boller, F., Bracco, L., Breteler, M., Brun, A., Cacabelos, R., Cairns, N., Cappa, S., Cipolotti, T., Collinge, J., Englund, E., Forleo, P., F\u00f6rstl, H., Grassi, E., Harvey, R., Hodges, J., Gustafson, L., Kurz, A., Lantos, P., Lauten-Schlager, N., Lebert, F., Muggia, S., Pasquier, F., Passant, V., Ravid, R., Rossor, M., Sorbi, S., Spinnler, H., Stevens, J, van Swieten, J., Warrington, E., Xuereb, J. Provisional clinical and neuroradiological criteria for the diagnosis of Pick\u2019s disease. Eur. J. Neurol., 5:519-520 (1998).<\/p>\n

Lombardi, V.R.M., Garcia, M., Cacabelos, R. APOE-induced microglial activation: An in vitro assay to screen sera from Alzheimer\u2019s disease patients and novel therapeutic compounds. Meth. Find. Exp. Clin. Pharmacol., 20:377-386 (1998).<\/p>\n

Lombardi, V.R.M., Garc\u00eda, M., Cacabelos, R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J. Neurosc. Res., 54:539-553 (1998).<\/p>\n

Cacabelos, R. Bio\u00e9tica asistencial del anciano con enfermedad neurodegenerativa y prevenci\u00f3n gen\u00e9tica de la demencia. Bio\u00e9tica y Ciencias de la Salud, 3:35-40 (1998).<\/p>\n

Lao, J.I., Beyer, K., Fern\u00e1ndez-Novoa, L., Cacabelos, R. A novel mutation in the predicted TM2 domain of presenilin 2 gene in Spanish patient with late-onset Alzheimer\u2019s disease. Neurogenetics, 1:293-296 (1998).<\/p>\n

Sellers, A., P\u00e9rez, L., Carrera, C., Bustos, J.C., Caama\u00f1o, J.M., Rodr\u00edguez, B., Mouzo, R., P\u00e9rez, P., Lao, J.I., Beyer, K., \u00c1lvarez, X.A., Cacabelos, R. Cognitive and non-cognitive symptoms in senile dementia. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 317-322 (1998).<\/p>\n

Sellers, A., P\u00e9rez, L., Rodr\u00edguez, B., Pichel, V.M., Caama\u00f1o, J.M., Laredo, M., Alcaraz, M., \u00c1lvarez, X.A., Cacabelos, R. Dementia-associated sleep disorders. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 323-327 (1998).<\/p>\n

\u00c1lvarez, A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Sempere, J.M., Cacabelos, R. Anapsos improves learning and memory in rats with \uf062A(1-28) deposits into the hippocampus. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 699-703 (1998).<\/p>\n

Miguel-Hidalgo, J.J., \u00c1lvarez, X.A., Cacabelos, R. In vivo neurotoxicity of \uf062-amyloid 1-40 in the rat hippocampus. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 705-709 (1998).<\/p>\n

Corzo, L., Fern\u00e1ndez-Novoa, L., Zas, R., Beyer, K., Lao, J.I., \u00c1lvarez, X.A., Cacabelos, R. Influence of the APOE-genotype on serum ApoE levels in Alzheimer\u2019s disease patients. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 765-771 (1998).<\/p>\n

Lao, J.I., Beyer, K., Cacabelos, R. Centromeric disturbances affecting all chromosomes of cultured lymphocytes obtained from Alzheimer\u2019s disease patients. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 793-798.<\/p>\n

Mouzo, R., \u00c1lvarez, X.A., Pichel, V.M., Sellers, A., Caama\u00f1o, J.M., Laredo, M., Beyer, K., Lao, J.I., P\u00e9rez, P., Alcaraz, M., R\u00faa, M.C., Corzo, L., Fern\u00e1ndez-Novoa, L., Fern\u00e1ndez, R., Cacabelos, R. APOE genotype-related blood pressure in senile dementia. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 799-803 (1998).<\/p>\n

Pichel, V.M., Caama\u00f1o, J.M., Sellers, A., Mouzo, R., \u00c1lvarez, X.A., P\u00e9rez, P., Laredo, M., Cacabelos, R. Changes in cerebral blood flow associated with disease staging and APOE genotyping in patients with senile dementia. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 811-815 (1998).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer: Bases etiopatog\u00e9nicas. En: Salud Mental y Psiquiatr\u00eda en el Umbral del Nuevo Milenio. Asociaci\u00f3n Psiqui\u00e1trica Peruana y Asociaci\u00f3n Psiqui\u00e1trica de Am\u00e9rica Latina. Lima, Per\u00fa, pp. 111-134 (1998).<\/p>\n

Cacabelos, R., Beyer, K., Lao, J.I., Mesa, M.D., Fern\u00e1ndez-Novoa, L. Association of genetic risk factors in Alzheimer\u2019s disease and a novel mutation in the predicted TM2 domain of presenilin-2 in late-onset AD. In: Alzheimer\u2019s Disease and Related Disorders. Iqbal, K., Swaab, D.F., Winblad, B., Wisniewski, H.M. (Eds.). John Wiley & Sons, Chichester, pp. 93-102 (1999).<\/p>\n

Lombardi, V.R.M., Cacabelos, R. 19\/20 kDa low molecular weight serum protein pattern: a novel potential biochemical prognostic marker for different types of dementia. Neurosci. Lett., 260:61-64 (1999).<\/p>\n

Lombardi, V.R.M., Cacabelos, R. E-SAR-94010: A marine fish extract obtained by advanced biotechnological methods. Drugs Future, 24:167-176 (1999).<\/p>\n

Cacabelos, R., Takeda, M., Winblad, B. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer\u2019s disease. Int. J. Geriat. Psychiatry, 14:3-47 (1999).<\/p>\n

Lombardi, V.R.M., Windisch, M., Garc\u00eda, M., Cacabelos, R. Effects of cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Meth. Find. Exp. Clin. Pharmacol., 21:331-338 (1999).<\/p>\n

Cacabelos, R. The search for new health care models, integrated treatments and prevention for dementia. Ann. Psychiatry, 7:XVII-XX (1999).<\/p>\n

Mesa, M.D., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Association of genetic risk factors in Alzheimer\u2019s disease. Ann. Psychiatry, 7:35-45 (1999).<\/p>\n

Laredo, M., \u00c1lvarez, X.A., P\u00e9rez, P., Cacabelos, R. Psychometric evaluation and apolipoprotein E genotyping in senile dementia. Ann. Psychiatry, 7:67-75 (1999).<\/p>\n

P\u00e9rez, P., \u00c1lvarez, X.A., Laredo, M., Pichel, V., Cacabelos, R. Brain electrical activity mapping, disease staging and apolipoprotein E genotyping in senile dementia. Ann. Psychiatry, 7:77-85 (1999).<\/p>\n

Pichel, V.M., Caama\u00f1o, J.M., Figueroa, J., Hern\u00e1ndez, A., \u00c1lvarez, X.A., P\u00e9rez, P., Laredo, M., Cacabelos, R. Changes in brain hemodynamic parameters associated with disease staging and apolipoprotein E genotyping in patients with senile dementia. Ann. Psychiatry, 7:87-92 (1999).<\/p>\n

Mouzo, R., \u00c1lvarez, X.A., Pichel, V.M., Alcaraz, M., Cacabelos, R. Apolipoprotein E-related blood pressure parameters in senile dementia. Ann. Psychiatry, 7:93-97 (1999).<\/p>\n

Corzo, L., Fern\u00e1ndez-Novoa, L., Zas, R., Laredo, M., Alcaraz, M., \u00c1lvarez, X.A., Cacabelos, R. Apolipoprotein E genotype-related serum apolipoprotein E and lipid levels in Alzheimer\u2019s disease. Ann. Psychiatry, 7:99-107 (1999).<\/p>\n

Fern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., Laredo, M., P\u00e9rez, P., Pichel, V., Mesa, M.D., Cacabelos, R. Blood histamine levels, brain hemodynamic parameters and risk factors in Alzheimer\u2019s disease and vascular dementia. Ann. Psychiatry, 7:109-117 (1999).<\/p>\n

\u00c1lvarez, X.A., Sampedro, C., Cacabelos, R. Antiapoptotic effects of CDP-choline in a combined (A\uf0624\/hypoperfusion) animal model of hippocampal neurodegeneration. Ann. Psychiatry, 7:147-156 (1999).<\/p>\n

Lombardi, V.R.M., Garc\u00eda, M., Cacabelos, R. Genotype-specific microglial response in cell culture systems for the identification of novel therapeutic compounds in Alzheimer\u2019s disease and neuroimmune disorders. Ann. Psychiatry, 7:157-170 (1999).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Lombardi, V. Alzheimer\u2019s disease: Pharmacoeconomics, glutamate-induced neurodegeneration and preventive strategies. Ann. Psychiatry, 7:195-239 (1999).<\/p>\n

Lombardi, V.R.M., Garc\u00eda, M., Cacabelos, R. Evolution of senescence: Cellular aging, apoptosis, immune surveillance and tumor development. Ann. Psychiatry, 7:279-308 (1999).<\/p>\n

\u00c1lvarez, X.A., Mouzo, R., Pichel, V., P\u00e9rez, P., Laredo, M., Fern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J., Lozano, R., Cacabelos, R. Effects of citicoline on cognitive performance, brain bioelectrical activity and brain hemodynamics in Alzheimer\u2019s disease patients: A double-blind placebo-controlled study. Ann. Psychiatry, 7:331-352 (1999).<\/p>\n

\u00c1lvarez, X.A., Sampedro, C., Lozano, R., Cacabelos, R. Citicoline protects hippocampal neurons against apoptosis induced by brain \uf062-amyloid deposits plus cerebral hypoperfusion in rats. Meth. Find. Exp. Clin. Pharmacol., 21:535-540 (1999).<\/p>\n

\u00c1lvarez, X.A., Mouzo, R., Pichel, V., P\u00e9rez, P., Laredo, M., Fern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J.J., Lozano, R., Cacabelos, R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer\u2019s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Meth. Find. Exp. Clin. Pharmacol., 21:633-644 (1999).<\/p>\n

\u00c1lvarez, X.A., Sampedro, C., Cacabelos, R. Citicoline reduces neuronal apoptosis in rats with brain hypoperfusion and hippocampal \uf062-amyloid implants. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 239-243 (1999).<\/p>\n

\u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Sampedro, C., Lombardi, V., Windisch, M., Cacabelos, R. Neuroimmunotrophic effects of Cerebrolysin in an animal model of hippocampal degeneration induced by \uf062-amyloid. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 233-237 (1999).<\/p>\n

de Olano, M., Mesa, M.D., Fern\u00e1ndez-Novoa, L., Corzo, L., Blanco, A., Cacabelos, R. Angiotensin-converting enzyme I\/D polymorphism and ansiotensinogen M235T polymorphism in cerebrovascular pathology. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 207-210 (1999).<\/p>\n

Laredo, M., Couceiro, V., Corzo, L., P\u00e9rez, P., Anido, R., \u00c1lvarez, X.A., Cacabelos, R. Sleep disorders in vascular dementia and Alzheimer disease. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 129-133 (1999).<\/p>\n

Lombardi, V.R., Garc\u00eda, M., Rey, L., Cacabelos, R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer\u2019s disease individuals. J. Neuroimmunol., 97:163-171 (1999).<\/p>\n

Allison, A.C., Cacabelos, R., Lombardi, V.R.M., \u00c1lvarez, X.A., Vigo, C. Central nervous system effects of Celastrol, a potent antioxidant and antiinflammatory agent. CNS Drug Rev., 6:45-62 (2000).<\/p>\n

\u00c1lvarez, X.A., Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Garc\u00eda, M., Sampedro, C., Cagiao, A., Cacabelos, R., Windisch, M. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J. Neural Transm., 59:281-292 (2000).<\/p>\n

\u00c1lvarez, X.A., Lombardi, V.R.M., Corzo, L., P\u00e9rez, P., Pichel, V., Laredo, M., Hern\u00e1ndez, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Windisch, M., Cacabelos, R. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J. Neural Transm., 59:315-328 (2000).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Lombardi, V., Fern\u00e1ndez-Novoa, L., Corzo, L., P\u00e9rez, P., Laredo, M., Pichel, V., Hern\u00e1ndez, A., Varela, M., Figueroa, J., Prous Jr. J., Windisch, M., Vigo, C. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today, 36:415-499 (2000).<\/p>\n

Cacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. Drug News Perspect., 13:252-254 (2000).<\/p>\n

\u00c1lvarez, X.A., Pichel, V., P\u00e9rez, P., Laredo, M., Corzo, D., Zas, R., Fern\u00e1ndez-Novoa, L., Sempere, J.M., D\u00edaz, J., Cacabelos, R. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: Effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth. Find. Exp. Clin. Pharmacol., 22:585-594 (2000).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Lombardi, V.R.M. A pharmacogenomic approach to Alzheimer\u2019s disease. Acta Neurol. Scand., 102(Suppl. 176):12-19 (2000).<\/p>\n

Isaza, C.A., Henao, J., L\u00f3pez, A.M., Cacabelos, R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 22:695-705 (2000).<\/p>\n

Cacabelos, R. Psychogeriatric research: A conceptual introduction to aging and geriatric neuroscience. Psychogeriatrics, 1:158-188 (2001).<\/p>\n

Allison, A.C., Cacabelos, R., Lombardi, V.R.M., \u00c1lvarez, X.A., Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer\u2019s disease. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 25:1341-1357 (2001).<\/p>\n

Cacabelos, R., Santamar\u00eda, J.L. Hipertensi\u00f3n y Demencia. Mecanismos etiopatog\u00e9nicos y factores gen\u00e9ticos. Hipertensi\u00f3n Cl\u00ednica, IV\/3:626-659 (2001).<\/p>\n

Fern\u00e1ndez-Novoa, L., Cacabelos, R. Histamine function in brain disorders. Behav. Brain Res., 124:213-233 (2001).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Presente terap\u00e9utico y retos futuros (I). Rev. Colomb. Psiquiatr\u00eda, XXX\/3:215-238 (2001).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Presente terap\u00e9utico y retos futuros (II). Rev. Colomb. Psiquiatr\u00eda, XXX\/4:323-350 (2001).<\/p>\n

Lombardi, V.R.M., Cagiao, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Corzo, M.D., Zas, R., Sampedro, C., Cacabelos, R. Short term food supplementation effects of a fish derived extract on the immunological status of pregnant rats and their sucking pups. Nutrition Res., 21:1425-1434 (2001).<\/p>\n

Cacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. Min. Rev. Medic. Chem., 2:59-84 (2002).<\/p>\n

Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 34:357-379 (2002).<\/p>\n

Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Corzo, D., Zas, R., Cacabelos, R. Enhancement in immune function and growth using E-JUR-94013 supplementation. Meth. Find. Exp. Clin. Pharmacol., 24:573-578 (2002).<\/p>\n

Miguel-Hidalgo, J.J., \u00c1lvarez, X.A., Cacabelos, R., Quack, G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res., 958:210-221 (2002).<\/p>\n

Cacabelos, R. The histamine-citokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. In: Mapping the Progress of Alzheimer\u2019s and Parkinson\u2019s Disease. Mizuno, Y., Fisher, A., Hanin, I. (Eds.). Advances in Behavioral Biology, 51:59-64 (2002).<\/p>\n

Takeda, M., Cacabelos, R., Ray, O., F\u00f6rstl, H., Hoon Oh, B. International perspective on the diagnosis and treatment of dementia. Cognition & Dementia, 2:53-63 (2003).<\/p>\n

Takeda, M., Okochi, M., Sugaya, K., De-Maw, C., Hashimoto, R., Kuroda, S., Shinosaka, K., Kudo, T., Tanaka, T., Cacabelos, R. Research strategy for understanding neuronal plasticity and degeneration. Seishin Shinkeigaku Zasshi, 105:43-46 (2003).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Takeda, M. Genetic variation and pharmacogenomics in Alzheimer disease. Psychiat. Neurol. Jap., 105:47-67 (2003).<\/p>\n

Lombardi, V.R.M., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Cacabelos, R. In vitro regulation of rat-derived microglia. Neurotox. Res., 5:201-212 (2003).<\/p>\n

Lombardi, V.R.M., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Blanco, A., D\u00edaz, J., Cacabelos, R. Extracts from Polypodium ferns upregulate the expression of CD95 in human peripheral blood lymphocytes. Orient. Pharm. Exper. Med., 3:90-99 (2003).<\/p>\n

\u00c1lvarez, X.A., Sampedro, C., P\u00e9rez, P., Laredo, M., Couceiro, V., Hern\u00e1ndez, A., Figueroa, J., Varela, M., Arias, D., Corzo, L., Zas, R., Lombardi, V., Fern\u00e1ndez-Novoa, L., Pichel, V., Cacabelos, R., Windisch, M., Aleixandre, M., Moessler, H. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Intern. Clin. Psychopharmacol., 18:271-278 (2003).<\/p>\n

Cacabelos, R. The application of functional genomics to Alzheimer\u2019s disease. Pharmacogenomics, 4:597-621 (2003).<\/p>\n

Isaza, C., Henao, J., L\u00f3pez, A.M., Cacabelos, R. Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 25:423-429 (2003).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Corzo, L., Pichel, V., Kubota, Y. Cerebrovascular risk factors in Alzheimer\u2019s disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res., 25:567-580 (2003).<\/p>\n

Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Neuroglia and neurotrophic factors (NTFs): potential targets for future therapeutics. Current Topics in Pharmacology, 7:229-246 (2003).<\/p>\n

Pichel, V., Etcheverr\u00eda, I., Amado, L., Kubota, Y., Cacabelos, R. Cerebrovascular risk factors and brain hemodynamics in dementia. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 23-27 (2003).<\/p>\n

Lombardi, V.R.M., Amado, L., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Flow cytometry analysis of CD28-\/CD8+ suppressor cell precursor and CD45RO+\/CD4+ memory T lymphocytes in the peripheral blood of Alzheimer\u2019s disease patients. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 57-61 (2003).<\/p>\n

Corzo, L., Zas, R., Fern\u00e1ndez-Novoa, L., Cacabelos, R. SERUM nitric oxide in Alzheimer disease. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 63-68 (2003).<\/p>\n

Kubota, Y., Pichel, V., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Combination therapy in Alzheimer disease: a pharmacogenomic study. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 87-90 (2003).<\/p>\n

Etcheverr\u00eda, I., Pichel, V., Amado, L., Fern\u00e1ndez-Novoa, L., Lombardi, V., Cacabelos, R. APOE genotype-related brain atrophy in the Spanish population. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 91-96 (2003).<\/p>\n

Fern\u00e1ndez-Novoa, L., Lombardi, V.R.M., Seoane, S., Etcheverr\u00eda, I., Corzo, L., Cacabelos, R. The ACE gene in Alzheimer\u2019s disease. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 123-126 (2003).<\/p>\n

Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Association between APOE-4 allele and increased expression of CD95 on T cells from patients with Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 26:523-529 (2004).<\/p>\n

Cacabelos, R., Corzo, L., Fern\u00e1ndez-Novoa, L., Lombardi, V. Histamine in Alzheimer\u2019s disease pathogenesis: Biochemistry and functional genomics. Meth. Find. Exp. Clin. Pharmacol., 26(Suppl. 2):9-16 (2004).<\/p>\n

Cacabelos, R., Vallejo, A.I., Lombardi, V., Fern\u00e1ndez-Novoa, L., Pichel, V. E-SAR-94010 (LipoEsar\u00ae): A pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Rev., 10:200-201 (2004).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Corzo, L., Pichel, V., Lombardi, V., Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exp. Clin. Pharmacol., 26:421-444 (2004).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Corzo, L., Amado, L., Pichel, V., Lombardi, V., Kubota, Y. Phenotypic profiles and functional genomics in Alzheimer\u2019s disease and in dementia with a vascular component. Neurol. Res., 26:459-480 (2004).<\/p>\n

Cacabelos, R. Genomic characterization of Alzheimer\u2019s disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 5:1049-1105 (2004).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Pichel, V., Lombardi, V., Kubota, Y., Takeda, M. Pharmacogenomic studies with a combination therapy in Alzheimer\u2019s disease. In: Molecular Neurobiology of Alzheimer\u2019s Disease and Related Disorders. Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Karger, Basel, pp. 94-107 (2004).<\/p>\n

Cacabelos, R., Lombardi, V., Fern\u00e1ndez-Novoa, L., Kubota, Y., Corzo, L., Pichel, V., Takeda, M. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Molecular Neurobiology of Alzheimer\u2019s Disease and Related Disorders. Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Karger, Basel, pp. 236-285 (2004).<\/p>\n

Isaza, C., Henao, J., Ram\u00edrez, E., Cuesta, F., Cacabelos, R. Polymorphic variants of the beta-2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 27:237-244 (2005).<\/p>\n

Cacabelos, R. Funci\u00f3n cerebrovascular en la enfermedad de Alzheimer (2005) www.sinapsis.org\/.<\/p>\n

Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Effects of fish-derived lipoprotein extracts on activation markers, Fas expression and apoptosis in peripheral blood lymphocytes. Intern. Immunopharmacol., 5:253-262 (2005).<\/p>\n

Cacabelos, R., Kubota, Y., Isaza, C., Henao, J., Fern\u00e1ndez-Novoa, L., Lombardi, V.R.M., Corzo, L., Pichel, V. Functional genomics and pharmacogenetics in Alzheimer\u2019s disease. In: Recent Progress in Alzheimer\u2019s and Parkinson\u2019s Diseases. Hanin, I., Cacabelos, R., Fisher, A. (Eds.). Taylor & Francis, London, pp. 89-102 (2005).<\/p>\n

Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Regulating factors for microglial activation: implication for Alzheimer\u2019s disease and brain damage. In: Recent Progress in Alzheimer\u2019s and Parkinson\u2019s Diseases. Hanin, I., Cacabelos, R., Fisher, A. (Eds.). Taylor & Francis, London, pp. 171-176 (2005).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Kubota, Y., Takeda, M. Molecular genetics of Alzheimer\u2019s disease and aging. Meth. Find. Exp. Clin. Pharmacol., 27(Suppl. A):1-573 (2005).<\/p>\n

Cacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer\u2019s disease. Aging Health, 1:303-348 (2005).<\/p>\n

Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer\u2019s disease. Expert Opin. Pharmacother., 6:1967-1987 (2005).<\/p>\n

Cacabelos, R. Role of nutrition in the prevention of Alzheimer\u2019s disease. Aging Health, 1:359-362 (2005).<\/p>\n

\u00c1lvarez, X.A., Corzo, L., Laredo, M., Sampedro, C., Cacabelos, R., Windisch, M., Moessler, H., Crook, T.H. Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjects. Meth. Find. Exper. Clin. Pharmacol., 27:493-487 (2005).<\/p>\n

Cacabelos, R. Homocysteine and cognition: from Galenic dogmatism to genetic relativism. Aging Health, 2:783-786 (2006).<\/p>\n

Lombardi VRM, Pereira J, Etcheverr\u00eda I, Fern\u00e1ndez-Novoa L, Seoane S, Cacabelos R. Improvement of immune function by means of Conger conger extract in an in vivo model of cold stress. Food and Agricultural Immunology 2006; 17(1-4): 115-127.<\/p>\n

\u00c1lvarez, X.A., Cacabelos, R., Laredo, M., Couceiro, V., Sampedro, C., Varela, M., Corzo, L., Fern\u00e1ndez-Novoa, L., Vargas, M., Aleixandre, M., Linares, C., Granizo, E., Muresanu, D., Moessler, H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer\u2019s disease. Eur. J. Neurol., 13:43-54 (2006).<\/p>\n

Cacabelos, R., Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer\u2019s disease. Drugs Future, 31(Suppl. B):5-146 (2006).<\/p>\n

Cacabelos, R. Molecular pathology and pharmacogenomics in Alzheimer\u2019s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 29(Supp. A):1-91 (2007).<\/p>\n

Takeda, M., Cacabelos, R. (Eds.). Alzheimer\u2019s disease genomics. Cognition and Dementia, 6(Suppl.):7-113 (2007).<\/p>\n

Cacabelos, R. Donepezil in Alzheimer\u2019s disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 3:303-333 (2007).<\/p>\n

\u00c1lvarez, A., Cacabelos, R., Sampedro, C., Garc\u00eda-Fantini, M., Aleixandre, M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-1 in Alzheimer\u2019s disease. Neurobiol. Aging, 28:533-536 (2007).<\/p>\n

Corzo, L., Zas, R., Rodr\u00edguez, S., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Decreased levels of serum nitric oxide in different forms of dementia. Neurosci. Lett., 420:263-267 (2007).<\/p>\n

Cacabelos, R (Ed.). Cholinesterase inhibitors in Dementia. Ten years of Donepezil in Alzheimer\u2019s Disease and CNS Disorders (1996-2006): Therapeutic Assessment and Pharmacogenetics. Gen-T\/The EuroEspes Journal, Suppl. 1:1-52 (2007).<\/p>\n

Cacabelos, R., Llovo, R., Fraile, C., Fern\u00e1ndez-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer\u2019s disease pharmacogenetics. Cur. Alzheimer Res., 4:479-500 (2007).<\/p>\n

Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer\u2019s disease. Mol. Diag. Ther., 11:385-405 (2007).<\/p>\n

Takeda, M., Cacabelos, R., Ray, O., F\u00f6rstl, H., Hoon Oh, B. Dementia in the World. Cogn. Dementia, 2:53-63 (2007).<\/p>\n

Harguindey, S., Orive, G., Cacabelos, R., Mel\u00e9ndez Hevia, E., D\u00edaz de Otazu, R., Arranz, J.L., Anitua, E. An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiat. Dis. Treat., 4:1073-1087 (2008).<\/p>\n

Cacabelos, R. Application of nutrigenomics to Alzheimer\u2019s disease. AgroFood, 19:37-40 (2008).<\/p>\n

Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 258(Suppl. 1):28-47 (2008).<\/p>\n

Cacabelos, R. Influence of pharmacogenetic factors on Alzheimer\u2019s disease therapeutics. Neurodegenerative Dis., 5:176-178 (2008).<\/p>\n

Cacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. Meth Mol. Biol., 448:213-357 (2008).<\/p>\n

Cacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. In: Pharmacogenomics and Personalized Medicine. Cohen, N. (Ed.). pp. 317-368 (2008).<\/p>\n

Cacabelos, R. Pleiotropic effects of Apolipoprotein E in dementia: Influence on functional genomics and pharmacogenetics. Adv. Behav. Biol., 57:355-367 (2008).<\/p>\n

\u00c1lvarez, X.A., Sampedro, C., Figueroa, J., Tellado, I., Gonz\u00e1lez, A., Garc\u00eda-Fantini, M., Cacabelos, R., Muresanu, D., Moessler, H. Reductions in qEEG slowing over 1 year and after treatment with cerebrolysin in patients with moderate-severe traumatic brain injury. J. Neural Transm., 115:683-692 (2008).<\/p>\n

\u00c1lvarez, X.A., Sampedro, C., Cacabelos, R., Linares, C., Aleixandre, M., Garc\u00eda-Fantini, M., Moessler, H. Reduced TNF-\u03b1 and increased IGF-I levels in the serum of Alzheimer\u2019s disease patients treated with the neurotrophic agent Cerebrolysin. Int. J. Neuropsychopharmacol., 12:867-872 (2009).<\/p>\n

Cacabelos, R. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Vol. IV: Molecular Genetic and Genomic Markers. Ritsner, M.S. (Ed.). Springer, pp. 3-63 (2009).<\/p>\n

Cacabelos, R., Mart\u00ednez-Bouza, R., Fern\u00e1ndez-Novoa, L., Carril, J.C., Llovo, R., Tellado, I., Corzo, L., Fraile, C., Cacabelos, N., Bello, A., McKay, A., Bermo, A., Carrera, I., \u00c1lvarez, A., Lombardi, V. Personalized medicine of dementia. Pharmacogenomics of Alzheimer\u2019s disease. Gen-T\/The EuroEspes Journal, 4:18-48 (2009).<\/p>\n

Lombardi, V.R.M., Mart\u00ednez, E., Chacon, R., Etcheverr\u00eda, I., Cacabelos, R. Effects of FR-91 on human tumor cell lines. Gen-T\/The EuroEspes Journal, 4:50-60 (2009).<\/p>\n

Cacabelos, R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diag., 9:567-611 (2009).<\/p>\n

Lombardi, V.R.M., Mart\u00ednez, E., Chac\u00f3n, R., Etcheverr\u00eda, I., Cacabelos, R. Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma. J. Biomed. Biotech., DOI: 10.1155\/2009\/187015 (2009).<\/p>\n

Cacabelos, R. Pharmacogenomic protocols in CNS disorders and dementia. Neurodegenerative Dis., 7:167-169 (2010).<\/p>\n

Cacabelos, R., Mart\u00ednez-Bouza, R. Genomics and pharmacogenomics of schizophrenia. CNS Neuroscience & Therapeutics. DOI: 10.111_j.1755-5949.2010.00187.<\/p>\n

Cacabelos, R., Mart\u00ednez-Bouza, R. Genomics and pharmacogenomics of dementia. CNS Neurosciences & Therapeutics. DOI: 10.111_j.1755-5949.2010.00189.<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Mart\u00ednez-Bouza, R., McKay, A., Carril, J.C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., Alcaraz, M., Rodr\u00edguez, S., Casas, A., Couceiro, V., Alvarez, A. Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. Pharmaceuticals 3:3040-3100 (2010); doi: 10.3390\/ph3103040.<\/p>\n

Cacabelos, R., Mart\u00ednez-Bouza, R., Carril, J.C., Fern\u00e1ndez-Novoa, L., Llovo, R., Carrera, I., Corzo, L., Fraile, C., Telladi, I., McKay, A., Bello, A., Cacabelos, N., Lombardi, V. Tarjeta Farmacogen\u00e9tica EuroEspes: La personalizaci\u00f3n del tratamiento farmacol\u00f3gico. Gen-T 5:36-60 (2010).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Mart\u00ednez-Bouza, R., Carril, R., Carrera, I., Fraile, C., Tellado, I., Corzo, L., Lombardi, V. Los genes de la locura. Gen\u00f3mica de la esquizofrenia y los trastornos psic\u00f3ticos. Gen-T 6:34-57 (2010).<\/p>\n

Takeda, M., Mart\u00ednez, R., Kudo, T., Tanaka, T., Okochi, M., Tagami, S., Morihara, T., Hashimoto, R., Cacabelos, R. Apolipoprotein E and central nervous system disorders: Reviews of clinical findings. Psychiat Clin Neurosci 64:592-607 (2010).<\/p>\n

Lombardi, V.R.M., Cacabelos, R. Neuron-Glia interactions and neurodegeneration. Psychogeriatria Polska 7(4):115-130 (2010).<\/p>\n

Cacabelos, R. Genomics of psychosis. Gen-T (EuroEspes J Int Ed) 3:3 (2011).<\/p>\n

Cacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Carril, J.C., Corzo, L., Carrera, I., Tellado, I., Mart\u00ednez, R., McKay, A., Takeda, M. Genomics of schizophrenia and psychotic disorders. Gen-T (EuroEspes J Int Ed) 3:6-86 (2011).<\/p>\n

Carril, J.C., Mart\u00ednez-Bouza, R., Fern\u00e1ndez-Novoa, L., Carrera, I., Corzo, L., Fraile, C., Tellado, I., McKay, A., Bello, A., Lombardi, V., Cacabelos, R. The EuroEspes Pharmacogenetic Card. Personalization of pharmacological treatment. Gen-T (EuroEspes J Int Ed) 3:88-118 (2011).<\/p>\n

Carrera, I., Lombardi, V.R.M., Etcheverr\u00eda, I., Mart\u00ednez, E., Chac\u00f3n, R., Cacabelos, R. Prevenci\u00f3n de colitis experimental cr\u00f3nica inducida por dextr\u00e1n sulfato s\u00f3dico (DSS) en ratones tratados con FR-91. Gen-T 7:19-30 (2011).<\/p>\n

Cacabelos, R., Mart\u00ednez-Bouza, R., Tellado, I., Alcaraz, M., Nebril, L., Casas, A., Gonz\u00e1lez, Y., L\u00f3pez, L., Couceiro, V., Fraile, C., Rodr\u00edguez, S., Corzo, L., Carril, J.C., Lombardi, V., Carrera, I., Fern\u00e1ndez-Novoa, L. Estados depresivos. Gen-T 7:42-74 (2011).<\/p>\n

Carrera, I., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Lombardi, V., Vigo, C., Cacabelos, R. Desarrollo de la vacuna EuroEspes EB101 contra la enfermedad de Alzheimer. Gen-T 8: 38-52 (2011).<\/p>\n

Cacabelos, R. Alzheimer\u2019s disease 2011: Where are we heading. Gen-T 8:54-86 (2011).<\/p>\n

Cacabelos, R. Pharmacogenomics of Alzheimer\u2019s disease. Metabolomics 1:3, 1000106e (2011). http:\/\/dx.doi.org\/10.4172\/2153-0769.1000106e.<\/p>\n

Alvarez, X.A., Cacabelos, R., Sampedro, C., Couceiro, V., Aleixandre, M., Vargas, M., Linares, C., Granizo, E., Garc\u00eda-Fantini, M., Baurecht, W., Doppler, E., Moessler, H. Combination treatment in Alzheimer\u2019s disease: Results of a randomized, controlled trial with cerebrolysin and donepezil. Cur Alzheimer Res 8:583-591 (2011).<\/p>\n

Alvarez, X.A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., Doppler, E., Moessler, H. Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer\u2019s disease: results of a randomized, doubled-blind, controlled trial investigating three dosages of cerebrolysin. Eur J Neurol 18:59-68 (2011).<\/p>\n

Cacabelos, R., Hashimoto, R., Takeda, M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiat Clin Neurosci 65:3-19 (2011).<\/p>\n

Cacabelos, R., Mart\u00ednez-Bouza, R., Carril, J.C., Fern\u00e1ndez-Novoa, L., Lombardi, V., Carrera, I., Corzo, L., McKay, A. Genomics and pharmacogenomics of brain disorders. Current Pharmaceutical Biotechnology 13:674-725 (2012).<\/p>\n

Lombardi, V.R.M., Etcheverr\u00eda, I., Carrera, I., Cacabelos, R., Chac\u00f3n, A. Prevention of chronic experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91. J. Biomed. Biotech., (2012). Doi:10.1155\/2012\/826178.<\/p>\n

Cacabelos, R., Mart\u00ednez, R., Fern\u00e1ndez-Novoa, L., Carril, J.C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., Takeda, M. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Intern. J. Alzheimer Dis., (2012). Doi:10.1155\/2012\/518901.<\/p>\n

Carrera I., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Lombardi, V., Cacabelos, R., Vigo, C. Vaccine development to treat Alzheimer\u2019s disease neuropathology in APP\/PS1 transgenic mice. Intern. J. Alzheimer Dis., (2012). Doi:10.1155\/2012\/376138.<\/p>\n

Canuet, L., Tellado, I., Couceiro, V., Fraile, C., Fern\u00e1ndez-Novoa, L., Ishii, R., Takeda, M., Cacabelos, R. Resting-state network disruption and APOE genotype in Alzheimer\u2019s disease: A lagged functional connectivity study. PLoS ONE (2012) 7(9): e46289. Doi:10.1371\/journal.pone.0046289.<\/p>\n

Cacabelos, R. Pharmacogenomics of central nervous system (CNS) drugs. Drug Development Research, 73:461-476 (2012).<\/p>\n

Cacabelos, R. The metabolomics paradigm of pharmacogenomics in complex disorders. Metabolomics (2012), 2:5. http\/\/dx.doi.org\/10.4172\/2153-0769.1000e119.<\/p>\n

Cacabelos, R., Cacabelos, P., Aliev, G. Genomics and pharmacogenomics of antipsychotic drugs. Open J. Psychiatry 3:46-139 (2013). Doi:10.4236\/ojpsych.2013.31008.<\/p>\n

Romero, A., Cacabelos, R., Oset-Gasque, M.J., Samadi, A., Marco-Contelles, J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer\u2019s disease. Bioorganic & Medicinal Chemistry Lett., (2013). Doi: http:\/\/dx.doi.org\/10.1016\/j.bmcl.2013.02.017.<\/p>\n

Carrera, I., Cacabelos, R. Novel immunotherapeutic procedures for prevention of Alzheimer\u2019s disease. Drug Des., 2013, 2:2. http:\/\/dx.doi.org\/10.4172\/2169-0138.1000107.<\/p>\n

Aliev, G., Obrenovich, M.E., Tabrez, S., Jabir, N.R., Reddy, V.P., Li, Y., Burnstock, G., Cacabelos, R., Kamal, M.A. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxidative Medicine and Cellular Longevity (2013). http:\/\/dx.doi.org\/10.1155\/2013\/962984.<\/p>\n

Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer. Drug Des., (2013), 2:1. http:\/\/dx.doi.org\/10.4172\/2169-0138.1000103.<\/p>\n

Carrera, I., Etcheverr\u00eda, I., Li, Y., Fern\u00e1ndez-Novoa, L., Lombardi, V., Vigo, C., Palacios, H.H., Benberin, V., Cacabelos, R., Aliev, G. Immunocytochemical characterization of Alzheimer disease hallmarks in APP\/PS1 transgenic mice treated with a new anti-amyloid-\u03b2 vaccine. BioMed Research International (2013). http:\/\/dx.doi.org\/10.1155\/2013\/709145.<\/p>\n

Torrellas, C., Fraile, C., Carril, J.C., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Importancia de la farmacogen\u00e9tica en el tratamiento de la hypertension arterial. Gen-T (EuroEspes J.), 9:15-30 (2013).<\/p>\n

Corzo, L., Rodr\u00edguez, S., Lombardi, V., Alejo, R., Cacabelos, R. Propiedades biol\u00f3gicas de Mineraxin. Gen-T (EuroEspes J.), 9:31-40 (2013).<\/p>\n

Romero, A., Cacabelos, R., Marco-Contelles, J. Derivados de tacrina contra la enfermedad de Alzheimer. Gen-T (EuroEspes J.), 9:57-64 (2013).<\/p>\n

Canuet, L., Tellado, I., Couceiro, V., Fraile, C., Fern\u00e1ndez-Novoa, L., Ishii, R., Takeda, M., Cacabelos, R. Influencia del genotipo APOE sobre la actividad cerebral en la enfermedad de Alzheimer. Gen-T (EuroEspes J.), 9:65-74 (2013).<\/p>\n

Fern\u00e1ndez-Novoa, L., Corzo, L., Seoane, S., Cacabelos, R. Histamina:una mol\u00e9cula polifac\u00e9tica. Gen-T (EuroEspes J.), 9:75-86 (2013).<\/p>\n

Cacabelos, R. Primera Gu\u00eda Mundial de Farmacogen\u00f3mica. Del genoma humano a los retos futuros de la medicina gen\u00f3mica. Gen-T (EuroEspes J.), 9:89-114 (2013).<\/p>\n

Carril, J.C., Seoane, S., Cacabelos, R. Utilidad de la familia de enzimas CYP3A4 como marcadores de inter\u00e9s en farmacogen\u00e9tica. Gen-T (EuroEspes J.), 9:115-124 (2013).<\/p>\n

Tellado, I., Canuet, L., Cacabelos, R. Farmacogen\u00f3mica de los agentes transportadores SLC. Gen-T (EuroEspes J.), 9:125-142 (2013).<\/p>\n

Lombardi, V.R.M., Cacabelos, R. Nuevas dianas terap\u00e9uticas en la lucha contra el cancer. Gen-T (EuroEspes J.), 9:143-154 (2013).<\/p>\n

Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA, Benberin VV, Bachurin SO. Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease. Curr Med Chem. 2013 Dec 27. [Epub ahead of print].<\/p>\n

Cacabelos R, Cacabelos P, Torrellas C, Carrera I. Inmunoterapia en la enfermedad de Alzheimer: Vacunas y farmacogen\u00f3mica. Cuadernos de Autoinmunidad 2014; 7(1):42-54.<\/p>\n

Cacabelos R, L\u00f3pez-Mu\u00f1oz F. The ABCB1 transporter in Alzheimer\u2019s disease. Clin Exp Pharmacol 2014; 4: e128. Doi:10.4172\/2161-1459.1000e128.<\/p>\n

Torrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenetics in the management of hypertension. J Pharmacogenomics Pharmacoproteomics 2014; 5: 126. Doi:10.4172\/2153-0645.1000126.<\/p>\n

Siest G, Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. Pharmacogenomics: from cell to clinic (Part 1). Pharmacogenomics. 2014 Apr;15(5):593-9. doi: 10.2217\/pgs.14.35.<\/p>\n

Siest G, Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. Conference scene: pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics. 2014 Apr;15(6):739-44. doi: 10.2217\/pgs.14.36.<\/p>\n

Cacabelos R. The pathogenic component of the APOE-TOMM40 region in Alzheimer\u2019s disease: Its implications in Metabolomics and Pharmacogenomics. Metabolomics 2014; 4: 1000e129. Doi:10.4172\/2153-0769.1000e129.<\/p>\n

Cacabelos R. Metabolomics of epigenetic drugs: precautionary measures. Metabolomics 2014; 4: e126. Doi:10.4172\/2153-0769.1000e126.<\/p>\n

Cacabelos R, Torrellas C, L\u00f3pez-Mu\u00f1oz F. Epigenomics of Alzheimer\u2019s disease. J Exp Med 2014; 6(3):75-82. http:\/\/dx.doi.org\/10.1016\/j.jecm.2014.03.010.<\/p>\n

Cacabelos R1, Torrellas C. Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov. 2014 Sep;9(9):1059-86. doi: 10.1517\/17460441.2014.930124. Epub 2014 Jul 3.
\nSee comment in PubMed Commons below
\nCacabelos R1, Cacabelos P, Torrellas C, Tellado I, Carril JC. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323-556. doi: 10.1007\/978-1-4939-0956-8_13.<\/p>\n

Cacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res. 2014 Sep;75(6):348-65. doi: 10.1002\/ddr.21219.<\/p>\n

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, Corzo D, Carril JC, Roses AD. APOE-TOMM40 in the Pharmacogenomics of demetia. J Pharmacogenomics Pharmacoproteomics 2014; 5: 135. Doi:10.4172\/2153-0645.1000135.<\/p>\n

Cherif O, Allouche F, Chabchoub F, Chioua M, Soriano E, Y\u00e1\u00f1ez E, Cacabelos R, Romero A, L\u00f3pez MG, Marco-Contelles J. Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer\u2019s Disease. Future Med Chem 2014; 6(17):1883-1891.<\/p>\n

Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM,Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA, Benberin VV, Bachurin SO. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Current Medicinal Chemistry 2014; 21:2208-2217.<\/p>\n

Carrera I, Etcheverr\u00eda I, Fern\u00e1ndez-Novoa L, Lombardi VRM, Lakshmana MK, Cacabelos R, Vigo C. A comparative evaluation of a novel vaccine in APP\/PS1 mouse models of Alzheimer\u2019s Disease. BioMed Research International 2015; ID 807146. Dx.doi.org\/10.1155\/2015\/807146.<\/p>\n

Chioua M, P\u00e9rez M, Bautista-Aguilera OM, Y\u00e1\u00f1ez M, L\u00f3pez MG, Romero A, Cacabelos R, Puig de la Bellacasa R, Brogi S, Butini S, Borrell JI, Marco-Contelles J. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer\u2019s disease. Mini-Reviews in Medicinal Chemistry 2015; 15:648-658.<\/p>\n

Cacabelos R, Torrellas C, Carrera I. Opportunities in Pharmacogenomics for the treatment of Alzheimer\u2019s Disease. Future Neurology 2015; 10(3):229-252.<\/p>\n

Cacabelos R. New insights into the pathogenesis and pharmacogenomics of attention deficit hyperactivity disorder. Metabolomics 2015, 5:146. Doi:10.4172\/2153-0769.1000146.<\/p>\n

Cacabelos R.Pharmacoepigenomics and the metabolomics of drug efficacy and safety. Metabolomics 5:e140. Doi:10.4172\/2153-0760.10000e140.<\/p>\n

Cacabelos R, Goldgaber D, Roses AD, Vostrov A, Matsuki H, Torrellas C, Cacabelos P, Corzo D, Carril JC, Fern\u00e1ndez-Novoa L, Carrera I. Gene interactions in the Pharmacogenomics of Alzheimer\u2019s Disease. Sciforschen Genetics and Gene Therapy 2015; 1(1): http:\/\/dx.doi.org\/10.16966\/sggt.102.<\/p>\n

Perianes-Cachero A, Canellas S, Aguado-Llera D, Frago LM, Toledo-Lobo MV, Carrera I, Cacabelos R, Chowen JA,Argente J, Arilla-Ferreiro E, Barrios V. Reduction in A\u03b2-induced cell death in the hippocampus of 17\u03b2-estradiol-treated female rats is associated with an increase in IGF-1 signaling and somatostatinergic tone. J Neurochem 2015 (Oct 7) doi:10.1111\/jnc.13381.<\/p>\n

Cacabelos R, Torrellas C. Pharmacogenomics of antidepressants. HSOA Journal ofPsychiatry, Depression& Anxiety 2015; 1:001.<\/p>\n

Cacabelos R. Impact of genomic medicine on the future of Neuropsychopharmacology. J Neuropsychopharmacol Mental Health 2015, 1:1. Http:\/\/dx.doi.org\/10.4172\/jnpmh.1000e101.<\/p>\n

Cacabelos R. Epigenetic biomarkers in cancer. Clin Med Biochemistry 2015, 1:1. http:\/\/dx-doi.org\/10.4172\/cmbm.1000e101.<\/p>\n

Cacabelos R. Metabolomics of drug resistance in cancer: The Epigenetic Component. Metabolomics 2015;5:4. http:\/\/dx-doi-org\/10.4172-0769.1000e141.<\/p>\n

Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer\u2019s disease: Implications for pharmacogenomics and drug response. International Journal of Molecular Sciences 2015; 16:30483-30543; doi:10.3390\/ijms161226236.<\/p>\n

Cacabelos R. Proteoepigenomic biomarkers of brain disorders. Metabolomics 2015; 5: e143.
\ndoi:10.4172\/2153-0769.1000e143.<\/p>\n

Torrellas C, Risso A, Carril JC, Cacabelos R. Optimizaci\u00f3n del uso deantidepresivos con estrategias farmacogen\u00e9ticas. Gen-T 2015; 10:17-26.<\/p>\n

Ramos E, Marco Contelles J, Cacabelos R, Romero A. Potencial terap\u00e9utico de la melatonina en combinaci\u00f3n con otros f\u00e1rmacos frente a la neurodegeneraci\u00f3n. Gen-T 2015; 10:43-52.<\/p>\n

Del Coso J, Lara B, Salinero JJ, Areces F, Gallo-Salazar C, Ruiz-Vicente D, Cacabelos R. La importancia del sodio para el rendimiento y la salud del deportista. La fisiolog\u00eda del ejercicio y la gen\u00e9tica como elementos clave para el dise\u00f1o de las futuras bebidas deportivas y los suplementos nutricionales. Gen-T 2015; 10:63-71.<\/p>\n

Carril JC, Cacabelos R. La Tarjeta Farmacogen\u00e9tica Inteligente. Desarrollo de la nueva Tarjeta Farmacogen\u00e9tica EuroEspes para el tratamiento farmacol\u00f3gico personalizado. Gen-T 2015; 10:72-114.<\/p>\n

Tellado I, Carril JC, Couceiro V, Fraile C, Torrellas C, Cacabelos R. Impacto del genotipo AGT sobre la actividad cerebral en la demencia vascular. Gen-T 2015; 10:137-142.<\/p>\n

Aliev G1, Cacabelos R, Prakash Reddy V. Editorial: Metabolic Disorders, Drug Development, Drug Design and Biomarkers. Curr Pharm Des. 2015 Dec 27. [Epub ahead of print]<\/p>\n

Del Coso J1, Lara B1, Salinero JJ1, Areces F1, Ruiz-Vicente D1, Gallo-Salazar C1, Abi\u00e1n-Vic\u00e9n J1, Cacabelos R2. CFTR genotype-related body water and electrolyte balance during a marathon. Scand J Med Sci Sports. 2015 Aug 17. doi: 10.1111\/sms.12542. [Epub ahead of print<\/p>\n

Cacabelos R. Proteomic biomarkers in Alzheimer\u2019s disease. Diagn Pathol Open 2016; 1:1. http:\/\/dx.doi.org\/10.4172\/DPO.1000103.<\/p>\n

Cacabelos R. Nutriepigenomics: Mending ideas in nutrition, health and disease. J Nutr Sci 2016; 6:1. http:\/\/doi.org\/10.4172\/2155-9600.100e124.<\/p>\n

Cacabelos R1,2, Teijido O1,3, Carril JC1,4. Can cloud-based tools accelerate Alzheimer’s disease drug discovery? Expert Opin Drug Discov. 2016 Mar;11(3):215-23. doi: 10.1517\/17460441.2016.1141892. Epub 2016 Feb 3.<\/p>\n

Cacabelos R, Reddy VP, Aliev G1. Editorial: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications. CNS Neurol Disord Drug Targets. 2016;15(2):126.<\/p>\n

Cacabelos R1, Torrellas C, Carrera I, Cacabelos P, Corzo L, Fern\u00e1ndez-Novoa L, Tellado I, Carril JC, Aliev G. Novel Therapeutic Strategies for Dementia. CNS Neurol Disord Drug Targets. 2016;15(2):141-241.<\/p>\n

Cacabelos R. ADHD: Challenges for a better future. Gen-T International 2016; 4:3-5.<\/p>\n

Cacabelos R, Torrellas C, Tellado I, Cacabelos P. Genomics, pathogenesis, treatment and Pharmacogenomics of attention-deficit\/hyperactivity disorder. Gen-T International 2016; 4:8-134.<\/p>\n

Cacabelos R, Torrellas C, Fern\u00e1ndez-Novoa L, Aliev G. Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Curr Pharm Des. 2016;22(7):819-48.<\/p>\n

Carrera I1, Fernandez-Novoa L, Aliev G, Vigo C, Cacabelos R. Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine. Curr Pharm Des. 2016;22(7):849-58.<\/p>\n

Cacabelos R. Trial-and-Error versus Personalized Treatment in Depression: The Power of Pharmacogenomics. J Psychiatry Depress Anxiety 2016; 2:004.<\/p>\n

Cacabelos R. Histamine: The Missing Link in the Pathogenesis of Some Brain Disorders. Journal of Clinical and Experimental Neuroimmunology 2016; 1:1. http:\/\/dx.doi.org\/10.4172\/jceni.1000103.<\/p>\n

Cacabelos R. Epigenetics of Brain Disorders: The Paradigm of Alzheimer\u2019s disease. J Alzheimers Dis Parkinsonism 2016; 6:229. Doi: 10.4172\/2161-0460.1000220.<\/p>\n

Cacabelos R. The complexity of Alzheimer\u2019s disease pharmacogenomics and metabolomics in drug development. Metabolomics 2016; 2:6. http:\/\/dx-doi.org\/10.4172\/2153-0769.1000e145.<\/p>\n

Cap\u00edtulos de Libros y Monograf\u00edas<\/h2>\n

Cacabelos, R. Effect of social and individual factors on the inner organization and efficiency of a multidisciplinary Group. In: Naka, S. Ed. Proc. 10th World Cong. Soc. Psychiatry, Inter Group Corp., Osaka, pp. 140 (1984).<\/p>\n

Wada, H., Watanabe, T., Yamatodani, A., Cacabelos, R., Takeda, N., Itoi, N., Shiosaka, S., Tohyama, M., Kiyono, S., Seo, M., Nagai, K., Nakagawa, H. Distribution of the histaminergic neuron system and its physiological function in the rat brain. In: Proc. 13th Symp. Pharmacol. Act. Mechan., Kyoto, pp. 39-44 (1984).<\/p>\n

Cacabelos, R. Histamina cerebral. JANO Med. Hum., 636:40-42 (1984).<\/p>\n

Wada, H., Cacabelos, R. Introducci\u00f3n a la histamina cerebral. JANO Med. Hum., 636:43-54 (1984).<\/p>\n

Cacabelos, R. Papel de la histamina en el sistema neuroendocrino. JANO Med. Hum., 638:46-61 (1984).<\/p>\n

Cacabelos, R. Neurotransmisi\u00f3n histamin\u00e9rgica. JANO Med. Hum., 638:31-45 (1984).<\/p>\n

Cacabelos, R., Yamatodani, A., Watanabe, T., Hariguchi, S., Nishimura, T., Wada, H. Acciones centrales de la histamina. JANO Med. Hum., 638:62-85 (1984).<\/p>\n

Wada, H., Watanabe, T., Yamatodani, A., Maeyama, K., Itoi, N., Cacabelos, R., Seo, M., Kiyono, S., Nagai, K., Kanagawa, H. Physiological functions of histamine in the brain. In: Ganellin, C.R., Schwartz, J.C. (Eds.). Pergamon Press, Oxford, pp. 225-235 (1985).<\/p>\n

Nishimura, T., Niigawa, H., Cacabelos, R., Tada, K., Hariguchi, S. Changes in histamine and neuropeptides in dementia. In: Iizuka, R. (Ed.) Koseisho, Tokyo, pp. 97-106 (1986).<\/p>\n

Cacabelos, R., Niigawa, H., Ikemura, Y. Neuroendocrine correlates in senile dementia of the Alzheimer type. In: Sinha, K.K. (Ed.). Neurological Society of India, Catholic Press, Ranchi, 2:231-247 (1986).<\/p>\n

Cacabelos, R., Niigawa, H., Otero, F., Fern\u00e1ndez, M., Couto, D.F., Nishimura, T., Rodr\u00edguez, A. Disfunci\u00f3n neuropeptid\u00e9rgica en la enfermedad de Alzheimer: Estrategias neuroqu\u00edmicas con fines diagn\u00f3stico-terap\u00e9uticos. En: Seva D\u00edaz, A. (Ed.). Actas XIII R. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 341-348 (1988).<\/p>\n

Cacabelos, R. Actividad neurobiol\u00f3gica del GRF: Marcador diagn\u00f3stico en demencia senil y retraso mental. En: Tresguerres, J.F., Casanueva, F., S\u00e1nchez Franco, F., V\u00e1zquez, J.A. (Eds.). Posibilidades diagn\u00f3sticas del GRF(1- 29)NH2. Editorial Garsi, S.A., Madrid, pp. 99-122 (1989).<\/p>\n

Cacabelos, R. Acciones de los neurop\u00e9ptidos sobre el sistema nervioso central. En: Tresguerres, J.F. (Ed.). Fisiolog\u00eda endocrina, Endema, S.A., Madrid, pp. 571-649 (1989).<\/p>\n

Cacabelos, R. Marcadores diagn\u00f3sticos na demencia senil. Proc. I Xornada sobre Demencia Senil. Xunta de Galicia, Santiago de Compostela, pp. 47-63 (1989).<\/p>\n

Cacabelos, R. Alternativas terap\u00e9uticas na demencia senil. Proc I Xornada sobre Demencia Senil. Xunta de Galicia, Santiago de Compostela, pp. 85-101 (1989).<\/p>\n

Cacabelos, R. Demencia senil. Desafio biom\u00e9dico y sociosanitario. Monograf\u00edas M\u00e9dicas JANO, 3:255-266 (1989).<\/p>\n

Cacabelos, R., Couto, D.F., Otero, F., Albarr\u00e1n, M., P\u00e9rez, A., Fern\u00e1ndez, M., \u00c1lvarez, X.A. Demencia senil. Etiopatogenia. Monografias M\u00e9dicas JANO, 3:279-283 (1989).<\/p>\n

Cacabelos, R., Couto, D.F. Demencia senil. Neurobiolog\u00eda. Monografias M\u00e9dicas JANO, 3:285-295 (1989).<\/p>\n

Cacabelos, R., Rodr\u00edguez, A. Demencia senil. Cl\u00ednica. Monografias M\u00e9dicas JANO, 3:339-344 (1989).<\/p>\n

Cacabelos, R. Demencia senil. Marcadores diagn\u00f3sticos. Monografias M\u00e9dicas JANO, 3:347-354 (1989).<\/p>\n

Otero, F., Fern\u00e1ndez, M., Cacabelos, R. Demencia senil. Marcadores diagn\u00f3sticos perif\u00e9ricos. Monografias M\u00e9dicas JANO, 3:383-386 (1989).<\/p>\n

Albarr\u00e1n, M., P\u00e9rez, A., \u00c1lvarez, X.A., Ortiz, T., Rodr\u00edguez, A., Cacabelos, R. Marcadores neuropsicol\u00f3gicos en la enfermedad de Alzheimer. Monograf\u00edas M\u00e9dicas JANO, 3:357-363 (1989).<\/p>\n

Cacabelos, R., Otero, F., Fern\u00e1ndez, M., P\u00e9rez, A., Albarr\u00e1n, M., \u00c1lvarez, X.A., Couto, D.F., Niigawa, H., Nishimura, T., Rodr\u00edguez, A. Demencia senil. Alternativas terap\u00e9uticas. Monograf\u00edas M\u00e9dicas JANO, 3:403-414 (1989).<\/p>\n

Cacabelos, R., Otero, F., Fern\u00e1ndez, M., \u00c1lvarez, X.A., Albarr\u00e1n, M.A., P\u00e9rez, A., Borr\u00e1s, C.G., Rodr\u00edguez, A. Growth hormone-releasing factor [GRF(1-29)NH2]: Marcador diagn\u00f3stico en trastornos neuropsiqui\u00e1tricos. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 28-37 (1989).<\/p>\n

Albarr\u00e1n, M.A., P\u00e9rez, A., Cacabelos, R. Influencia del growth hormone-releasing factor (GRF) sobre hormona de crecimiento (GH) en pacientes con retraso mental (RM). Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 38-43 (1989).<\/p>\n

Lorenzo Lago, A,, Cacabelos, R., Pardi\u00f1as, M.C., Salazar Bernard, I., Rodr\u00edguez L\u00f3pez, A. Marcadores biol\u00f3gicos en el alcoholismo: Transferrina y GRF. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 43-46 (1989).<\/p>\n

Cacabelos, R., Niigawa, H., Nishimura, T. Eficacia terap\u00e9utica del growth hormone-releasing factor (GRF) en demencia senil: Estudios en un modelo animal de enfermedad de Alzheimer y resultados cl\u00ednicos preliminares. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 88-94 (1989).<\/p>\n

P\u00e9rez, A., Otero, F., \u00c1lvarez, X.A., Fern\u00e1ndez, M., Albarr\u00e1n, M.A., Cacabelos, R. Estudio bioqu\u00edmico de fluidos corporales en pacientes con demencia senil tipo Alzheimer y demencia multiinfarto. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 95-102 (1989).<\/p>\n

Fern\u00e1ndez, M., Otero, F., \u00c1lvarez, X.A., P\u00e9rez, A., Albarr\u00e1n, M.A., Niigawa, H., Nishimura, T., Cacabelos, R. Respuesta de GH a GRF en pacientes con demencia senil tipo Alzheimer. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 103-108 (1989).<\/p>\n

Otero, F., Fern\u00e1ndez, M., P\u00e9rez, A., Albarr\u00e1n, M., \u00c1lvarez, X.A., Ver\u00edsimo, J., Serrano, F., P\u00e9rez, T., Di\u00e9guez, C., Fraiz, J., Lois, J.L., Borr\u00e1s, C.G., Rodr\u00edguez, A., Cacabelos, R. Eficacia diagn\u00f3stica del test de GRF en trastornos psiqui\u00e1tricos. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 602-608 (1989).<\/p>\n

\u00c1lvarez, X.A., Fern\u00e1ndez, M., Otero, F., Albarr\u00e1n, M.A., P\u00e9rez, A., Couto, D.F., Ver\u00edsimo, J., Otero, T., P\u00e9rez, T., Serrano, F., Di\u00e9guez, C., Borr\u00e1s, C.G., Salazar, I., Lorenzo, A., Rodr\u00edguez, A., Cacabelos, R. Growth hormone-releasing factor (GRF): Marcador diagn\u00f3stico en neuropatolog\u00eda alcoh\u00f3lica. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 662-668 (1989).<\/p>\n

Cacabelos, R., P\u00e9rez, A., Fern\u00e1ndez, M., Otero, F., \u00c1lvarez, X.A., Albarr\u00e1n, M. Neuroendocrine markers in Alzheimer\u2019s disease: New prospects for diagnosis and treatment. In: Recent advances in basic and clinical neuroendocrinology. Casanueva, F.F., Di\u00e9guez, C. (Eds.). Elsevier Science Publishers, Amsterdam, pp. 383-391 (1989).<\/p>\n

Cacabelos, R. Neuroendocrinolog\u00eda en la enfermedad de Alzheimer. En: Marcadores biol\u00f3gicos y perspectivas terap\u00e9uticas en la enfermedad de Alzheimer. Acar\u00edn, N., Alom, J. (Eds.). MCR Ed., Barcelona, pp. 55-68 (1989).<\/p>\n

Cacabelos, R., Otero, F., Fern\u00e1ndez, M., Fari\u00f1as, F., \u00c1lvarez, X.A. Marcadores neuroqu\u00edmicos para el diagn\u00f3stico diferencial entre depresi\u00f3n involutiva y demencia senil. En: Las depresiones en el anciano. PTD-Espa\u00f1a. Espaxs, S.A., Barcelona, pp. 53-91 (1990).<\/p>\n

Rodr\u00edguez. A., Cacabelos, R., Mateos, R. Estrategias epidemiol\u00f3gicas en el estudio de la enfermedad de Alzheimer. En: Aspectos actuales del envejecimiento normal y patol\u00f3gico. Hayflick, L., Barcia, D., Miquel, J. (Eds.). ELA, Ar\u00e1n Ed., Madrid, pp. 105-112 (1990).<\/p>\n

Cacabelos, R. Marcadores neuroqu\u00edmicos en la enfermedad de Alzheimer. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 39-59 (1990).<\/p>\n

Rodr\u00edguez, A., Mateos, R., Cacabelos, R., Mazaira, J. Diagn\u00f3stico evolutivo de los cuadros demenciales. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 262-276 (1990).<\/p>\n

Albarr\u00e1n, M.A., Salazar, I., P\u00e9rez, I., Rodr\u00edguez, A., Cacabelos, R. Hiporrespuesta de GH a GRF en toxic\u00f3manos. Actas X1V Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 466-472 (1990).<\/p>\n

P\u00e9rez, A., Fern\u00e1ndez, M., Cornes, J.M., Albarr\u00e1n, M.A., Cacabelos, R. Respuesta de GH a GRI: (Growth hormone releasing factor) en pacientes con demencia multiinfarto (DMI). Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 473-480 (1990).<\/p>\n

Fern\u00e1ndez, M., Di\u00e9guez, C., Cornes, J.M., Cacabelos, R. Respuesta de GH a GRF en trastornos depresivos. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 481-486 (1990).<\/p>\n

Otero, F., Tortajada, I., Alonso, J., Blanco, J., Tabernero, J., Agra, S., Cornes, J.M., Di\u00e9guez, C., Cacabelos, R. Test de GRF: Potencial marcador diagn\u00f3stico en esquizofrenia. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 487-490 (1990).<\/p>\n

Cacabelos, R. Bases neuroqu\u00edmicas y psicofarmacol\u00f3gicas de la drogadicci\u00f3n. En: Drogodependencias y Sociedad. Fundaci\u00f3n Caixa Galicia, pp. 119-145 (1990).<\/p>\n

Cacabelos, R. Histaminergic regulation of the neuroendocrine system. En: Histaminergic Neurons: Morphology and Functions. Ch.14. Watanabe, T., Wada, H. (Eds.). CRC, Florida, pp. 241-270 (1991).<\/p>\n

Cacabelos, R., Rubia, F.J. Perspectivas neurobiol\u00f3gicas en hiperquinesia infantil. En: Neurotransmisi\u00f3n y plasticidad sin\u00e1ptica. Esquerda, J.E., Gallego, R., Gual, A., Ram\u00edrez, G., Rubia, F. Spaxs, Barcelona, pp. 261-291 (1991).<\/p>\n

Cacabelos, R., Franco-Maside, A., \u00c1lvarez, X.A. Neurobiolog\u00eda de la histamina cerebral. En: Biopatolog\u00eda de los sistemas histamin\u00e9rgicos cerebrales. Varela de Seijas, E. Duphar Pharmaceutica Ed., Madrid, pp. 11-48 (1991).<\/p>\n

Rubia, F.J., Mart\u00edn-Loeches, M., Gil, P., Exp\u00f3sito, F.J., Miguel, F., Cacabelos, R. Mapas de actividad el\u00e9ctrica cerebral en la demencia senil de tipo Alzheimer y en la demencia cerebrovascular durante tareas cognoscitivas. En: Bases neuroqu\u00edmicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar Ibabe, M.C. (Eds.). Univ. Granada, pp. 113-131 (1991).<\/p>\n

Mart\u00edn-Loeches, M., Gil, P., Miguel, F., Exp\u00f3sito, F.J., Cacabelos, R., Rubia, F.J. Potenciales evocados tard\u00edos en la enfermedad de Alzheimer. En: Bases neuroqu\u00edmicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar lbabe, M.C. (Eds.). Univ. Granada, pp. 133-148 (1991).<\/p>\n

Cacabelos, R., Rubia, F.J. Alteraciones neuroqu\u00edmicas en la enfermedad de Alzheimer. En: Bases neuroquimicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar Ibabe, M.C. (Eds.). Univ. Granada, pp. 289-312 (1991).<\/p>\n

Cacabelos, R. Nuevas estrategias terap\u00e9uticas en la enfermedad de Alzheimer: psicofarmacolog\u00eda molecular de los agentes nootropos y potencial utilidad de los factores neurotr\u00f3ficos. En; Proc. II Reun. Nac. Soc. Esp. Gerontopsiquiat. Psicogeriat., Bobes Garc\u00eda, J., Ar\u00e1n Ed., Madrid, pp. 57-78 (1991).<\/p>\n

Cacabelos, R. Avances en la enfermedad de Alzheimer. En: Gerontolog\u00eda 1992. Jim\u00e9nez Herrero, F. (Ed.). CEA Ed., Madrid, pp. 69-82 (1991).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A. Funci\u00f3n neuroinmune en trastornos mentales. Actas XV Reun. Soc. Esp. Psiq. Biol., C\u00f3rdoba, 1-3.XI.91. ELA, Madrid, 1:7-14 (1991).<\/p>\n

Cacabelos, R., Franco-Maside, A., \u00c1lvarez, X.A. Influence of the somatotropinergic system on mental function and psychomotor activity: Environmental factors, development, cognition, and neuropsychiatric disorders. In: Human Growth: Basic and Clinical Aspects. Hern\u00e1ndez, M., Argente, J. (Eds.). Elsevier, Amsterdam, pp. 161-172 (1992).<\/p>\n

Cacabelos, R. Brain histamine: Psychoneuroimmune regulator in physiological and pathological conditions. In: Proc. 1st Int. Congr. Vitamins and Biofactors in Life Sciences. Kobayashi, T., Ed. Center For Academic Publications, Japan, pp. 573-576 (1992).<\/p>\n

Cacabelos, R. Neurobiolog\u00eda molecular de la enfermedad de Alzheimer: Prospecciones terap\u00e9uticas. En: Actas I Simposio de Psicobiolog\u00eda. P\u00e1saro, E. Ed. Serv. Public. Univ. Coru\u00f1a, pp. 27-51 (1992).<\/p>\n

Cacabelos, R. Neurobiolog\u00eda del GRF: Aspectos b\u00e1sicos y aplicaciones cl\u00ednicas. En: P\u00e9ptidos reguladores gastrointestinales. Bl\u00e1zquez, E., Tamarit, J. (Eds.). Fundaci\u00f3n Areces, Madrid, pp. 185-204 (1992).
\nCacabelos, R., Frey, H., Nishimura, T., Winblad, B. Educational pathways for neurogerontology and psychogeriatrics. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 7-9 (1993).<\/p>\n

Cacabelos, R. Neurobiology of aging. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 33-38 (1993).<\/p>\n

G\u00f3mez, M.J., Cacabelos, R. Neuropsychological markers in psychogeriatrics. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T. Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 67-69 (1993).<\/p>\n

Franco-Maside, A., Cacabelos, R. Brain mapping in psychogeriatrics. In: I lnternational Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.) EuroEspes Foundation, La Coru\u00f1a, pp. 71-76 (l993).<\/p>\n

Caama\u00f1o, J., Cacabelos, R. Transcranial Doppler sonography in psychogeriatrics. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 77-82 (1993).<\/p>\n

\u00c1lvarez, X.A., Cacabelos, R. Effects of S-9977-2 on learning, behavior, and serum and brain interleukin-1\uf062 levels in rats. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 203- 206 (1993).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of Anapsos on behavior and brain cytokines in rats. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 211-214 (1993).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Novo, B., G\u00f3mez, M.J., Zas, R., Rettori, M.C., Kamoun, A., Polo, E., Garc\u00eda, M., Cacabelos, R. Effects of S-9977-2 on behavior and brain interleukin-1\uf062. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 219 (1993).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Zas, R., Novo, B., Cacabelos, R. Effects of anapsos on behavior and brain cytokines. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 220 (1993).<\/p>\n

\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Novo, B., G\u00f3mez, M.J., Zas, R., Cacabelos, R. Age-dependent variations in serum interleukin-1\uf062 and tumor necrosis factor alpha levels in humans. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 221 (1993).<\/p>\n

Caama\u00f1o, J., Franco, A., G\u00f3mez, M.J., Novo, B., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Acute effects of CDP-Choline on middle cerebral artery blood flow velocities in Alzheimer\u2019s disease: A transcranial Doppler study. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 222 (1993).<\/p>\n

Caama\u00f1o, J., Franco, A., G\u00f3mez, M.J., Novo, B., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Cerebrovascular effects of CDP-choline in patients with Alzheimer\u2019s disease: A transcranial Doppler study. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 223 (1993).<\/p>\n

Franco-Maside, A., Caama\u00f1o, J., G\u00f3mez, M.J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Novo, H., Cacabelos, R. CDP-Choline-induced brain mapping changes in patients with Alzheimer\u2019s disease. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 224 (1993).<\/p>\n

Franco-Maside, A., Caama\u00f1o, J., Cacabelos, R. Brain electrical activity mapping correlates with cerebral blood flow velocity in Alzheimer\u2019s disease. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 225 (1993).<\/p>\n

G\u00f3mez, M.J., Cacabelos, R. Relationship between word recall and location in a ten-word list of the Alzheimer\u2019s Disease Assessment Scale. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 227 (1993).<\/p>\n

G\u00f3mez, M.J., \u00c1lvarez, X.A., Cacabelos, R. Dementia mood assessment scale in elderly controls and in patients with depression and\/or cognitive impairment. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 228 (1993).<\/p>\n

Cacabelos, R., \u00c1lvarez, X.A., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J. Influence of CDP-choline on cognition and interleukin-1\uf062 in Alzheimer\u2019s disease and multi-infarct dementia. In: Alzheimer\u2019s disease and related disorders. Nicolini, M., Zatta, P.F., Corain, B. (Eds.). Advances in Biosciences. Vol. 87. Pergamon Press, London, pp. 347-348 (1993).<\/p>\n

Cacabelos, R. Etiopatogenia de la enfermedad de Alzheimer. En: Demencia: Un nuevo reto para la asistencia de ancianos. J.C. Caballero Garc\u00eda, Ed. Barcelona, pp. 43-57 (1993).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Bases etiopatog\u00e9nicas para nuevas estrategias terap\u00e9uticas. En: Neuroinmunoprotecci\u00f3n en la demencia senil. Estrategias terap\u00e9uticas pleiotr\u00f3picas en la enfermedad de Alzheimer. Grupo ASAC. Alicante, pp. 9-39 (1994).<\/p>\n

Cacabelos, R. Diagnosis of Alzheimer\u2019s disease. Definition of AD phenotype\/genotype. The Karolinska Institute Postgraduate Education Series. Alzheimer\u2019s disease: Advances in Research and Clinical Practice. Winblad, B., Nordberg, A. (Eds.). pp. 42-45 (1994).<\/p>\n

Cacabelos, R. New strategies for Alzheimer\u2019s disease treatment: Pleiotropic drugs and multifactorial intervention. In: Alzheimer Disease: Therapeutic Strategies. E. Giacobini, R. Becker. (Eds.). Birkhauser, Boston, pp. 493-498 (1994).<\/p>\n

Cacabelos, R., Caama\u00f1o, J., G\u00f3mez, M.J., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer\u2019s disease: Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. In: The Neurobiology of Alzheimer\u2019s Disease. Crowdon, J.H., Nitsch R.M., Corkin S., Wurtman R.J. (Eds.). Proc. Eighth Meeting International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Zurich, pp. 471-475 (1995).<\/p>\n

Cacabelos, R. IRIS Ed. Newsletters 4:1 (1995).<\/p>\n

Cacabelos, R. Demencia senil. Enfermedad de Alzheimer. Estrategias terap\u00e9uticas. Grupo ASAC (1995).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Etiopatogenia y tratamiento actual. Proc. V Congreso Comunidad Valenciana M\u00e9dicos Rurales y Generalistas. Para una mejor Sanidad en la Comunidad. Soc. Espa\u00f1ola de Medicina Rural y Generalista. SEMERGEN, pp. 69-74 (1995).<\/p>\n

G\u00f3mez, M.J., Caama\u00f1o, J., Vinagre, D., Cacabelos, R. Evaluaci\u00f3n neuropsicol\u00f3gica de la demencia senil. 7\u00ba Curso de Geriatr\u00eda \u201cCiudad de San Sebasti\u00e1n\u201d. Fundaci\u00f3n Matia, pp. 65-91 (1995).<\/p>\n

Caama\u00f1o, J., Vinagre, D., G\u00f3mez, M.J., Franco, A., Cacabelos, R. Demencia: Diagn\u00f3stico diferencial. 7\u00ba Curso de Geriatr\u00eda \u201cCiudad de San Sebasti\u00e1n\u201d. Fundaci\u00f3n Matia, pp. 92-119 (1995).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. 7\u00ba Curso de Geriatr\u00eda \u201cCiudad de San Sebasti\u00e1n\u201d. Fundaci\u00f3n Matia, pp. 153-171 (1995).
\nCacabelos, R. Enfermedad de Alzheimer: Experiencia Cl\u00ednica con Citicolina. Baliarda, Buenos Aires, 1995.<\/p>\n

Cacabelos, R. Demencia senil. Enciclopedia Iberoamericana de Psiquiatr\u00eda. Macropedia. Vol II:359-381 (1995).
\nCacabelos, R. Enfermedad de Alzheimer: Factores etiopatog\u00e9nicos y evaluaci\u00f3n gen\u00e9tica. Programa de Formaci\u00f3n permanente. Federaci\u00f3n Farmac\u00e9utica, Valencia, A\u00f1o II, Tomo 10:1-40.
\nCacabelos, R. Claridad mental y autonom\u00eda de comportamiento. Aprender a envejecer sano y activo. IMSERSO. Instituto de Ciencias del Hombre. Madrid, pp. 27-29 (1996).<\/p>\n

Cacabelos, R. Bases moleculares del envejecimiento cerebral. En: Temas de Gerontolog\u00eda II. Universidad de Granada\/Ministerio de Trabajo y Asuntos Sociales, pp. 29-41 (1997).
\nCacabelos, R. Bases biol\u00f3gicas del envejecimiento cerebral. En: Gerontolog\u00eda Social. R. Fern\u00e1ndez-Ballesteros, Pir\u00e1mide Ed., Madrid, pp. 105-151 (2000).<\/p>\n

Cano Guti\u00e9rrez, C.A., Cacabelos, R., G\u00f3mez Restrepo, C., Jacquier, M., Lopera, F., Manssur Calder\u00f3n, R.A., Mantallana Eslava, D.L., Monta\u00f1\u00e9s R\u00edos, P., Rom\u00e1n, G., T\u00e9llez Vargas, J.E. Consenso Colombiano de Enfermedad de Alzheimer. Noosfera Ed., Santa Fe de Bogot\u00e1, 2001.<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Perspectivas de futuro. En: Libro Blanco sobre la Enfermedad de Alzheimer y Trastornos Afines. R. Fern\u00e1ndez-Ballesteros, J. D\u00edez Nicol\u00e1s (Eds.). Obra Social Caja Madrid, Editorial M\u00e9dica Panamericana, Madrid, pp. 449-522 (2001).<\/p>\n

Cacabelos, R. The histamine-citokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. En: Mapping the Progress of Alzheimer\u2019s and Parkinson\u2019s Disease. Mizuno, Y., Fisher, A., Hanin, I. (Eds.). Advances in Behavioral Biology, 51:59-64 (2002).<\/p>\n

Cacabelos, R. Prevenci\u00f3n de Riesgo Cerebral en Altos Ejecutivos. En: Emprendedores con Valores. El directivo ante el nuevo encuentro Europa-Am\u00e9rica. Confederaci\u00f3n Espa\u00f1ola de Directivos y Ejecutivos-CEDE (2002).
\nCacabelos R (Ed). Preface. The Path to Pharmacogenomics. In: World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012: v-vi.
\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. A2M (alpha-2-macroglobulin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:811-812.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. ABCA1 (ATP-binding cassette, sub-family A (ABC1), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:812-824.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. ABCB1 (ATP-binding cassette, sub-family B (MDR\/TAP), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:824-928.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCB11 (ATP-binding cassette, sub-family B (MDR\/TAP), member 11). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:928-930.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC1 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:930-944.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC2 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:944-962.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC3 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:963-965.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC4 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:965-971.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC6 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:971-979.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC8 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:979-985.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCG1 (ATP-binding cassette, sub-family G (WHITE), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:985-996.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCG2 (ATP-binding cassette, sub-family G (WHITE), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:996-1024.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ABL1 (c-abl oncogene 1, non-receptor tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1025-1026.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACACA (acetyl-coA carboxylase alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1026-1027.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACE (angiotensin I converting enzyme (peptidyl-dipeptidase A) 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1027-1034.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACE2 (angiotensin I converting enzyme (peptidyl-dipeptidase A) 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1034-1036.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACHE (acetylcholinesterase (Yt blood group)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1036-1041.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACOX1 (acyl-CoA oxidase 1, palmitoyl). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1041-1042.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL1 (acyl-CoA synthetase long-chain family member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1042-1043.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL3 (acyl-CoA synthetase long-chain family member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1043-1044.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL4 (acyl-CoA synthetase long-chain family member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1044-1045.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL5 (acyl-CoA synthetase long-chain family member 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1045-1046.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL6 (acyl-CoA synthetase long-chain family member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1046.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACVRL1 (activin A receptor type II-like 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1046-1047.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADA (adenosine deaminase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1047-1049.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADCY9 (adenylate cyclase 9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1049-1050.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADD1 (adducin 1 (alpha)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1050-1052.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1A (alcohol dehydrogenase 1A (class 1), alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1052-1053.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1B (alcohol dehydrogenase 1B (class 1), beta polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1053-1054.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1C (alcohol dehydrogenase 1C (class 1), gamma polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1054-1056.<\/p>\n

Lombardi V, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADIPOQ (adiponectin, C1Q and collagen domain containing). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1056-1060.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADORA2A (adenosine A2a receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1060-1062.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA1A (adrenergic, alpha-1A-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1062-1064.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA2A (adrenergic, alpha-2A-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1064-1067.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA2C (adrenergic, alpha-2C-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1067-1069.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB1 (adrenergic, beta-1-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1069-1073.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB2 (adrenergic, beta-2-, receptor, surface). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1073-1080.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB3 (adrenergic, beta-3-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1080-1082.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acetyltransferase, beta)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1082-1083.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGT (angiotensinogen (serpin peptidase inhibitor, clade A, member 8)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1083-1088.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGTR1 (angiotensin II receptor, type 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1088-1092.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGXT (alanine-glyoxylate aminotransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1092-1093.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AHR (aryl hydrocarbon receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1093-1098.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AKR1C4 (aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1098-1099.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALAD (aminolevulinate dehydratase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1099-1100.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH1A1 (aldehyde dehydrogenase 1 family, member A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1100-1103.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH2 (aldehyde dehydrogenase 2 family (mitochondrial)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1103-1106.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH3A1 (aldehyde dehydrogenase 3 family, member A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1106-1108.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALOX5 (arachidonate 5-lipoxygenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1108-1111.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AOX1 (aldehyde oxidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1111.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APC (adenomatous polyposis coli). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1112-1115.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOA1 (apolipoprotein A-I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1115-1116.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOA5 (apolipoprotein A-V). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1116-1118.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOB (apolipoprotein B (including Ag(x) antigen)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1118-1119.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOC3 (apolipoprotein C-III). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1119-1120.<\/p>\n

Carril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOD (apolipoprotein D). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1120-1121.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. APOE (apolipoprotein E). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1121-1161.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Lombardi V, Takeda M, Cacabelos R. APP (amyloid beta (A4) precursor protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1161-1183.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AR (androgen receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1183-1189.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ARG1 (arginase, liver). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1189-1190.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AS3MT (arsenic (+3 oxidation state) methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1190-1191.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase\/IMP cyclohydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1191-1192.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ATP7A (ATPase, Cu2+ transporting, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1192-1193.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCAR1 (breast cancer anti-estrogen resistance 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1194.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCHE (butyrylcholinesterase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1194-1196.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCR (breakpoint cluster region). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1196-1197.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BDKRB2 (bradykinin receptor B2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1197.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BDNF (brain-derived neurotrophic factor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1198-1200.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BLK (B lymphoid tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1200-1201.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BLMH (bleomycin hydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1201-1202.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BMPR2 (bone morphogenetic protein receptor, type II (serine\/threonine kinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1202-1203.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRAF (v-raf murine sarcoma viral oncogene homolog B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1203-1204.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRCA1 (breast cancer 1, early onset). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1204-1208.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRCA2 (breast cancer 2, early onset). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1208-1209.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CACNG2 (calcium channel, voltage-dependent, gamma subunit 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1210.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CALU (calumenin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1210-1211.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CASR (calcium-sensing receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1211-1212.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CAT (catalase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1212-1217.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBR1 (carbonyl reductase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1217-1218.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBR3 (carbonyl reductase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1218-1219.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBS (cystathionine beta-synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1219-1220.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CCND1 (cyclin D1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1220-1223.<\/p>\n

Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CCR5 (chemokine (C-C motif) receptor 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1223-1229.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDA (cytidine deaminase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1229.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK1 (cyclin-dependent kinase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1229-1232.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK2 (cyclin-dependent kinase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1232-1234.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK4 (cyclin-dependent kinase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1234-1236.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK6 (cyclin-dependent kinase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1236-1238.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDKN2A (cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1238-1241.<\/p>\n

Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CES1 (carboxylesterase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1241-1242.<\/p>\n

Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CES2 (carboxylesterase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1242-1243.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CETP (cholesteryl ester transfer protein, plasma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1243-1244.<\/p>\n

Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CFH (complement factor H). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1244-1245.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CFTR (cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1245-1248.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHAT (choline O-acetyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1248-1249.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHDH (choline dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1249.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM1 (cholinergic receptor, muscarinic 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1249-1250.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM2 (cholinergic receptor, muscarinic 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1250-1251.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM3 (cholinergic receptor, muscarinic 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1251-1252.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA1 (cholinergic receptor, nicotinic, alpha 1 (muscle)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1252.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA4 (cholinergic receptor, nicotinic, alpha 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1253-1254.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA5 (cholinergic receptor, nicotinic, alpha 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1254-1255.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNB2 (cholinergic receptor, nicotinic, beta 2 (neuronal)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1255-1256.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHST3 (carbohydrate (chondroitin 6) sulfotransferase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1256-1257.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CNR1 (cannabinoid receptor 1 (brain)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1257-1259.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. COL1A1 (collagen, type I, alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1259-1262.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. COMT (catechol-O-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1262-1264.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CREB1 (cAMP responsive element binding protein 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1264-1265.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRHR1 (corticotropin releasing hormone receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1265-1267.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRHR2 (corticotropin releasing hormone receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1267.<\/p>\n

Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRP (C-reactive protein, pentraxin-related). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1267-1270.<\/p>\n

Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CSF1R (colony stimulating factor 1 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1270-1272.<\/p>\n

Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CSNK1E (casein kinase 1, epsilon). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1272-1273.<\/p>\n

Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1273-1274.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1275-1297.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1A2 (cytochrome P450, family 1, subfamily A, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1297-1334.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1335-1347.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1347-1356.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2B6 (cytochrome P450, family 2, subfamily B, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1356-1368.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C8 (cytochrome P450, family 2, subfamily C, polypeptide 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1368-1377.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1377-1401.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C18 (cytochrome P450, family 2, subfamily C, polypeptide 18). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1401-1404.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1404-1423.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Tellado I, Takeda M. CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1423-1589.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2E1 (cytochrome P450, family 2, subfamily E, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1589-1613.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2J2 (cytochrome P450, family 2, subfamily J, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1613-1622.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1622-1901.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1901-1902.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP4B1 (cytochrome P450, family 4, subfamily B, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1902-1906.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP4F2 (cytochrome P450, family 4, subfamily F, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1906-1911.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP7A1 (cytochrome P450, family 7, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1911-1932.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP11B2 (cytochrome P450, family 11, subfamily B, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1932-1943.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP19A1 (cytochrome P450, family 19, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1943-1979.<\/p>\n

Cacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP27A1 (cytochrome P450, family 27, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1979-1986.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DCK (deoxycytidine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1987-1988.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1988-1989.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DHODH (dihydroorotate dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1989-1990.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DIO2 (deiodinase, iodothyronine, type II). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1990-1992.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPP4 (dipeptidyl-peptidase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1992-1993.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPYD (dihydropyrimidine dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1993-1995.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPYS (dihydropyrimidinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1995-1996.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD1 (dopamine receptor D1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1996-1998.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD2 (dopamine receptor D2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1998-2002.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD3 (dopamine receptor D3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2002-2004.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD4 (dopamine receptor D4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2004-2006.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD5 (dopamine receptor D5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2006-2008.<\/p>\n

Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DTNBP1 (dystrobrevin binding protein 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2008-2010.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EDN1 (endothelin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2011-2013.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EDNRA (endothelin receptor type A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2013-2015.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EGFR (epidermal growth factor receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2015-2019.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EPHX1 (epoxide hydrolase 1, microsomal (xenobiotic)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2020-2022.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERAP1 (endoplasmic reticulum aminopeptidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2022-2023.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro\/glioblastoma derived oncogene homolog (avian)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2023-2026.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERBB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2026-2028.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC1 (excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2028-2029.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC2 (excision repair cross-complementing rodent repair deficiency, complementation group 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2029-2032.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC6 (excision repair cross-complementing rodent repair deficiency, complementation group 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2032-2034.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ESR1 (estrogen receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2034-2042.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ESR2 (estrogen receptor 2 (ER beta)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2042-2046.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F2 (coagulation factor II (thrombin)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2047-2049.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F5 (coagulation factor V (proaccelerin, labile factor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2049-2050.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F7 (coagulation factor VII (serum prothrombin conversion accelerator)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2050-2051.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FABP1 (fatty acid binding protein 1, liver). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2052-2053.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FABP2 (fatty acid binding protein 2, intestinal). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2053-2054.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCER2 (Fc fragment of IgE, low affinity II, receptor for (CD23)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2054-2055.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCGR2A (Fc fragment of IgG, low affinity IIa, receptor (CD32)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2055-2057.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCGR3A (Fc fragment of IgG, low affinity IIIa, receptor (CD16a)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2057-2059.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FGB (fibrinogen beta chain). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2059-2061.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FKBP5 (FK506 binding protein 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2061-2062.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FLT3 (fms-related tyrosine kinase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2062-2064.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO1 (flavin containing monooxygenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2064-2066.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO2 (flavin containing monooxygenase 2 (non-functional)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2066-2067.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO3 (flavin containing monooxygenase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2067-2068.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMR1 (fragile X mental retardation 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2068-2069.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FOS (FBJ murine osteosarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2069-2074.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FSHR (follicle stimulating hormone receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2074-2075.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. G6PD (glucose-6-phosphate dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2076-2078.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GABRA6 (gamma-aminobutyric acid (GABA) A receptor, alpha 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2078-2079.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GCH1 (GTP cyclohydrolase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2079-2082.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GGCX (gamma-glutamyl carboxylase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2082-2083.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GGH (gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2083-2085.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GH1 (growth hormone 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2085-2086.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GHR (growth hormone receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2086-2088.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GNAS (GNAS complex locus). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2089-2091.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GNB3 (guanine nucleotide binding protein (G protein), beta polypeptide 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2091-2093.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIA3 (glutamate receptor, ionotrophic, AMPA 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2093-2095.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIK2 (glutamate receptor, ionotropic, kainate 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2095-2096.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIK4 (glutamate receptor, ionotropic, kainate 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2096-2097.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRINA (glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2097.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRK5 (protein-coupled receptor kinase 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2097-2098.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRM3 (glutamate receptor, metabotropic 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2098-2099.<\/p>\n

Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSK3B (glycogen synthase kinase 3 beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2099-2101.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSS (glutathione synthetase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2102-2104.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTA1 (glutathione S-transferase alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2104-2106.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTK1 (glutathione S-transferase kappa 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2106-2107.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTM1 (glutathione S-transferase mu 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2107-2111.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTO1 (glutathione S-transferase omega 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2111-2113.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTO2 (glutathione S-transferase omega 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2113.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTP1 (glutathione S-transferase pi 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2113-2118.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTT1 (glutathione S-transferase theta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2118-2121.<\/p>\n

Carril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HBB (hemoglobin, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2122-2125.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HCP5 (HLA complex P5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2125-2126.<\/p>\n

Carril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HFE (hemochromatosis). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2126-2129.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-A (major histocompatibility complex, class I, A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2129-2131.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-B (major histocompatibility complex, class I, B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2131-2135.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-C (major histocompatibility complex, class I, C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2135-2137.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DPB1 (major histocompatibility complex, class II, DP beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2137-2139.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DQA1 (major histocompatibility complex, class II, DQ alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2139-2141.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DRB1 (major histocompatibility complex, class II, DR beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2141-2145.<\/p>\n

Carril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2145-2147.<\/p>\n

Corzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HNF4A (hepatocyte nuclear factor 4, alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2147-2150.<\/p>\n

Corzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HOXB13 (homeobox B13). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2150-2152.<\/p>\n

Corzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HP (haptoglobin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2152-2153.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HRH1 (histamine receptor H1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2153-2155.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HRH2 (histamine receptor H2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2155.<\/p>\n

Corzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HSD17B1 (hydroxysteroid (17-beta) dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2155-2156.<\/p>\n

Lombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HSPA1L (heat shock 70kDa protein 1-like). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2156-2157.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1A (5-hydroxytryptamine (serotonin) receptor 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2157-2159.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1B (5-hydroxytryptamine (serotonin) receptor 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2159-2161.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1D (5-hydroxytryptamine (serotonin) receptor 1D). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2161.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR2A (5-hydroxytryptamine (serotonin) receptor 2A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2161-2164.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR2C (5-hydroxytryptamine (serotonin) receptor 2C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2164-2165.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3A (5-hydroxytryptamine (serotonin) receptor 3A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2165-2168.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3B (5-hydroxytryptamine (serotonin) receptor 3B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2168-2169.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3C (5-hydroxytryptamine (serotonin) receptor 3, family member C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2169.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR6 (5-hydroxytryptamine (serotonin) receptor 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2169-2170.<\/p>\n

Carril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTT (huntingtin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2170-2174.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ICAM1 (intercellular adhesion molecule 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2175-2178.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNA1 (interferon, alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2178-2179.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNB1 (interferon, beta 1, fibroblast). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2179-2181.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNG (interferon, gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2181-2186.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IGF1 (insulin-like growth factor 1 (somatomedin C)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2186-2189.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IGF2 (insulin-like growth factor 2 (somatomedin A)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2189-2190.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL1B (interleukin 1, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2190-2196.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL1RN (interleukin 1 receptor antagonist). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2196-2198.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL2 (interleukin 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2198-2201.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL4 (interleukin 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2201-2204.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL6 (Interleukin 6 (interferon, beta 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2204-2210.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL6R (interleukin 6 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2210-2211.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL8RA (interleukin 8 receptor, alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2211-2212.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL8RB (interleukin 8 receptor, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2212-2213.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL10 (interleukin 10). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2213-2218.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL12B (interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2218-2221.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL17RB (interleukin 17 receptor B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2221-2222.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. IMPDH1 (IMP (inosine monophosphate) dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2222-2223.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. INPP1 (inositol polyphosphate-1-phosphatase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2223.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IRF1 (interferon regulatory factor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2223-2224.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ITGA2 (integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2224-2225.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ITGB3 (integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2225-2227.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ITPA (inosine triphosphatase (nucleoside triphosphate pyrophosphatase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2227.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNE1 (potassium voltage-gated channel, Isk-related family, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2228-2229.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNE2 (potassium voltage-gated channel, Isk-related family, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2229-2230.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNH2 (potassium voltage-gated channel, subfamily H (eag-related), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2230-2232.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2232-2234.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2234-2236.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. KDR (kinase insert domain receptor (a type III receptor tyrosine kinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2236-2237.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2237-2238.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2239-2241.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. LCK (lymphocyte-specific protein tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2242.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. LCT (lactase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2243.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LDLR (low density lipoprotein receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2243-2246.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LEP (leptin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2246-2248.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LEPR (leptin receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2248-2249.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LIPC (lipase, hepatic). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2249-2250.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LOXL1 (lysyl oxidase-like 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2250-2251.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LPL (lipoprotein lipase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2251-2253.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LRRK2 (leucine-rich repeat kinase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2253-2254.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTA (lymphotoxin alpha (TNF superfamily, member 1)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2254-2256.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTA4H (leukotriene A4 hydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2256.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTC4S (leukotriene C4 synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2256-2257.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAOA (monoamine oxidase A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2258-2259.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAOB (monoamine oxidase B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2260-2261.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MAPK7 (mitogen-activated protein kinase 7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2261.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAPT (microtubule-associated protein tau). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2261-2266.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MC1R (melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2266-2267.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MEN1 (multiple endocrine neoplasia I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2267-2269.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MET (met proto-oncogene (hepatocyte growth factor receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2269-2270.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MGMT (O-6-methylguanine-DNA methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2270-2272.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2272-2274.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MMP2 (matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2274-2276.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MMP3 (matrix metalloproteinase 3 (stromelysin 1, progelatinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2276-2278.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2278-2279.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ATP6 (mitochondrially encoded ATP synthase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2279-2280.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-COI (mitochondrially encoded cytochrome c oxidase I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2280-2281.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND1 (mitochondrially encoded NADH dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2281-2282.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND4 (mitochondrially encoded NADH dehydrogenase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2282-2283.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND6 (mitochondrially encoded NADH dehydrogenase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2283.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-RNR1 (mitochondrially encoded 12S RNA). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2283-2284.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-TK (mitochondrially encoded tRNA lysine). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2284-2285.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-TL1 (mitochondrially encoded tRNA leucine 1 (UUA\/G)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2285.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTHFR (5,10-methylenetetrahydrofolate reductase (NADPH)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2285-2288.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTNR1A (melatonin receptor 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2288-2289.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTNR1B (melatonin receptor 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2289-2290.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTR (5-methyltetrahydrofolate-homocysteine methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2290-2291.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTTP (microsomal triglyceride transfer protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2291-2292.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NAT2 (N-acetyltransferase 2 (arylamine N-acetyltransferase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2293-2296.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NDUFB4 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2296.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NEU2 (sialidase 2 (cytosolic sialidase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2296.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NNMT (nicotinamide N-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2296-2298.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NOS3 (nitric oxide synthase 3 (endothelial cell)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2298-2301.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NOTCH3 (notch 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2301-2302.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NOX1 (NADPH oxidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2302-2303.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NPC1 (Niemann-Pick disease, type C1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2303-2304.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NPPA (natriuretic peptide precursor A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2304-2305.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NPY (neuropeptide Y). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2305-2306.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NQO1 (NAD(P)H dehydrogenase, quinone 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2306-2309.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NR1I2 (nuclear receptor subfamily 1, group I, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2309-2313.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NR1I3 (nuclear receptor subfamily 1, group I, member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2313-2314.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NR3C1 (nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2314-2318.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NRXN1 (neurexin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2318.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NTRK2 (neurotrophic tyrosine kinase, receptor, type 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2318-2320.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. OASL (2′-5′-oligoadenylate synthetase-like). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2321.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. OPRM1 (opioid receptor, mu 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2321-2323.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ORM1 (orosomucoid 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2323.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. P2RY1 (purinergic receptor P2Y, G-protein coupled, 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2324.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. P2RY12 (purinergic receptor P2Y, G-protein coupled, 12). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2324-2325.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PARK2 (parkinson protein 2, E3 ubiquitin protein ligase (parkin)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2325-2326.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDE1C (phosphodiesterase 1C, calmodulin-dependent 70kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2327.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDE5A (phosphodiesterase 5A, cGMP-specific). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2327-2328.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDGFRA (platelet-derived growth factor receptor, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2328-2330.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDGFRB (platelet-derived growth factor receptor, beta polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2330-2331.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PEMT (phosphatidylethanolamine N-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2331-2332.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2332-2333.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. POLG (polymerase (DNA directed), gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2333-2335.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PON1 (paraoxonase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2335-2338.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARA (peroxisome proliferator-activated receptor alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2338-2340.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARD (peroxisome proliferator-activated receptor delta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2340-2342.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARG (peroxisome proliferator-activated receptor gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2342-2345.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARGC1A (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2345-2347.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PRDX4 (peroxiredoxin 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2347.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PRNP (prion protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2347-2352.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PROC (protein C (inactivator of coagulation factors Va and VIIIa)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2352-2353.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PSEN1 (presenilin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2353-2357.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PSEN2 (presenilin 2 (Alzheimer disease 4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2357-2359.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER1 (prostaglandin E receptor 1 (subtype EP1), 42kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2359.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER2 (prostaglandin E receptor 2 (subtype EP2), 53kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2359-2360.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER3 (prostaglandin E receptor 3 (subtype EP3)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2360-2361.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER4 (prostaglandin E receptor 4 (subtype EP4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2361-2362.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGES (prostaglandin E synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2362-2363.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGFR (prostaglandin F receptor (FP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2363.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGIR (prostaglandin I2 (prostacyclin) receptor (IP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2363-2364.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGIS (prostaglandin I2 (prostacyclin) synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2364-2365.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGS1 (prostaglandin-endoperoxide synthase 1 (prostaglandin G\/H synthase and cyclooxygenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2365-2367.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGS2 (prostaglandin-endoperoxide synthase 2 (prostaglandin G\/H synthase and cyclooxygenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2367-2373.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RB1 (retinoblastoma 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2374-2377.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. REN (renin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2377.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RET (ret proto-oncogene). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2377-2379.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RGS2 (regulator of G-protein signaling 2, 24kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2379-2380.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RGS4 (regulator of G-protein signalling 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2380-2381.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RRAS2 (related RAS viral (r-ras) oncogene homolog 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2381-2382.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RRM1 (ribonucleotide reductase M1 polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2382.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RYR1 (ryanodine receptor 1 (skeletal)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2382-2383.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCARB1 (scavenger receptor class B, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2384-2385.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN1A (sodium channel, voltage-gated, type I, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2385-2386.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN1B (sodium channel, voltage-gated, type I, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2386.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN2A (sodium channel, voltage-gated, type II, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2386-2387<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN3A (sodium channel, voltage-gated, type III, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2387.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN4A (sodium channel, voltage-gated, type IV, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2387-2388.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN5A (sodium channel, voltage-gated, type V, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2388-2390.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN9A (sodium channel, voltage-gated, type IX, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2390-2391.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCNN1G (sodium channel, nonvoltage-gated 1, gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2391-2392.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC5A5 (solute carrier family 5 (sodium iodide symporter), member 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2392-2393.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC5A8 (solute carrier family 5 (iodide transporter), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2393-2394.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A2 (solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2394-2395.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A3 (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2395-2397.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A4 (solute carrier family 6 (neurotransmitter transporter, serotonin), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2397-2399.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC10A1 (solute carrier family 10 (sodium\/bile acid cotransporter family), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2399-2400.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC10A2 (solute carrier family 10 (sodium\/bile acid cotransporter family), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2400-2401.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC11A1 (solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2401-2402.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC12A3 (solute carrier family 12 (sodium\/chloride transporters), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2402.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC14A2 (solute carrier family 14 (urea transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2402-3.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC15A1 (solute carrier family 15 (oligopeptide transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2403-2404.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC15A2 (solute carrier family 15 (H+\/peptide transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2404.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC19A1 (solute carrier family 19 (folate transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2404-2405.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A1 (solute carrier family 22 (organic cation transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2406.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A2 (solute carrier family 22 (organic cation transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2406-2407.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A4 (solute carrier family 22 (organic cation\/ergothioneine transporter), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2407-2408.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A6 (solute carrier family 22 (organic anion transporter), member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2408-2409.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A7 (solute carrier family 22 (organic anion transporter), member 7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2409-2410.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A8 (solute carrier family 22 (organic anion transporter), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2410-2411.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A16 (solute carrier family 22 (organic cation\/carnitine transporter), member 16). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2411-2412.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC23A2 (solute carrier family 23 (nucleobase transporters), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2412.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC28A1 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2412-2413.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC28A2 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2413.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1A2 (solute carrier organic anion transporter family, member 1A2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2413-2414.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1B1 (solute carrier organic anion transporter family, member 1B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2414-2416.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1B3 (solute carrier organic anion transporter family, member 1B3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2416.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1C1 (solute carrier organic anion transporter family, member 1C1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2416-2417.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO2B1 (solute carrier organic anion transporter family, member 2B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2417-2418.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SNAP25 (synaptosomal-associated protein, 25kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2418.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SNCA (synuclein, alpha (non A4 component of amyloid precursor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2418-2420.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SOD2 (superoxide dismutase 2, mitochondrial). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2420-2424.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SOD3 (superoxide dismutase 3, extracellular). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2424-2425.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SPG7 (spastic paraplegia 7 (pure and complicated autosomal recessive)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2425.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SRD5A2 (steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2425-2427.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SSTR2 (somatostatin receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2427.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SSTR5 (somatostatin receptor 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2427-2428.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. STAT3 (signal transducer and activator of transcription 3 (acute-phase response factor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2428-2431.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A1 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2431-2432.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A2 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2432-2433.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A3 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2433-2435.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1C2 (sulfotransferase family, cytosolic, 1C, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2435.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1E1 (sulfotransferase family 1E, estrogen-preferring, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2435-2436.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TACR2 (tachykinin receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2437.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TAP1 (transporter 1, ATP-binding cassette, sub-family B (MDR\/TAP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2437-2438.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBX21 (T-box 21). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2438-2439.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBXA2R (thromboxane A2 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2439-2440.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBXAS1 (thromboxane A synthase 1(platelet)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2440.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TERT (telomerase reverse transcriptase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2440-2442.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TGFB1 (transforming growth factor, beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2442-2448.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TGFBR1 (transforming growth factor, beta receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2448-2449.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. THBD (thrombomodulin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2449-2450.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TIMP3 (TIMP metallopeptidase inhibitor 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2450-2451.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TLR4 (toll-like receptor 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2451-2453.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNF (tumor necrosis factor (TNF superfamily, member 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2453-2464.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNFRSF1A (tumor necrosis factor receptor superfamily, member 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2464-2465.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNFRSF1B (tumor necrosis factor receptor subfamily, member 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2465-2467.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TOP1 (topoisomerase (DNA) I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2467-2468.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TP53 (tumor protein p53). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2468-2474.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TPH1 (tryptophan hydroxylase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2474-2475.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TPH2 (tryptophan hydroxylase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2475-2476.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TPMT (thiopurine S-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2477.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TPRV1 (transient receptor potential cation channel, subfamily V, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2478-2479.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TYMS (thymidylate synthetase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2479-2481.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UCP2 (uncoupling protein 2 (mitochondrial, proton carrier)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2482-2483.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2483-2490.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A3 (UDP glucuronosyltransferase 1 family, polypeptide A3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2490-2493.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A4 (UDP glucuronosyltransferase 1 family, polypeptide A4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2493-2495.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A6 (UDP glucuronosyltransferase 1 family, polypeptide A6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2495-2497.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A7 (UDP glucuronosyltransferase 1 family, polypeptide A7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2497-2500.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A9 (UDP glucuronosyltransferase 1 family, polypeptide A9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2500-2502.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A10 (UDP glucuronosyltransferase 1 family, polypeptide A10). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2502-2506.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT2B7 (UDP glucuronosyltransferase 2 family, polypeptide B7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2506-2509.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT2B15 (UDP glucuronosyltransferase 2 family, polypeptide B15). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2509-2510.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. USF2 (upstream transcription factor 2, c-fos interacting). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2510-2511.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. USP5 (ubiquitin specific peptidase 5 (isopeptidase T)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2511.<\/p>\n

Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VCAM1 (vascular cell adhesion molecule 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2512-2513.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VDR (vitamin D (1,25- dihydroxyvitamin D3) receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2513-2516.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VEGFA (vascular endothelial growth factor A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2516-2520.<\/p>\n

Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VGF (VGF nerve growth factor inducible). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2520.<\/p>\n

Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VKORC1 (vitamin K epoxide reductase complex, subunit 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2520-2521.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. WNK1 (WNK lysine deficient protein kinase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2522-2523.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. WNT5B (Wingless-type MMTV integration site family, member 5B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2523.<\/p>\n

Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XDH (xanthyne deydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2524-2525.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XPA (xeroderma pigmentosum, complementation group A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2525-2526.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2526-2528.<\/p>\n

Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ZFAND6 (zinc finger, AN1-type, domain 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2529.<\/p>\n

Aliev, G., Reddy, V.P., Cacabelos, R. Role of electron microscopy-immunocytochemistry and in situ hybridization in the study of oxidative stress-induced mitochondrial abnormalities and the pathobiology of neurodegeneration and cancer. In: Current Microscopy Contributions to Advances in Science and Technology. M\u00e9ndez-Vilas, A. (Ed). pp. 366-385 (2012).<\/p>\n

Aliev G, Horecky J, Vancova O, Ashraf GM, Hassan I, Bragin V,Bragin I, Shevtsova E, Klochkov SG, Kosenso EA, Cacabelos R, Bachurin SO, Benberin VV, Kaminsky YG. The three-vessel occlusion as a model of vascular dementia \u2013 Oxidative stress and mitocondrial failure as an indicator of brain hypoperfusion. In: Systems Biology of Free Radicals and Antioxidants. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2023-2032. Doi: 10.1007\/978-3-642-30018-9.<\/p>\n

Aliev G, Ashraf GM, Horecky J, Vancova O, Gvozdjakova A, Kucharska J, Palacios HH, Li Y, Perveen A, Khan TA, Bragin V, Bragin I, Shetsova E, Klochkov SG, Kosenko EA, Cacabelos R, Kaminsky YG, Sudakov KV, Benberin VV, Bachurin SO. Potential preventive effects of Coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion. In: Systems Biology of Free Radicals and Antioxidants. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2033-2048. Doi: 10.1007\/978-3-642-30018-9.<\/p>\n

Aliev G, Li Y, Palacios HH, Obrenovich ME, Bragin V, Bragin I, Shevtsova E, Klochkov SG, Kosensko EA, Cacabelos R, Kaminsky YG, Bachurin SO, Benberin VV. Oxidative stress-induced mitocondrial damage as a hallmark for drug development in the context of the neurodegeneration, cardiovascular, and cerebrovascular diseases. In: Systems Biology of Free Radicals and Antioxidants. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2083-2126. Doi: 10.1007\/978-3-642-30018-9.<\/p>\n

Aliev G, Li Y, Palacios HH, Obrenovich ME, Bragin V, Bragin I, Shevtsova E, Klochkov SG, Kosensko EA, Kaminsky YG, Bachurin SO, Cacabelos R. Atherosclerotic lesions and mitocondrial DNA deletions as a primary hallmark of the brain microcirculation \u2013 Implication in the pathogenesis of Alzheimer\u2019s disease. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2127-2145. Doi: 10.1007\/978-3-642-30018-9.<\/p>\n

Aliev G, Burzynski G, Ashraf GM, Jabir NR, Cacabelos R, Benberin VV, Burzynski SR. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2325-2147. Doi: 10.1007\/978-3-642-30018-9.<\/p>\n

Cacabelos R, Cacabelos P, Torrellas C. Personalized medicine of Alzheimer\u2019s disease. In: Handbook of Pharmacogenomics and Stratified Medicine. Padmanabhan S (Ed). Elsevier, Amsterdam, 2014: pp. 563-615.<\/p>\n

Cacabelos R. Scientific leadership and mental health service to the community. In: Department of Psychiatry Osaka University Medical School. A 120-year history of growth and development. Takeda M (Ed). 2014; pp. 253-258.
\nCacabelos R. The first version of the EuroEspes Pharmacogenetic Card. In: Cacabelos R (Ed). Research Reports 2006-2010. Vol. 4, pp. 1-2, EuroEspes Publishing Co., Coru\u00f1a (2015).
\nCacabelos R. The First Guide of PharmacoGenomics, the EuroPharmaGenics (EPG) Database, and the first Chair of Genomic Medicine in Spain. In: Cacabelos R (Ed). Research Reports 2011-2014. Vol. 5, pp. 1-2. EuroEspes Publishing Co., Coru\u00f1a (2015).
\nCacabelos R. Designing the future. In: Cacabelos R (Ed). Camilo Jos\u00e9 Cela University Health Science Reports 2013; pp. 1-2, CJC University Press, Madrid (2015).<\/p>\n

Cacabelos R. Quality vs Quantity. Scientific Development to serve public welfare. In: Cacabelos R (Ed). Camilo Jos\u00e9 Cela University Health Science Reports 2014, pp. 1-2, CJC University Press, Madrid (2015).<\/p>\n

Cacabelos R, Torrellas C, Cacabelos P, Villanueva MJ, Pi\u00f1eiro S, Solveira. Pharmacogenetics of neurodegenerative disorders. In: Preventive and Predictive Genetics: Towards Personalized Medicine. Grech & Grossman Eds. Springer, 2015:173-240.<\/p>\n

Cacabelos R, Torrellas C, Tellado I, Cacabelos P, L\u00f3pez-Mu\u00f1oz F. Genomics, therapeutics and Pharmacogenomics of attention-deficit\/hyperactivity disorder. In: Attention Deficit Hyperactivity Disorder (ADHD). L\u00f3pez-Mu\u00f1oz F, \u00c1lamo C (Eds). Nova Science Publishers, 2015:65-256.<\/p>\n

Cacabelos R, Torrellas C, L\u00f3pez-Mu\u00f1oz F. Pharmacogenomics of antidepressants drugs. In: Srinivasa V (ed). Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer-India. 2016; dOI 10.1007\/978-81-322-2803-5_35.<\/p>\n

Art\u00edculos de Divulgaci\u00f3n y Opini\u00f3n<\/h2>\n

Cacabelos, R. La esfera sociosanitaria japonesa. JANO Med. Hum., 606:15-19 (1984).<\/p>\n

Cacabelos, R. Violencia en la escuela y delincuencia juvenil: enfermedades de la juventud japonesa. JANO Med. Hum., 608:15-16 (1984).<\/p>\n

Cacabelos, R. Una sociedad enferma de poder. JANO Med. Hum., 609:15-16 (1984).<\/p>\n

Cacabelos, R. Alcoholismo: Una irresponsabilidad con apolog\u00eda. JANO Med. Hum., Extra Mayo, pp 7-11 (1984).<\/p>\n

Cacabelos, R. El suicidio en Jap\u00f3n. JANO Med, Hum., 619:18-26 (1984).<\/p>\n

Cacabelos, R. La lecci\u00f3n de un s\u00edndrome. JANO Med. Hum., 626: l3-16 (1984).<\/p>\n

Cacabelos, R. Hiroshima y Nagasaki (I). An\u00e1lisis y consecuencias de la cat\u00e1strofe nuclear 39 a\u00f1os despu\u00e9s. JANO Med. Hum., 630:96-118 (1984).<\/p>\n

Cacabelos, R. Salud Mental versus Hombre Integral. JANO Med. Hum., 628:15-21 (1984).<\/p>\n

Cacabelos, R. El mundo se interesa por la salud de los lagos. La enfermedad de Minamata. JANO Med. Hum., 637:17-21 (1984).<\/p>\n

Cacabelos, R. La desplanificaci\u00f3n familiar internacional y el modelo japon\u00e9s. JANO Med. Hum., 632:16-24 (1984).<\/p>\n

Cacabelos, R. Interfer\u00f3n japon\u00e9s. Producci\u00f3n masiva de interfer\u00f3n a partir del gusano de seda por ingenier\u00eda gen\u00e9tica. JANO Med. Hum., Extra Diciembre, pp. 10-14 (1984).<\/p>\n

Cacabelos, R. LXI aniversario del gran terremoto de Tokio. JANO Med. Hum., 640:16-20 (1984).<\/p>\n

Cacabelos, R. El quebradizo entorno econ\u00f3mico del mundo de las computadoras y su relaci\u00f3n con la medicina. JANO Med. Hum., 644:19-21 (1985).<\/p>\n

Cacabelos, R. Nuevas perspectivas en el uso de animales de experimentaci\u00f3n. JANO Med. Hum., 649:25-29 (1985).<\/p>\n

Cacabelos, R. El alcohol en el mundo: algo m\u00e1s que un problema psicosocial. JANO Med. Hum., 659:160-168 (1985).<\/p>\n

Cacabelos, R. La edad de la as\u00edntota o la enfermedad de los pa\u00edses avanzados. JANO Med. Hum., 660:24-26 (1985).<\/p>\n

Cacabelos, R. Jap\u00f3n honra a Rebecca Lancefield. JANO Med. Hum., 662:761-762 (1985).<\/p>\n

Cacabelos, R. La ciencia se dio cita en Tsukuba Expo \u00b485. JANO Med. Hum., 663:1007-1017 (1985).<\/p>\n

Cacabelos, R. Tabaco japon\u00e9s: entre la ciencia y la alevos\u00eda. JANO Med. Hum., 666: 1763-1766 (1985).<\/p>\n

Cacabelos, R. Los priones: Una revoluci\u00f3n en el campo de la biolog\u00eda. JANO Med. Hum., 664:1253-1256 (1985).<\/p>\n

Cacabelos, R. Alzheimer y biotecnolog\u00eda: modas en Jap\u00f3n. JANO Med. Hum., 665:1506-1508 (1985).<\/p>\n

Cacabelos, R. Medio siglo de terapia convulsionante. JANO Med. Hum., 707:41-50 (1986).<\/p>\n

Cacabelos, R. El \u201ctechnostress\u201d invade Jap\u00f3n. JANO Med. Hum., 709:205-207 (1986).<\/p>\n

Cacabelos, R. Jap\u00f3n: tercer pa\u00eds del mundo en inversiones cient\u00edficas. JANO Med. Hum., 722:1627-1628 (1986).<\/p>\n

Cacabelos, R. Los pueblos se quedan sin gente y sin asistencia sanitaria digna. JANO Med. Hum., 713:645-650 (1986).<\/p>\n

Cacabelos, R. La investigaci\u00f3n cient\u00edfica en Jap\u00f3n. JANO Med. Hum., 724:1876-1880 (1986).<\/p>\n

Cacabelos, R. Grave crisis en la psiquiatr\u00eda japonesa. JANO Med. Hum., 726:2116-2119 (1986).<\/p>\n

Cacabelos, R. OUCEM-86: Un sistema computadorizado para estudiar memoria, conducta y aprendizaje. JANO Med. Hum., 758:28-32 (1987).<\/p>\n

Cacabelos, R. Microscop\u00eda electr\u00f3nica. JANO Med. Hum., 760:22-25 (1987).<\/p>\n

Cacabelos, R. Perfil de la inteligencia artificial en medicina: una perspectiva internacional. JANO Med. Hum., 770:22-32 (1987).<\/p>\n

Cacabelos, R. Condicionantes transculturales y profesionales en el diagn\u00f3stico de procesos psiqui\u00e1tricos menores en China, Jap\u00f3n y los EE.UU. JANO Med. Hum., 763:27-28 (1987).<\/p>\n

Cacabelos, R. Incipiente educaci\u00f3n sexual escolar y contracepci\u00f3n farmacol\u00f3gica. JANO Med. Hum., 765:24-27 (1987).<\/p>\n

Cacabelos, R. Espa\u00f1oles en Jap\u00f3n: una poblaci\u00f3n de alto riesgo con abundantes problemas sociosanitarios. JANO Med. Hum., 766:17-20 (1987).<\/p>\n

Cacabelos, R. Presente y futuro de la neuropsiquiatr\u00eda japonesa. JANO Med. Hum., 777:21-29 (1987).<\/p>\n

Cacabelos, R. Las ra\u00edces de la medicina japonesa. JANO Med. Hum., 779:16-21 (1987).<\/p>\n

Cacabelos, R. C\u00f3mo fabricar un cient\u00edfico japon\u00e9s. JANO Med. Hum., 786:19-21 (1987).<\/p>\n

Cacabelos, R. Estrategia japonesa ante el desafio de una sociedad geri\u00e1trica. JANO Med. Hum., 787: 16-22 (1987).<\/p>\n

Cacabelos, R. Comentarios epidemiol\u00f3gicos, etiopatog\u00e9nicos y preventivos sobre el retraso mental. JANO Med. Hum., 788:27- 30 (1987).<\/p>\n

Cacabelos, R. El gobierno japon\u00e9s proh\u00edbe la comercializaci\u00f3n y experimentaci\u00f3n humana con growth hormone-releasing factor (GRF). JANO Med. Hum., 788:35-37 (1987).<\/p>\n

Cacabelos, R. Leupeptin: \u00bfUna alternativa terap\u00e9utica en lesiones nerviosas? JANO Med. Hum., 789:23-26 (1987).<\/p>\n

Cacabelos, R. KOGAIBYO: Enfermedades producidas por contaminaci\u00f3n ambiental. JANO Med. Hum., 790:21-25 (1987).<\/p>\n

Cacabelos, R. Recientes estudios sobre amiloidosis hereditaria y polineuropat\u00eda craneal idiop\u00e1tica. JANO Med. Hum., 792:16-21 (1987).<\/p>\n

Cacabelos, R. El hemisferio dominante de un narcisismo circunspecto. JANO Med. Hum., 793:25-26 (1987).<\/p>\n

Cacabelos, R. Influencia de los desastres naturales sobre la aparici\u00f3n de trastornos psiqui\u00e1tricos en Nagasaki. JANO Med. Hum., 794:16-19 (1987).<\/p>\n

Cacabelos, R. Aspectos gen\u00e9ticos de la epilepsia. JANO Med. Hum., 795:18-22 (1987).<\/p>\n

Cacabelos, R. Estudios cromos\u00f3micos en enfermos mentales japoneses. JANO Med. Hum., 796:25-26 (1987).<\/p>\n

Cacabelos, R. KAMPO: Medicina tradicional japonesa. JANO Med. Hum., 802:17-18 (1988).<\/p>\n

Cacabelos, R. Pluralismo m\u00e9dico: una alternativa para paliar deficiencias de la biomedicina moderna. JANO Med. Hum., 806:19-20 (1988).<\/p>\n

Cacabelos, R. Las paradojas de la higiene popular japonesa. JANO Med. Hum., 807:18-20 (1988).<\/p>\n

Cacabelos, R. El rol m\u00e9dico de la religi\u00f3n japonesa o las reliquias m\u00e1gico-m\u00edticas de una sociedad superindustrializada. JANO Med. Hum., 811:25-29 (1988).<\/p>\n

Cacabelos, R. Programa de desarrollo de investigaci\u00f3n biom\u00e9dica para el bienestar social: Tecnificaci\u00f3n de la salud y ayuda a los incapacitados. JANO Med. Hum., 813:27-29 (1988).<\/p>\n

Cacabelos, R. Factores de riesgo coronario en Jap\u00f3n. JANO Med. Hum., 815:16-19 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Evoluci\u00f3n hist\u00f3rica de la ciencia de los ordenadores. JANO Med. Hum., 815:69-82 (1988).<\/p>\n

Cacabelos, R. Correlaci\u00f3n de los factores de riesgo cardiaco en Asia y Europa. JANO Med. Hum., 816:20-24 (1988).<\/p>\n

Cacabelos, R. Epidemiolog\u00eda oncol\u00f3gica: \u00bfPrevenci\u00f3n \u00f3 supervivencia posterap\u00e9utica? JANO Med. Hum., 817:16-19 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en Medicina. Organizaci\u00f3n y funcionamiento de los ordenadores; Hardware y Software. JANO Med. Hum., 817:65-72 (1988).<\/p>\n

Cacabelos, R. Investigaci\u00f3n oncol\u00f3gica: De la ciencia al negocio. JANO Med. Hum., 818:25-26 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Aplicaciones generales y espec\u00edficas de los ordenadores. JANO Med. Hum., 819:87-101 (1988).<\/p>\n

Cacabelos, R. Treinta a\u00f1os de neuroqu\u00edmica japonesa. JANO Med. Hum., 820:33-34 (1988).<\/p>\n

Cacabelos, R. Parkinsonismo yatrog\u00e9nico y discinesia tard\u00eda en pacientes japoneses: \u00bfdiferencias \u00e9tnicas con respecto a Occidente? JANO Med. Hum., 821:33 (1988).<\/p>\n

Cacabelos, R. Demencia senil: M\u00e1s frecuente en Europa y Am\u00e9rica que en Asia. JANO Med. Hum., 822:15-16 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Inteligencia artificial. JANO Med. Hum., 822:77-95 (1988).<\/p>\n

Cacabelos, R. La nueva generaci\u00f3n l\u00e1ser en medicina. JANO Med. Hum., 823:18-20 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Rob\u00f3tica. JANO Med. Hum., 824:71-78 (1988).<\/p>\n

Cacabelos, R. La dial\u00e9ctica del tabaquismo o el ejercicio de la libertad. JANO Med. Hum., 825:15-16 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Perspectivas de futuro en ordenadores y telem\u00e1tica. JANO Med. Hum., 826:60-66 (1988),<\/p>\n

Cacabelos, R. Enfermedad Moyamoya. JANO Med. Hum., 829:21-22 (1988).<\/p>\n

Cacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Contribuci\u00f3n japonesa a la ciencia de los ordenadores. JANO Med. Hum., 831:63-71 (1988).<\/p>\n

Cacabelos, R. Farmacolog\u00eda molecular de la terapia anti-SIDA. JANO Med. Hum., 835:25-26 (1988).<\/p>\n

Cacabelos, R. Inmunofarmacolog\u00eda: Una expresi\u00f3n biotecnol\u00f3gica vanguardista en medicina. JANO Med. Hum., 836:26-27 (1988).<\/p>\n

Cacabelos, R. Degeneraci\u00f3n espinocerebelar: nuevas perspectivas cl\u00ednicoterap\u00e9uticas. JANO Med. Hum., 837:41-43 (1988).<\/p>\n

Cacabelos, R. Proyecto TRH: neurobiolog\u00eda molecular e ingreso de los neurop\u00e9ptidos en la farmacopea japonesa. JANO Med. Hum., 838:21-26 (1988).<\/p>\n

Cacabelos, R. Esclerosis lateral amiotr\u00f3fica en Jap\u00f3n. JANO Med. Hum., 843:16-20 (1988).<\/p>\n

Cacabelos, R. Algunos datos sobre la depresi\u00f3n entre la poblaci\u00f3n japonesa. JANO Med. Hum., 846: 19-21 (1989).<\/p>\n

Cacabelos, R. Investigaciones sobre la enfermedad de Creutzfeldt-Jakob. JANO Med. Hum., 848:21-24 (1989).<\/p>\n

Cacabelos, R. Demencia senil. JANO Med. Hum., 851:34-43 (1989).<\/p>\n

Cacabelos, R. Ciencia, medicina y cooperaci\u00f3n industrial en Jap\u00f3n. Hacia una remodelaci\u00f3n de las estrategias cient\u00edfico-industriales. JANO Med. Hum., 853:21-22 (1989).<\/p>\n

Cacabelos, R. La fiabilidad m\u00e9dica y el dilema del paciente en Jap\u00f3n. Los m\u00e9dicos deben ser ejemplo de escrupulosa moralidad social. JANO Med. Hum., 856:21-22 (1989).<\/p>\n

Cacabelos, R. La tercera edad en Jap\u00f3n, un problema por resolver. Jano Med. Hum., 857:19-23 (1989).<\/p>\n

Cacabelos, R. Propiedades de la lectina y acci\u00f3n antibacteriana de las sarcotoxinas. JANO Med. Hum., 858:27-28 (1989).<\/p>\n

Cacabelos, R. Impacto de la inform\u00e1tica en el medio sociocultural y biom\u00e9dico. JANO Med. Hum., 859:17-22 (1989),<\/p>\n

Cacabelos, R. SIDA cerebral. JANO Med. Hum., 862:32-43 (1989).<\/p>\n

Cacabelos, R. Estrategias para alcanzar un liderazgo cient\u00edfico a nivel mundial. JANO Med. Hum., 865:23-24 (1989).<\/p>\n

Cacabelos, R. Nuevas estrategias para el control de la natalidad en China. JANO Med. Hum., 879:21-22 (1989).<\/p>\n

Cacabelos, R. La formaci\u00f3n del m\u00e9dico en Jap\u00f3n (I). El M\u00e9dico, 338:DLXXV-DLXXX (1989).<\/p>\n

Cacabelos, R. La formaci\u00f3n del m\u00e9dico en Jap\u00f3n (II). El M\u00e9dico, 339:DLXXXI-DLXXXVI (1989).<\/p>\n

Cacabelos, R. Salud Mental. Hacia un nuevo concepto de salud integral, prevenci\u00f3n de los trastornos mentales y cobertura social en psiquiatr\u00eda. JANO Med. Hum., 884:77-89 (1989).<\/p>\n

Cacabelos, R. Enfermedad mental y psiquiatr\u00eda en Jap\u00f3n. Investigaci\u00f3n M\u00e9dica Permanente. Psiquiatr\u00eda, 4:197-198 (1989).<\/p>\n

Cacabelos, R. Contribuci\u00f3n japonesa al desarrollo de la biotecnolog\u00eda. JANO Med. Hum., 892:17-22 (1990).<\/p>\n

Cacabelos, R. Jap\u00f3n invierte en alta tecnolog\u00eda para la investigaci\u00f3n biom\u00e9dica. JANO Med. Hum., 894:22-26 (1990).<\/p>\n

Cacabelos, R. Envejecimiento poblacional, mercado de salud para la tercera edad. JANO Med Hum., 896:24-27 (1990).<\/p>\n

Cacabelos, R. Repercusiones cient\u00edficas del proyecto del genoma humano (PGH). JANO Med. Hum., 897:24-26 (1990).<\/p>\n

Cacabelos, R. Problemas \u00e9ticos, sociales y religiosos han paralizado la pr\u00e1ctica de los trasplantes de \u00f3rganos que ven\u00edan practic\u00e1ndose en Jap\u00f3n. JANO Med. Hum., 898:20-21 (1990).<\/p>\n

Cacabelos, R. Bases neurobiol\u00f3gicas de la adicci\u00f3n alcoh\u00f3lica. JANO Med. Hum., 900:75-93 (1990).<\/p>\n

Cacabelos, R. La industria farmac\u00e9utica de Jap\u00f3n dispone ya de los requisitos esenciales para poder dedicarse a la conquista del mercado exterior. JANO Med. Hum., 901:20-21 (1990).<\/p>\n

Cacabelos, R. El aumento de la inversi\u00f3n para la investigaci\u00f3n del c\u00e1ncer revela una vez m\u00e1s que existe gran preocupaci\u00f3n del gobierno y la sociedad japonesas. JANO Med. Hum., 902:23-24 (1990).<\/p>\n

Cacabelos, R. Pensando en el futuro de las ciencias m\u00e9dicas, las autoridades del Jap\u00f3n invierten en biotecnolog\u00eda, biolog\u00eda molecular y gen\u00e9tica molecular. JANO Med. Hum., 904:23-24 (1990).<\/p>\n

Cacabelos, R. En los \u00faltimos a\u00f1os, la industria farmac\u00e9utica japonesa ha estado viviendo una de las \u00e9pocas econ\u00f3micamente m\u00e1s venturosas de los ochenta. JANO Med. Hum., 905:27-28 (1990).<\/p>\n

Cacabelos, R. Depresi\u00f3n senil. JANO Med. Hum., 916:25-40 (1990).<\/p>\n

Cacabelos, R. Alzheimer\u2019s disease: Towards an understanding of aetiology and pathogenesis. Med. Clin., 95:399 (1990).<\/p>\n

Cacabelos, R. Envejecimiento cerebral. JANO Med. Hum., 927:43-48 (1990).<\/p>\n

Cacabelos, R. Jap\u00f3n, dispuesto a demostrar que sus cient\u00edficos son tan creadores como los europeos y americanos. La estrategia actual radica en invertir m\u00e1s en investigaci\u00f3n b\u00e1sica. JANO Med. Hum., 925:22-23 (1990).<\/p>\n

Cacabelos, R. La participaci\u00f3n industrial en la investigaci\u00f3n acad\u00e9mica. JANO Med. Hum., 936:26 (1991).<\/p>\n

Cacabelos, R. Desarrollo de la psicolog\u00eda y de las ciencias cognitivas en Jap\u00f3n. JANO Med. Hum., 939:23-24 (1991).<\/p>\n

Cacabelos, R. Las autoridades niponas dise\u00f1an estrategias en la lucha antidroga. JANO Med. Hum., 938:24-26 (1991).<\/p>\n

Cacabelos, R. La medicina tradicional china (Kampo) sigue estando vigente en Jap\u00f3n. JANO Med. Hum., 940:32-33 (1991).<\/p>\n

Cacabelos, R. Gen\u00e9tica de la enfermedad de Alzheimer. JANO Med. Hum., 948:44-64 (1991)<\/p>\n

Cacabelos, R. Las estrategias de control de calidad en Jap\u00f3n ayudan a abaratar la sanidad, simplificar los esquemas asistenciales y mejorar la salud. JANO Med. Hum., 954:23-24 (1991).<\/p>\n

Cacabelos, R. Calidad de vida y bienestar: influencia de la medicina japonesa. JANO Med. Hum., 963:27-28 (1991).<\/p>\n

Cacabelos, R. Gesti\u00f3n cient\u00edfica: un embri\u00f3n de buenas intenciones. S\u00edstole, 84:9 (1991).<\/p>\n

Cacabelos, R. D\u00e9cadas de tradici\u00f3n, evoluci\u00f3n y progreso en la medicina japonesa. JANO Med. Hum., 970:28-32 (1991).<\/p>\n

Cacabelos, R. Una de las preocupaciones de un amplio sector de la sociedad japonesa se centra en buscar salida al sufrimiento de los enfermos terminales. JANO Med. Hum., 972:28-30 (1991).<\/p>\n

Cacabelos, R. Estrategias cient\u00edficas ante el siglo XXI. Anuario S\u00edstole. 101 (1992).<\/p>\n

Cacabelos, R. En Jap\u00f3n hay en la actualidad 14 millones de personas mayores de 65 a\u00f1os. JANO Med. Hum., 977:21 (1992).<\/p>\n

Cacabelos, R. Demencia-SIDA. JANO Med. Hum., 984:31-44 (1992).<\/p>\n

Cacabelos, R. Planificaci\u00f3n sanitaria. S\u00edstole, 98:4 (1992).<\/p>\n

Cacabelos, R. Tratamiento actual de la enfermedad de Alzheimer. S\u00edstole, 100:51 (1992).<\/p>\n

Cacabelos, R. La fase de recesi\u00f3n econ\u00f3mica en la que ha entrado Jap\u00f3n podr\u00eda llegar a originar cambios muy importantes en su pol\u00edtica cient\u00edfica. JANO Med. Hum., 996:35 (1992).<\/p>\n

Cacabelos, R. Futuro de la investigaci\u00f3n sobre la enfermedad de Alzheimer. Noticias M\u00e9dicas, 3468:89-90 (1992).<\/p>\n

Cacabelos, R. Neurociencias, econom\u00eda y salud. S\u00edstole, 107:4 (1992).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer: El reto de la psicofarmacolog\u00eda molecular. JANO Med. Hum., 1000:161-164 (1992).<\/p>\n

Cacabelos, R. La inteligencia artificial en Jap\u00f3n tras el fracaso de la quinta generaci\u00f3n de ordenadores. JANO Med. Hum., 999:34-36 (1992).<\/p>\n

Cacabelos, R. Perspectivas de futuro para el Alzheimer. Diario M\u00e9dico, 14 Julio, 1992.<\/p>\n

Cacabelos, R. Soluciones a la crisis sanitaria (I). S\u00edstole 120:2 (1992).<\/p>\n

Cacabelos, R. Soluciones a la crisis sanitaria (II). S\u00edstole l23:2 (1992).<\/p>\n

Cacabelos, R. Soluciones a la crisis sanitaria (III). S\u00edstole 125:2 (1992).<\/p>\n

Cacabelos, R. Soluciones a la crisis sanitaria (IV). S\u00edstole 126:2 (1992).<\/p>\n

Cacabelos, R. Demencia senil: prioridad sanitaria. El Correo Gallego. Medicina. 20.12.92, pp. 5 (1992).<\/p>\n

Cacabelos, R. El reto de las neurociencias. Anuario S\u00edstole, pp. 78-79 (1993).<\/p>\n

Cacabelos, R. Sistema de salud japon\u00e9s: un modelo de rentabilidad y eficacia. JANO Med. Hum., 1048:19-20 (1993).<\/p>\n

Cacabelos, R. Avances en el tratamiento del mal de Alzheimer. ABC Cultural de la Ciencia, Madrid, 7 Enero, pp. 56 (1994).<\/p>\n

Cacabelos, R. Tetrahidroaminoacridina: Una esperanza terap\u00e9utica para la enfermedad de Alzheimer. JANO Med. Hum., 1082:57-60 (1994).<\/p>\n

Cacabelos, R. New functional aspects of the suprachiasmatic nucleus of the hypothalamus. Med. Clin. 102:526,531,539 (1994).<\/p>\n

Cacabelos, R. Nuevas posibilidades terap\u00e9uticas en la enfermedad de Alzheimer. Diario M\u00e9dico, Junio 6, pp. 12 (1994).<\/p>\n

Cacabelos, R. Alzheimer: Nuevas esperanzas para una enfermedad temible. ABC Cultural. ABC de la Ciencia. Julio 1, pp. 52-53 (1994).<\/p>\n

Cacabelos, R. Neurofarmacolog\u00eda molecular de la enfermedad de Alzheimer. Primeras generaciones de f\u00e1rmacos anti-demencia. Direcci\u00f3n Farmac\u00e9utica 5:48-54 (1994).<\/p>\n

Cacabelos, R. Alzheimer: Aspectos m\u00e9dicos y sociofamiliares. Punto de Encuentro, 9:20-23 (1995).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer: Muerte celular y riesgo gen\u00e9tico. Diario M\u00e9dico, 20 Sept., pp. 15 (1996).<\/p>\n

Cacabelos, R. El reto de la enfermedad de Alzheimer. ABC Cultural. ABC de la Ciencia. (27.9.1996), 256:62 (1996).<\/p>\n

Cacabelos, R. Pr\u00f3logo a \u201cEnfermedad de Alzheimer. Aspectos psicosociales\u201d. Autor: J.A. Fl\u00f3rez Lozano. EDIKAMed, Barcelona, 1996.<\/p>\n

Adeva Candenas, J., Fl\u00f3rez-Lozano, J.A., Caballero-Garc\u00eda, J.C., Cacabelos, R., Garc\u00eda Garc\u00eda, M.C., Mart\u00ednez Lage, J.M., Ma\u00fajo Iglesias, B.A. Las demencias en el presente y en el futuro. JANO LII\/1203:929\/33 (1997).<\/p>\n

Cacabelos, R. Demencia senil: El reto del siglo XXI. JANO LII\/1203:930-936\/34-40 (1997).<\/p>\n

Cacabelos, R. Un juicio a la bioingenier\u00eda. ABC de la Ciencia. 279:55 (1997).<\/p>\n

Cacabelos, R. El Alzheimer, prioridad sociosanitaria para el siglo XXI. El Diario Monta\u00f1\u00e9s, pp. 4 (9.5.1997)<\/p>\n

Cacabelos, R. Cerebro y conciencia. Recensiones bibliogr\u00e1ficas. Med. Cl\u00edn., 109:288 (1997).<\/p>\n

Cacabelos, R. Premio a la perseverancia innovadora. La Vanguardia, pp. 27 (7.10.1997).<\/p>\n

Cacabelos, R. Pr\u00f3logo a \u201cManual de cuidados b\u00e1sicos de una enfermedad familiar (Enfermedad de Alzheimer)\u201d. Autor: Miguel Mu\u00f1oz-Cruzado y Barba. Drug Farma, Madrid, 1998.<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Reto y compromiso. DKV Previasa Magazine. 2:13-17 (1998).<\/p>\n

Cacabelos, R. Educaci\u00f3n, madurez cerebral y prevenci\u00f3n del fracaso escolar. Programa ADI, CIBE, La Coru\u00f1a (2000).<\/p>\n

Cacabelos, R. Operaci\u00f3n Genoma. Europa pagar\u00e1 un alto precio por quedarse atr\u00e1s. Muy Interesante 229:28 (2000).<\/p>\n

Cacabelos, R. La geograf\u00eda del pri\u00f3n. El Cultural, 7\/2:56-57 (2001).<\/p>\n

Cacabelos, R. Medicina Predictiva y Genoma. ByN Dominical II\/57:70 (2001).<\/p>\n

Cacabelos, R. Salud mental y prevenci\u00f3n de riesgo cerebral en altos ejecutivos. ECO 130:71 (2002).<\/p>\n

Cacabelos, R. Plan de prevenci\u00f3n gen\u00e9tica de la enfermedad de Alzheimer. ECO 131:50 (2002).<\/p>\n

Cacabelos, R. Progreso biotecnol\u00f3gico. ECO 132:60 (2002).<\/p>\n

Cacabelos, R. Impacto del Genoma Humano en la Econom\u00eda Mundial. ECO 133:50 (2002).<\/p>\n

Cacabelos, R. Econom\u00eda y Salud. ECO 135:44 (2002).<\/p>\n

Cacabelos, R. Saber o no saber: Esa es la diferencia. ECO 136:44 (2002).<\/p>\n

Cacabelos, R. Criterios de Excelencia. ECO 137:78 (2002).<\/p>\n

Cacabelos, R. Pensando en Jap\u00f3n. ECO 138:52 (2002).<\/p>\n

Cacabelos, R. Salvemos el mar. ECO 139:52 (2002).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Retos para el futuro. Alzheimer en Asturias. N\u00ba 2, Julio-Diciembre (2002).<\/p>\n

Cacabelos, R. Educaci\u00f3n y Fugas\u2026de Cerebros. ECO 140:70 (2003).<\/p>\n

Cacabelos, R. Patolog\u00eda vascular y demencia: asociaci\u00f3n de alto riesgo. Consejos de tu Farmac\u00e9utico 35:16-17 (2002).<\/p>\n

Cacabelos, R. Gen\u00e9tica de los trastornos mentales. Consejos de tu Farmac\u00e9utico 36:20-21 (2002).<\/p>\n

Cacabelos, R. Enfermedad de Alzheimer. Retos para el futuro. J\u00fabilo 47:24-27 (2003).<\/p>\n

Cacabelos, R. Progreso biotecnol\u00f3gico en Espa\u00f1a. Ejecutivos 134: 46-47 (2003).<\/p>\n

Cacabelos, R. La Medicina Gen\u00f3mica del Futuro. Bolet\u00edn das Ciencias, 62:67-69 (2006).<\/p>\n

Cacabelos, R. Funci\u00f3n cerebrovascular en la enfermedad de Alzheimer. Sinapsis. www.sinapsis.org (2006).<\/p>\n

Cacabelos, R. Exposici\u00f3n Fotogr\u00e1fica: Por la Galicia Natural. Fundaci\u00f3n Ebiotec y Ayuntamiento de A Coru\u00f1a (2006).<\/p>\n

Cacabelos, R. Specula orbis. Gen-T\/The EuroEspes Journal, 1:3 (2007).<\/p>\n

Cacabelos, R. Medicina gen\u00f3mica y enfermedad de Alzheimer. Gen-T\/The EuroEspes Journal, 1:30-38 (2007).<\/p>\n

Cacabelos, R. Stultia mentis. Gen-T\/The EuroEspes Journal, 2:3 (2007).<\/p>\n

Cacabelos, R. Gen\u00e9tica del dolor de cabeza. El enigma de la herencia en las migra\u00f1as. Gen-T\/The EuroEspes Journal, 2:32-44 (2007).<\/p>\n

Cacabelos, R. La gen\u00e9tica familiar es el primer factor de riesgo para padecer Alzheimer. Acofar, 469: 16-18 (2007).<\/p>\n

Cacabelos, R. La Uni\u00f3n Europea se abraza a la Farmacogen\u00f3mica. El Global, 10-16 Sept. (2007).<\/p>\n

Cacabelos, R. Los retos de la medicina gen\u00f3mica y el paradigma de la farmacogen\u00e9tica. Rev. Esp. Econom\u00eda Salud, 7:5-6 (2008).<\/p>\n

Cacabelos, R. Medicina personalizada versus medicina numeralizada. Gen-T\/The EuroEspes Journal, 3:3 (2008).<\/p>\n

Cacabelos, R. Los genios de la locura. Evoluci\u00f3n del conocimiento sobre la enfermedad mental. Gen-T\/The EuroEspes Journal, 3:28-45 (2008).<\/p>\n

De la Torre, J., Cacabelos, R. Patolog\u00eda cardio-cerebrovascular en la enfermedad de Alzheimer. Gen-T\/The EuroEspes Journal, 3:56-65 (2008).<\/p>\n

Harguindey, S., Orive, G., Anitua, E., Arranz, J.L., Cacabelos, R., D\u00edaz de Otazu, R., Mel\u00e9ndez Hevia, E. Hacia un enfoque integrado de las enfermedades neurodegenerativas. Gen-T\/The EuroEspes Journal, 3:82-89 (2008).<\/p>\n

Cacabelos, R. The abyssal waters of personalized medicine. Gen-T\/The EuroEspes Journal, International Edition, 2:5-7 (2008).<\/p>\n

Cacabelos, R. Paso a la cultura del conocimiento. Gen-T\/The EuroEspes Journal, 4:3 (2009).<\/p>\n

Terr\u00f3n, F., Kiener, P.A., Ortiz, P., Cacabelos, R., Hug, P. Biotecnolog\u00eda. En: Ponencias VI Congreso de Directivos CEDE. Liderando en positivo. Pamplona, 29-30 Oct. Sodena. Sociedad de Desarrollo de Navara, pp. 279-312 (2010).<\/p>\n

Cacabelos, R. La crisis de la salud social. Gen-T 5:3 (2010).<\/p>\n

Cacabelos, R. Consejos a un hijo (adolescente). Gen-T 5:97-98 (2010).<\/p>\n

Cacabelos, R. Reforma sanitaria. Gen-T 6:3 (2010).<\/p>\n

Cacabelos, R. Consejos a un colega (m\u00e9dico). Gen-T 6:97-98 (2010).<\/p>\n

Cacabelos, R. Pepinos, par\u00e1sitos e intoxicaciones. Gen-T 7:3 (2011).<\/p>\n

Cacabelos, R. Consejos a un Presidente. Gen-T 7:96-98 (2011).<\/p>\n

Cacabelos, R. El Alzheimer comienza 30 a\u00f1os antes de manifestarse. El Correo Gallego. http:\/\/www.elcorreogallego.es\/popImprimir.php?idWeb=1&idNoticia=702652.<\/p>\n

Cacabelos, R. Historias de la aldea, un poco de paz navide\u00f1a (\u2026 y feliz traspaso de incompetencias). Gen-T 8:3 (2011).<\/p>\n

Cacabelos, R. La biblia de la gen\u00f3mica. Gen-T 9:3-5 (2013).<\/p>\n

Cacabelos, R. \u00c9tica de progreso en tiempo de crisis. Alterius non sit qui sus ese potest. Gen-T 9:177-178 (2013).<\/p>\n

Cacabelos R. Priorizar las inversiones y una buena gesti\u00f3n ser\u00e1n clave para salir de la crisis. El Correo Gallego. 31 Diciembre,pp. 28-29, 2014.<\/p>\n

Cacabelos R. El mundo de Jonathan Livingston Harguindey. El Correo Gallego, 4 Enero, pp. 6, 2015.<\/p>\n

Cacabelos R. The challenges of Pharmacogenomics and Personalized medicine in an aged population. Adjacent Government 7. http:\/\/edition.pagesuite-professional.co.uk. Page 368. 2015. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.<\/p>\n

Cacabelos R. Genomic Medicine: the reconceptualization of Health and Disease. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.http:\/\/www.adjacentgovernment.co.uk\/category\/ebooks\/<\/p>\n

Cacabelos R. Drug development for Alzheimer\u2019s disease. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.http:\/\/edition.pagesuite-professional.co.uk\/launch.aspx?eid=793abb3f-e692-439f-9236-554269c9e570<\/p>\n

Cacabelos R. Alzh\u00e9imer: prevenci\u00f3n contra el riesgo y tratamiento personalizado contra el da\u00f1o. El Faro de Vigo, 18 Septiembre, pp. 17, 2015.<\/p>\n

Cacabelos R. Cuando perdemos la memoria. El Correo Gallego, 20 Septiembre, pp. 7, 2015<\/p>\n

Cacabelos R. El martillo del Herrero. El Correo Gallego, 27 Septiembre, pp. 7, 2015.<\/p>\n

Cacabelos R. Soluciones al gasto por enfermedad. http:\/\/diario.eleconomista.es\/1\/578734-eleconomista-sanidad-01-octubre-2015.<\/p>\n

Cacabelos R. El papel es nuestra vida. El Correo Gallego, 11 Octubre, pp. 6, 2015.<\/p>\n

Cacabelos R. \u00c9gloga a mi presidente (I). El Correo Gallego, 22 Octubre, pp. 16, 2015.<\/p>\n

Cacabelos R. \u00c9gloga a mi presidente (II). El Correo Gallego, 23 Octubre, pp. 18, 2015.<\/p>\n

Cacabelos R. Medicina gen\u00f3mica de los trastornos mentales. La nueva revoluci\u00f3n conceptual en psiquiatr\u00eda. http:\/\/www.psiquiatria.com\/psiq_general_y_otras_areas\/genetica\/medicina-genomica-de-los-trastornos-mentales-la-nueva-revolucion-conceptual-en-psiquiatria\/<\/p>\n

Cacabelos R. Investigaci\u00f3n Biom\u00e9dica y Medicina Personalizada. La Cultura del Conocimiento. El Correo Gallego. Especial Medicina. 16 Dic. Pp. 3-5 (2015).<\/p>\n

Cacabelos R. Desvar\u00edos en el lupanar pol\u00edtico. Gen-T 2015; 10:3.<\/p>\n

Cacabelos R. Al profesor universitario. Gen-T 2015; 10:199-200.<\/p>\n

Cacabelos R. Misuse of pharmacotherapy: Danger on the horizon. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.<\/p>\n

Cacabelos R. Epigenetics: The missing link at the frontier of health and disease. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Publicaciones Art\u00edculos y Trabajos Cient\u00edficos Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Nishimura, T. Histamine within the hypothalamo-hypophyseal system after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:342-344. Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Tada, K., Takeda, M., Nishimura, T., Takagi, T., Sugita, T., Tanizawa, O. On the chronological changes in hypothalamic […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"

Art\u00edculos y Trabajos Cient\u00edficos<\/h2>\r\nCacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Nishimura, T. Histamine within the hypothalamo-hypophyseal system after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:342-344.\r\n\r\nCacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Tada, K., Takeda, M., Nishimura, T., Takagi, T., Sugita, T., Tanizawa, O. On the chronological changes in hypothalamic catecholamines and plasma ACTH after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:345-347.\r\n\r\nCacabelos, R., Yamatodani, A., Watanabe, T., Takagi, T., Tanizawa, O., Hariguchi, S., Nishimura, T., Wada, H. Effects of alpha-fluoromethylhistidine on ACTH, vasopressin, and oxytocin in the hypothalamo-hypophyseal system and plasma. Bull. Japn. Neurochem. Soc., 23:403-405 (1984).\r\n\r\nCacabelos, R. Histaminolog\u00eda. Med. Clin., 84:524-527 (1985).\r\n\r\nCacabelos, R., Takagi, T., Otsuki, Y., Sugita, S., Hariguchi, S., Nishimura, T., Tanizawa, O. An\u00e1lisis cronobiol\u00f3gico de los efectos producidos por la adrenalectom\u00eda sobre los sistemas oxitocin\u00e9rgico y vasopresin\u00e9rgico. Endocrinolog\u00eda, 32:126-135 (1985).\r\n\r\nCacabelos, R., Yamatodani, A., Fukui, H., Watanabe, T., Hariguchi, S., Nishimura, T., Wada, H. Age- and sex-related changes in histamine in the central nervous system. Bull. Jpn. Neurochem. Soc., 24:337-339 (1985).\r\n\r\nCacabelos, R., Yamatodani, A., Fukui, H., Watanabe, T., Hariguchi, S., Nishimura, T., Wada, H. Nature of histaminergic neuromodulation of the corticotropinergic system. Biogenic Amines, 3:9-19 (1985).\r\n\r\nNishimura, T., Takeda, M., Tada, K., Hariguchi, S., Cacabelos, R., Yamashita, T., Okabe, T. Experimental model of senile and vascular dementia. A biochemical hypothesis. Ronenkai-no-shogai-no-rinsho. Haseikiyo. Chiryo-ni-kansuru- kenkyu. Kenkyuseika-hokokusho, 59:15-23 (1985).\r\n\r\nCacabelos, R., Niigawa, H., Hariguchi, S. Hypothalamo-hypophyseal system and brain function. J. Clin. Sci., 2:1108-1120 (1986).\r\n\r\nNiigawa, H., Cacabelos, R., Miyake, A., Tanaka, J., Murakoshi, K., Tada, K., Hariguchi, S., Nishimura, T. Study of the effects of histamine and histamine antagonists in the gonadotropinergic system. Implications for aging. Bull. Jpn. Neurochem. Soc., 25:298-300 (1986).\r\n\r\nCacabelos, R., Yamatodani, A., Fukui, H., Takeda, M., Nishimura, T., Wada, H. Age-and sex-related changes in histamine and H-1 receptors in the central nervous system following a long-term castration. Bull. Jpn. Neurochem. Soc., 25:271-273 (1986).\r\n\r\nCacabelos, R., Niigawa, H., Nishimura, T. Neuroendocrine system in aging. Gerontopsychiatry, 3:691-711 (1986).\r\n\r\nNishimura, T., Yamashita, T., Tada, K., Cacabelos, R., Niigawa, H., Suzuki, H. Recent advances in biochemical studies of dementia in the elderly. Brain Nerve, 39:9-16 (1987).\r\n\r\nCacabelos, R., Niigawa, H., Nishimura, T. Neuroendocrine function in psychiatric disorders and dementia. Jap. J. Neuropsychopharmacol., 9:13-49 (1987).\r\n\r\nCacabelos, R., Niigawa, H., Nishimura, T. Neurochemistry of senile dementia. Changes in neuropeptides. Clin. Neurosci., 5:1111-1115 (1987).\r\n\r\nCacabelos, R. Sistema vasopresin\u00e9rgico (I). Med. Clin., 88:160-168 (1987).\r\n\r\nCacabelos, R. Sistema vasopresin\u00e9rgico (II). Med. Clin., 88:334-343 (1987).\r\n\r\nCacabelos, R., Yamatodani, A., Niigawa, H., Harigmchi, S., Nishimura, T., Wada, H. Histaminergic neuromodulation of the release of vasopressin. Neuroendocrinology, 45:368-375 (1987).\r\n\r\nCacabelos, R., Niigawa, H., Hariguchi, S., Nishimura, T. Influence of somatostatin and growth hormone-releasing factor on locomotion and learning in rats. OUCEM-86: A computerized system to study behavioral parameters in small mammals. Prog. Med., 7:763-773 (1987).\r\n\r\nCacabelos, R., Yamatodani, A., Fukui, H., Niigawa, H., Miyake, A., Watanabe, T., Nishimura, T., Wada, H. Time- and dose-dependent responses of brain histamine to intracerebroventricular and intraperitoneal administrations of growth hormone-releasing factor (GRF1-44). Tohoku J. Exp. Med., 151:429-442 (1987).\r\n\r\nCacabelos, R., Niigawa, H., Nishimura, T., Yamatodani, A., Wada, H. Somatostatin-induced histamine response in the rat central nervous system. Tohoku J. Exp. Med., 152:397-405 (1987).\r\n\r\nCacabelos, R., Niigawa, H., Yamatodani, A., Fukui, H., Wada, H., Nishimura, T. Vasopressin-induced histamine response in the CNS. Bull. Jpn. Neurochem. Soc., 26:559-561 (1987).\r\n\r\nNiigawa, H., Yamatodani, A., Nishimura, T., Wada, H., Cacabelos, R. Effect of neurotoxic lesions in the mammillary bodies on the distribution of brain histamine. Bull. Jpn. Neurochem. Soc., 26:556-558 (1987).\r\n\r\nCacabelos, R., Niigawa, H., Ikemura, T., Yanagi, Y., Tanaka, S., Rodr\u00edguez-Arnao, M.D., G\u00f3mez-Pan, A., Nishimura, T. GHRH- induced GH response in patients with senile dementia of the Alzheimer type. Acta Endocrinol. (Copenh.), 117:295-301 (1988).\r\n\r\nCacabelos, R., Niigawa, H., Yamatodani, A., G\u00f3mez-Pan, A., Nishimura, T., Wada, H. Antagonistic effects of growth hormone-releasing factor and somatostatin on brain histamine. Endocrinology, 122:1269-1276 (1988).\r\n\r\nCacabelos, R. Nuevas perspectivas en el abordaje cl\u00ednico de la enfermedad de Alzheimer. Rev. Esp. Geriat. Gerontol., 23:67-69 (1988).\r\n\r\nCacabelos, R., Niigawa, H., Nishimura, T. Antagonistic effects of somatostatin and growth hormone-releasing factor on behavior. Jpn. J. Psychopharmacol., 8:235-236 (1988).\r\n\r\nNiigawa, H., Murakoshi, K., Nishimura, T., Cacabelos, R. Effects of chronic administration of L-histidine on behavior and learning. Jpn. J. Psychopharmacol., 8:169-170 (1988).\r\n\r\nMurakoshi, K., Niigawa, H., Nishimura, T., Cacabelos, R. Computerized analysis of the effects of L-histidine, histamine, and antihistaminics on behavioral parameters. Jpn. J. Psychopharmacol., 8:167-168 (1988).\r\n\r\nNiigawa, H., Cacabelos, R., Hariguchi, S. Functions of biogenic amines. Effects of aging. Clin. Neurosci., 6:522-524 (1988).\r\n\r\nCacabelos, R., Niigawa, H., Rodr\u00edguez-Arnao, M.D., G\u00f3mez-Pan, A., Nishimura, T. Influence of somatostatin and growth hormone-releasing factor on behavior. Clinical and therapeutic implications in neuropsychiatric disorders. Horm. Res., 29:129-132 (1988).\r\n\r\nNiigawa, H., Yamatodani, A., Nishimura, T., Wada, H., Cacabelos, R. Effect of neurotoxic lesions in the mammillary bodies on the distribution of brain histamine. Brain Res., 459:183-186 (1988).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer: Alternativas cl\u00ednico-terap\u00e9uticas. Med. Clin., 91:454-474 (1988).\r\n\r\nNiigawa, H., Cacabelos, R., Hariguchi, S., Nishimura, T. Effects of lesions in the nucleus basalis of Meynert on stress-induced neuropeptide release. Bull. Jpn. Neurochem. Soc., 27:232-233 (1988).\r\n\r\nCacabelos, R. Factor liberador de la hormona de crecimiento en la enfermedad de Alzheimer. Med. Clin., 92:299-301 (1989).\r\n\r\nCacabelos, R. Neurobiolog\u00eda y utilizaci\u00f3n del GRF como marcador diagn\u00f3stico en trastornos mentales. Endocrinolog\u00eda, 36:71-77 (1989).\r\n\r\nCacabelos, R., Yamatodani, A., Niigawa, H., Hariguchi, S., Tada, K., Nishimura, T., Wada, H., Brandeis, L., Pearson, J. Brain histamine in Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 11:353-360 (1989).\r\n\r\nCacabelos, R. Growth hormone-releasing factor in mental disorders: A diagnostic marker and therapeutic alternative. Meth. Find. Exp. Clin. Pharmacol., 11:421-436 (1989).\r\n\r\nCacabelos, R. Growth hormone-releasing factor in mental disorders. Drug News Perspect., 2:133-140 (1989).\r\n\r\nCacabelos, R. Organizaci\u00f3n funcional y biolog\u00eda molecular del sistema neuroendocrino. Endocrinolog\u00eda, 36:332-344 (1989).\r\n\r\nNiigawa, H., Cacabelos, R., Hariguchi, S., Nishimura, T. Neurochemical and behavioral changes in rats with lesions in the mammillary bodies and basal forebrain. Bull. Jpn. Neurochem. Soc., 28:390-391 (1989).\r\n\r\nCacabelos, R. Neuroinmunoendocrinolog\u00eda: neurorregulaci\u00f3n peptid\u00e9rgica de la respuesta inmune y acciones intersist\u00e9micas. Endocrinolog\u00eda, 36:418-425 (1989).\r\n\r\nCacabelos, R. Recent advances in neuropsychopharmacology. Drug News & Perspectives, 2:439-442 (1989).\r\n\r\nItowi, N., Yamatodani, A., Cacabelos, R., Goto, M., Wada, H. Effect of histamine depletion on circadian variations of corticotropin and corticosterone in rats. Neuroendocrinology, 50:187-192 (1989).\r\n\r\nCacabelos, R. Acciones centrales de los neurop\u00e9ptidos hipofisiotropos. Endocrinolog\u00eda, 37:60-76 (1990).\r\n\r\nCacabelos, R., Albarr\u00e1n, M., Di\u00e9guez, C., Fari\u00f1as, F., del Pino, J.L., Exp\u00f3sito, J., Mart\u00edn-Loeches, M., Rubia, F.J. GRF-induced GH response in attention-deficit hyperactivity disorder. Meth. Find. Exp. Clin. Pharmacol., 12:79-85 (1990).\r\n\r\nMart\u00edn-Loeches, M., Gil Gregorio, P., Miguel Tobal, F., Exp\u00f3sito Torrej\u00f3n, F.J., Cacabelos Garc\u00eda, R., Rubia Vila, F.J. Relaci\u00f3n entre datos psicom\u00e9tricos y potenciales evocados tard\u00edos en la enfermedad de Alzheimer. Rev. Esp. Geriatr. Gerontol., 25:21-26 (1990).\r\n\r\nCacabelos, R. Brain histamine in Alzheimer\u2019s disease. Parkinson\/Alzheimer Digest, 2:26-27 (1990).\r\n\r\nCacabelos, R. Influencia de la gen\u00e9tica molecular en el futuro de la psiquiatr\u00eda. Anuario Psiqui\u00e1trico, 1:3-6 (1990).\r\n\r\n\u00c1lvarez, X.A., Couto, D.F., Fari\u00f1as, F., Fern\u00e1ndez, M., Otero, F., Cacabelos, R. Influencia del sistema somatotropin\u00e9rgico sobre la memoria de evocaci\u00f3n a corto plazo en sujetos j\u00f3venes sanos. Anuario Psiqui\u00e1trico, 1:259-269 (1990).\r\n\r\nNiigawa, H., Okado, T., Hariguchi, S., Nishimura, T., Cacabelos, R. Effect of scopolamine on behavioral parameters. A computerized analysis with the OUCEM-86 system. Anuario Psiqui\u00e1trico, 1:277-286 (1990).\r\n\r\nNiigawa, H., Nakamura, K., Hariguchi, S., Nishimura, T., Cacabelos, R. Effects of chronic administration of L-histidine on behaviour and learning. A computerized analysis with the OUCEM-86 system. Anuario Psiqui\u00e1trico, 1:287-298 (1990).\r\n\r\nNiigawa, H., Hariguchi, S., Nishimura, T., Cacabelos, R. Behavioral changes in rats with bilateral lesions in the nucleus basalis of Meynert. A computerized analysis with the OUCEM-86 system. Anuario Psiqui\u00e1trico, 1:299-305 (1990).\r\n\r\nFern\u00e1ndez, M., Fari\u00f1as, F., Cornes, J.M., Borr\u00e1s, C.G., Rodr\u00edguez, A., Cacabelos, R. Respuesta de GH a GRF en pacientes con trastorno depresivo mayor. Anuario Psiqui\u00e1trico, 1:347-353 (1990).\r\n\r\nOtero, F., Tortajada, I., Alonso, J., Tabernero, J., Seoane, J., Agra, S., Cornes, J.M., Cacabelos, R Respuesta de GH a GRF(1-29)NH2 en pacientes con esquizofrenia. Anuario Psiqui\u00e1trico, 1:355-362 (1990).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Efectos extraespec\u00edficos de la administraci\u00f3n aguda de GRF(l-29)NH2 en sujetos j\u00f3venes sanos. Anuario Psiqui\u00e1trico, 1:363-372 (1990).\r\n\r\nFari\u00f1as, F., Garc\u00eda-Alonso, L., Cacabelos, R. Respuesta de GH a GRF(1-29)NH2 en retrasos de crecimiento con patolog\u00eda neuropsiqui\u00e1trica asociada. Anuario Psiqui\u00e1trico, 1:383-388 (1990).\r\n\r\nRubia, F.J., Mart\u00edn-Loeches, M., Exp\u00f3sito, F,J., Miguel, F., Cacabelos, R. Effects of growth hormone-releasing factor and somatostatin on brain bioelectrical activity and cognitive functions. Anuario Psiqui\u00e1trico, 1:389-399 (1990).\r\n\r\ndel Pino, J.L., Mart\u00edn-Loeches, M., Exp\u00f3sito, J., Miguel, F., Cacabelos, R., Rubia, F.J. Mapas de actividad el\u00e9ctrica cerebral en la hipercinesia infantil. Anuario Psiqui\u00e1trico, 1:401-409 (1990).\r\n\r\nMart\u00edn-Loeches, M., Gil, P., Exp\u00f3sito, F.J., Miguel, F., Cacabelos, R., Rubia, F.J. Mapas de actividad el\u00e9ctrica cerebral en la demencia senil de tipo Alzheimer durante tareas cognoscitivas. Anuario Psiqui\u00e1trico, 1:419-428 (1990).\r\n\r\nFern\u00e1ndez, M., P\u00e9rez, A., Lois, J.M., Otero, F., Cacabelos, R. Evaluaci\u00f3n bioqu\u00edmica y estrategia terap\u00e9utica eficaz en un caso de depresi\u00f3n resistente. Anuario Psiqui\u00e1trico, 1:449-454 (1990).\r\n\r\nCacabelos, R. Gen\u00e9tica de los trastornos neuropsiqui\u00e1tricos. Med. Cl\u00edn., 94:699-701 (1990).\r\n\r\nCacabelos, R. Growth hormone-releasing factor in mental disorders: Diagnostic marker and therapeutic alternative. Psychiatry Digest, 3:20-21 (1990).\r\n\r\nCacabelos, R. Histaminergic system: Neuroendocrine function of brain histamine. Meth. Find. Exp. Clin. Pharmacol., 12:341-376 (1990).\r\n\r\nCacabelos, R., Niigawa, H., \u00c1lvarez, X.A., Mu\u00f1oz, M.D., Nishimura, T., Rubia, F.J. Antagonistic effects of growth hormone-releasing factor (GRF) and somatostatin on locomotor activity: GRF-induced hyperkinetic syndrome. Meth. Find. Exp. Clin. Pharmacol., 12:425-434 (1990).\r\n\r\nCacabelos, R. Histamine research in Europe. Drug News Perspect., 3:441-443 (1990).\r\n\r\nCacabelos, R. Neurobiolog\u00eda y gen\u00e9tica molecular de la enfermedad de Alzheimer: marcadores diagn\u00f3sticos y terap\u00e9utica. Med. Clin., 95:502-516 (1990).\r\n\r\n\u00c1lvarez, X.A., Cacabelos, R. Effects of GRF(1-29)NH2 on short-term memory: Neuroendocrine and neuropsychological assessment in healthy young subjects. Meth. Find. Exp. Clin. Pharmacol., 12:493-499 (1990).\r\n\r\nCacabelos, R. Psiquiatr\u00eda. La Medicina Interna en 1990. Medicine Extra, 99-105 (1990).\r\n\r\nCacabelos, R. Nuevas perspectivas en la enfermedad de Alzheimer. Rev. Cl\u00edn. Esp., 187:356-368 (1990).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Sistema psiconeuroendocrino y envejecimiento. Anal. Psicol., 6:115-146 (1990).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A. Histidine decarboxylase inhibition induced by alpha-fluoromethylhistidine provokes learning-related hypokinetic activity. Agents Actions, 33:131-134 (1991).\r\n\r\nCacabelos, R. Demencia senil: Estrategias para una d\u00e9cada. Rev. Clin. Esp., 189:51-53 (1991).\r\n\r\nCacabelos, R., Barquero, M., Garc\u00eda, P., \u00c1lvarez, X.A., Varela de Seijas, E. Cerebrospinal fluid interleukin-1\uf062 (IL-1\uf062) in Alzheimer\u2019s disease and neurological disorders. Meth. Find. Exp. Clin. Pharmacol., 13:455-458 (1991).\r\n\r\nCacabelos, R., Franco-Maside, A., \u00c1lvarez, X.A. Interleukin-l in Alzheimer\u2019s disease and multi-infarct dementia: Neuropsychological correlations. Meth. Find. Exp. Clin. Pharmacol., 13:703-708 (1991).\r\n\r\nP\u00e9rez-Trull\u00e9n, J.M., V\u00e1zquez-Andr\u00e9, M.C., Cacabelos, R. Los potenciales evocados en la enfermedad de Alzheimer. La onda P300. Anuario Psiqui\u00e1trico, 2:77-97 (1991).\r\n\r\nCacabelos, R. Funci\u00f3n neuroinmune en trastornos mentales. Anuario Psiqui\u00e1trico, 2:135-154 (1991).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Efectos de la somatotropina biosint\u00e9tica (r-hGH) y la somatoliberina [GRF(1-29)NH2] sobre la actividad psicomotriz. Anuario Psiqui\u00e1trico, 2:189-199 (1991).\r\n\r\nCacabelos, R. Alteraciones neuroqu\u00edmicas en la enfermedad de Alzheimer: Neurotransmisores cl\u00e1sicos, sistemas enzim\u00e1ticos y factores de membrana. Geriatrika, X:39-53 (1991).\r\n\r\n\u00c1lvarez, X.A., Cacabelos, R. Age- and sex-related serum growth hormone (GH) levels in psychiatric patients and healthy control subjects. A correlation study between GH values and cognitive performance. Exp. Clin. Endocrinol. (Life Sci. Adv.), 10:245-257 (1991).\r\n\r\nMart\u00edn-Loeches, M., Gil, P., Jim\u00e9nez, F., Exp\u00f3sito, F.J., Miguel, F., Cacabelos, R., Rubia, F.J. Topographic maps of brain electrical activity in primary degenerative dementia of the Alzheimer type and multiinfarct dementia. Biol. Psychiatry, 29:211-223 (1991).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Psiconeuroendocrinolog\u00eda geri\u00e1trica. Endocrinolog\u00eda, 39:135-145 (1992).\r\n\r\nCacabelos, R., Niigawa, H., Yamatodani, A., Fukui, H., Nishimura, T., Wada, H. Vasopressin-induced changes in brain histamine and H-1 receptors. Exp. Clin. Endocrinol. (Life Sci. Adv.), 11:37-44 (1992).\r\n\r\nCacabelos, R. Neurop\u00e9ptidos en psiquiatr\u00eda (I). Monogr. Psiquiatr\u00eda, 3:7-9 (1992).\r\n\r\nFranco, A., \u00c1lvarez, X.A., Cacabelos, R. Acciones centrales de los neurop\u00e9ptidos. Monogr. Psiquiatr\u00eda, 3:10-18 (1992).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Cacabelos, R. Neurop\u00e9ptidos y envejecimiento. Monogr. Psiquiatr\u00eda, 3:19-28 (1992).\r\n\r\nCacabelos, R. Alteraciones neuropeptid\u00e9rgicas en trastornos mentales. Monogr. Psiquiatr\u00eda, 4:3-12 (1992).\r\n\r\nCacabelos, R. Disfunci\u00f3n neuropeptid\u00e9rgica en la enfermedad de Alzheimer. Monogr. Psiquiatr\u00eda, 4:13-21 (1992).\r\n\r\nCacabelos, R. Factores neurotr\u00f3ficos: Neurobiolog\u00eda molecular y alteraciones en trastornos del sistema nervioso. Monogr. Psiquiatr\u00eda, 4:22-28 (1992).\r\n\r\nCacabelos, R. Marcadores gen\u00e9ticos en trastornos neuropsiqui\u00e1tricos: Mapeo gen\u00e9tico y prospecciones diagn\u00f3sticas y terap\u00e9uticas. Med. Clin., 99:505-514 (1992).\r\n\r\nCacabelos, R. Alzheimer\u2019s disease: News and prospects. Drug News Perspect., 5:501-506 (1992).\r\n\r\nCacabelos, R. Prof. Hiroshi Wada or the art of teamwork. Ann. Psychiat., 3:V-VI (1992).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A. Neuroimmune function of brain histamine: implications for neurotrophic activity and neurotoxicity. Ann. Psychiat., 3:147-200 (1992).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Valle-Incl\u00e1n, F. Therapeutic effects of CDP-choline in Alzheimer\u2019s disease and multi-infarct dementia: psychometric assessment and immune function. Ann. Psychiat., 3:233-245 (1992).\r\n\r\nCaama\u00f1o, J., Valle-Incl\u00e1n, F., Cacabelos, R. Middle cerebral artery blood flow velocity in patients with vascular dementia: assessment by transcranial Doppler ultrasonography. Ann. Psychiat., 3:273-280 (1992).\r\n\r\n\u00c1lvarez, X.A., Cacabelos, R. Psychoneuroendocrinology and the aging brain. Ann. Psychiat., 3:281-299 (1992).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of anapsos on behavior and brain cytokines in rats. Ann. Psychiat., 3:329-341 (1992).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., P\u00e9rez-Trull\u00e9n, J.M., Franco-Maside, A., \u00c1lvarez, X.A. Serum histamine in Alzheimer\u2019s disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol., 14:711-715 (1992).\r\n\r\nCacabelos, R. Marcadores gen\u00e9ticos en trastornos neuropsiqui\u00e1tricos: cartograf\u00eda gen\u00e9tica y prospecciones diagn\u00f3sticas y terap\u00e9uticas (II). Med. Clin., 100:28-36 (1993).\r\n\r\nCaama\u00f1o, J., G\u00f3mez, M.J., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia: Neuropsychological correlates. Meth. Find. Exp. Clin. Pharmacol., 15:193-199 (1993).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L. Dose- and time-dependent effects of histamine on hypothalamic levels of interleukin-1\uf062 in rats. Agents Actions, 38:C260- C262 (1993).\r\n\r\nCacabelos, R., Hofman, A., Mullan, M., Ferris, S.M., Portera, A., Frey, H., Swaab, D F., de Leon, M., Terry, R., Masters, C.L., Iqbal, K., Wisniewski, H.M., Takeda, M., Giacobini, E., Nordberg, A., Winbald, B. Alzheimer\u2019s disease: Scientific progress for future trends. Drug News Perspect., 6:242-244 (1993).\r\n\r\n\u00c1lvarez, X.A., Cacabelos, R. Influence of growth hormone (GH) and GH-releasing factor on locomotor activity in rats. Peptides, 14:707-712 (1993).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J. Effect of CDP-choline on cognition and immune function in Alzheimer\u2019s disease and multi-infarct dementia. Ann. New York Acad. Sci., 695:321-323 (1993).\r\n\r\nNiimi, M., Mochizuki, T., Cacabelos, R., Yamatodani, A. Increase of histidine decarboxylase activity in mice hypothalamus after intracerebroventricular administration of lipopolysaccharide. Meth. Find. Exp. Clin. Pharmacol., 15:509-514 (1993).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of S 9977-2 on psychomotor activity, learning and brain interleukin-1\uf062 levels in rats. Meth. Find. Exp. Clin. Pharmacol., 15:587-595 (1993).\r\n\r\nFern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Franco, A., Caama\u00f1o, J., Cacabelos, R. Histamine-induced interleukin-1 changes in the rat hypothalamus. Meth. Find. Exp. Clin. Pharmacol., 15:735-741 (1993).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J. Serum tumor necrosis factor (TNF) in Alzheimer\u2019s disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol., 16:29-35 (1994).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer: Disfunci\u00f3n neuroinmune y nuevas formas de intervenci\u00f3n terap\u00e9utica. Med. Clin., 102:420-422 (1994).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Franco, A., Mangues, R., Pellicer, A., Nishimura, T. Brain interleukin-1\uf062 in Alzheimer\u2019s disease and vascular dementia. Meth. Find. Exp. Clin. Pharmacol., 16:141-151 (1994).\r\n\r\nCaama\u00f1o, J., G\u00f3mez, M.J., Franco, A., Cacabelos, R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 16:211-218 (1994).\r\n\r\nFern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Franco-Maside, A., Caama\u00f1o, J., Cacabelos, R. CDP-choline-induced blood histamine changes in Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 16:279-284 (1994).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Agents Actions, 41:C70-C72 (1994).\r\n\r\nVinagre, D., Franco-Maside, A., G\u00f3mez, M.J., Caama\u00f1o, J., Cacabelos, R. Brain electrical activity mapping in cerebrovascular disorders and senile dementia. Drugs Today, 30:275-281 (1994).\r\n\r\nCaama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco-Maside, A., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia. Drugs Today, 30:283-293 (1994).\r\n\r\nCacabelos, R., Nordberg, A., Caama\u00f1o, J., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., G\u00f3mez, M.J., \u00c1lvarez, X.A., Takeda, M., Prous, J. Jr. Nishimura, T., Winblad, B. Molecular strategies for the first generations of anti-dementia drugs (I): Tacrine and related compounds. Drugs Today, 30:295-337 (1994)\r\n\r\nCacabelos, R., Winblad, B. Alzheimer\u2019s disease in a changing world. Ann. Psychiatry, 4:V-VI (1994).\r\n\r\nG\u00f3mez, M.J., Caama\u00f1o, J., Cacabelos, R. Alzheimer\u2019s disease assessment scale in senile dementia and in geriatric patients without cognitive impairment. Ann. Psychiatry, 4:69-81 (1994).\r\n\r\nVinagre, D., Franco-Maside, A., G\u00f3mez, M.J., Caama\u00f1o, J., Cacabelos, R. Brain electrical activity mapping in cerebrovascular disorders and senile dementia. Ann. Psychiatry, 4:195-204 (1994).\r\n\r\nCaama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco, A., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia. Ann. Psychiatry, 4:205-219 (1994).\r\n\r\nCacabelos, R., Nordberg, A., Caama\u00f1o, J., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., G\u00f3mez, M.J., \u00c1lvarez, X.A., Takeda, M., Prous, J., Nishimura, T., Winblad, B. Therapeutic strategies in Alzheimer\u2019s disease. Ann. Psychiatry, 4:221-279 (1994).\r\n\r\nCacabelos, R., Caama\u00f1o, J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Franco, A. Enfermedad de Alzheimer. Bases moleculares, criterios diagn\u00f3sticos y normativa terap\u00e9utica. JANO Med. Hum., 1103:39-64 (1994).\r\n\r\nCacabelos, R., Takeda, M., Nishimura, T. Tratamiento psicofarmacol\u00f3gico convencional para control de trastornos psiqui\u00e1tricos asociados a la enfermedad de Alzheimer. JANO Med. Hum., 1103:67-79 (1994).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Caama\u00f1o, J., Franco, A., Fern\u00e1ndez-Novoa, L., G\u00f3mez, M.J., Novo, B., Zas, R. Primeras generaciones de f\u00e1rmacos anti-demencia. JANO Med. Hum., 1104:25-59 (1994).\r\n\r\nCacabelos, R., Caama\u00f1o, J., Franco, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A. Agentes nootr\u00f3picos y f\u00e1rmacos polivalentes. JANO Med. Hum., 1105:25-55 (1994).\r\n\r\nFranco-Maside, A., Caama\u00f1o, J., G\u00f3mez, M.J., Cacabelos, R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 16:597-607 (1994).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of neurotoxic lesions in the posterior hypothalamic region on psychomotor activity and learning. Agents Actions, 43:21-23 (1994).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer; Bases etiopatog\u00e9nicas para nuevas estrategias terap\u00e9uticas. Cl\u00ednica, 7:31-53 (1994).\r\n\r\nFern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A., Cacabelos, R. Effects of histamine and alpha-fluoromethylhistidine on brain tumor necrosis factor levels in rats. Immun. Res., 44:55-57 (1995).\r\n\r\nCacabelos, R. From loyalty to efficacy. Ann. Psychiat., 5:1-111 (1995).\r\n\r\nTakeda, M., Cacabelos, R. Professor Nishimura and his work: Summary of a life devoted to Psychiatry. Ann. Psychiat., 5:1-13 (1995).\r\n\r\nG\u00f3mez, M.J., Caama\u00f1o, J., Vinagre, D., Franco-Maside, A., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Zas, R., Novo, R., Cacabelos, R. Non-cognitive impairment in senile dementia: A neuropsychological study. Ann. Psychiat., 5:31-40 (1995).\r\n\r\nKudo, T., Takeda, M., Cacabelos, R., Nishimura, T. Biomarkers for Alzheimer\u2019s disease in cerebrovascular fluids. Ann. Psychiat., 5:41-52 (1995).\r\n\r\nNakamura, Y., Cacabelos, R., Takeda, M. Impairment of axonal transport in Alzheimer\u2019s disease. Ann. Psychiat., 5:53-64 (1995).\r\n\r\nFern\u00e1ndez-Novoa, L., Cacabelos, R. The histaminergic system in Alzheimer\u2019s disease. Ann. Psychiat., 5:127-158 (1995).\r\n\r\nCaama\u00f1o, J., Vinagre, D., G\u00f3mez, M.J., Novo, B., Zas, R., Franco, A., Cacabelos, R. Schizophrenic patients show lower peripheral resistances in the middle cerebral artery territory than healthy subjects: A preliminary transcranial Doppler study. Ann. Psychiat., 5:159-166 (1995).\r\n\r\n\u00c1lvarez, X.A., Zas, R., Lagares, R., Franco, A., Beyer, K., Polo, E., Garc\u00eda, M., Guez, D., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of S9977-2, a new cognition-enhancing drug, on behavior and brain neurotransmitters in rats. Ann. Psychiat., 5:247-265 (1995).\r\n\r\n\u00c1lvarez, X.A., Zas, R., Lagares, R., Franco, A., Maneiro, E., Miguel-Hidalgo, J.J., Lao, J.I., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Cacabelos, R. Neuroimmunomodulatory and neurotrophic activity of Anapsos: Studies with laboratory animals. Ann. Psychiat., 5:267-280 (1995).\r\n\r\nFranco-Maside, A., Vinagre, D., Caama\u00f1o, J., G\u00f3mez, M.J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Zas, R., Novo, B., Polo, E., Garc\u00eda, M., Castagn\u00e9, I., Newman, E., Guez, D., Cacabelos, R. Effects of S12024 on brain electrical activity parameters in patients with Alzheimer\u2019s disease. Ann. Psychiat., 5:281-294 (1995).\r\n\r\nCacabelos, R., Caama\u00f1o, J., G\u00f3mez, M.J., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., Vinagre, D., Novo, B., Zas, R., \u00c1lvarez, X.A. Treatment of Alzheimer\u2019s disease with CDP-choline: Effects on mental performance, brain electrical activity, cerebrovascular parameters and cytokine production. Ann. Psychiat., 5:295-315 (1995).\r\n\r\nCacabelos, R. The multidisciplinary path to brain aging research and healthy environment for the elderly. Neurogerontol. Neurogeriat., 1:ix-x (1995).\r\n\r\nCacabelos, R., Frey, H., Nishimura, T., Takeda, M., Winblad, B. Introduction to neurogerontology and psychogeriatrics. Neurogerontol. Neurogeriat., 1:1-4 (1994).\r\n\r\nCacabelos, R. The aging process and theories of aging: Implications for neurogerontology. Neurogerontol. Neurogeriat., 1:5-20 (1995).\r\n\r\n\u00c1lvarez, X.A., Lagares, R., Zas, R., Fern\u00e1ndez-Novoa, L., Beyer, K., Maneiro, E., Franco-Maside, A., Lao, J.I., Miguel-Hidalgo, J.J., Cacabelos, R. Geriatric psychoneuroendocrinology. Neurogerontol. Neurogeriat., 1:61-83 (1995).\r\n\r\nG\u00f3mez, M.J., Caama\u00f1o, J., Vinagre, D., Franco, A., Cacabelos, R. Cognitive and non-cognitive profiles in cerebrovascular disorders and senile dementia: A neuropsychological study. Neurogerontol. Neurogeriat., 1:107-118 (1995).\r\n\r\nFranco-Maside, A., Vinagre, D., Caama\u00f1o, J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Novo, B., Zas, R., G\u00f3mez, M.J., Cacabelos, R. Brain mapping in neurogeriatrics. Neurogerontol. Neurogeriat., 1:119-139 (1995).\r\n\r\nCaama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Novo, B., Zas, R., Cacabelos, R. Transcranial Doppler ultrasonography in neurogeriatric disorders. Neurogerontol. Neurogeriat., 1:141-157 (1995).\r\n\r\nCacabelos, R. Alzheimer\u2019s disease: Etiopathogenic factors. Neurogerontol. Neurogeriat., 1:299-328 (1995).\r\n\r\nCacabelos, R., Caama\u00f1o, J., \u00c1lvarez, X.A., G\u00f3mez, M.J., Franco-Maside, A., Vinagre, D., Fern\u00e1ndez-Novoa, L., Lao, J.I., Beyer, K., Recuero, M., Sastre, I., Bellido, M.J., Valdivieso, F., Vigo-Pelfrey, C. Diagnostic criteria and genotyping in Alzheimer\u2019s disease. Neurogerontol. Neurogeriat., 1:329-353 (1995).\r\n\r\nCaama\u00f1o, J., G\u00f3mez, M.J., Vinagre, D., Franco, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Novo, B., Zas, R., Cacabelos, R. Transcranial Doppler ultrasonography in neurogeriatric disorders. Meth. Find. Exp. Clin. Pharmacol., 17:135-148 (1995).\r\n\r\nCacabelos, R. Tacrina: Primera generaci\u00f3n de f\u00e1rmacos antidemencia. Med. Clin., 105:105-115 (1995).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Parte I. Epidemiolog\u00eda y Etiopatogenia. FOMECO, 3:212-220 (1995).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Parte II. Diagn\u00f3stico y tratamiento. FOMECO, 3:268-281 (1995).\r\n\r\nFranco-Maside, A., Vinagre, D., Caama\u00f1o, J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Novo, B., Zas, R., G\u00f3mez, M.J., Cacabelos, R. Brain electrical activity in neurogerontology and psychogeriatric disorders. Meth. Find. Exp. Clin. Pharmacol., 17:207-224 (1995).\r\n\r\nCacabelos, R., Lao, J.I., Beyer, K., \u00c1lvarez, X.A., Franco-Maside, A. Genetic testing in Alzheimer\u2019s disease: ApoE genotyping and etiopathogenic factors. Meth. Find. Exper. Clin. Pharmacol., 18(Suppl. A):161-179 (1996).\r\n\r\nCacabelos, R. Clinical Neurosciences and Alzheimer\u2019s disease. Clin. Sci., 90:1 53-156 (1996).\r\n\r\nCacabelos, R., Caama\u00f1o, J., G\u00f3mez, M.J., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer\u2019s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. In: Neurobiology of Alzheimer\u2019s disease. Wurtman, R.J., Corkin, S., Growdon, J.H., Nitsch, R.M. (Eds.). Ann. New York Acad. Sci., 777:399-403 (1996).\r\n\r\nCacabelos, R. Diagnosis of Alzheimer\u2019s disease: Defining genetic profiles (genotype vs. phenotype). Acta Neurol. Scand. Suppl., 165:72-84 (1996).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Informaciones Psiqui\u00e1tricas, 142:443-456 (1995).\r\n\r\nFern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Det\u00f3lle-Sarbanch, S., Guez, D., Zas, R., Polo, E., Cacabelos, R. Effects of S-9977-2 on histamine levels in rats. Meth. Find. Exp. Clin. Pharmacol., 18;197-203 (1996).\r\n\r\nV\u00e1zquez, J., Fern\u00e1ndez-Shaw, C., Marina, A., Haas, C., Cacabelos, R., Valdivieso, F. Antibodies to human spectrin in Alzheimer\u2019s disease. J. Neuroimmunol., 68:39-44 (1996).\r\n\r\nLombardi, V.R.M., Miguel-Hidalgo, J.J., Mancino, G., Maneiro, E., Poccia, F., Pl\u00e1cido, R., Lagares, R., Cacabelos, R. Apoptosis during HIV infection and in neurodegenerative disorders. Meth. Find. Exp. Clin. Pharmacol., 18:539-555 (1996).\r\n\r\nManeiro, E., Lombardi, V.R.M., Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Meth. Find. Exp. Clin. Pharmacol., 18:615-645 (1996).\r\n\r\nCacabelos, R. Progress in neuropsychiatric disorders and Alzheimer\u2019s disease. Ann. Psychiat., 6:XIII- XIV (1996).\r\n\r\n\u00c1lvarez, X.A., Ayuso-Guti\u00e9rrez, J.L., Cacabelos, R. Somatotropinergic system: neurobiology and effects on brain activity and mental functions. Ann. Psychiat., 6:73-104 (1996).\r\n\r\nMiguel-Hidalgo, J.J., Cacabelos, R. Hippocampal neurodegeneration: animal models for Alzheimer\u2019s disease. Ann. Psychiat., 6:147-157 (1996).\r\n\r\n\u00c1lvarez, X.A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., Beyer, K., Lao, J.I., Vecino, B., Cacabelos, R. Behavioral deficits in rats with hippocampal neurodegeneration induced by \uf062- amyloid implants. Ann. Psychiat., 6:159-171 (1996).\r\n\r\nBeyer, K., Lao, J.I., Cacabelos, R. Molecular genetics and genotyping in Alzheimer\u2019s disease. Ann. Psychiat., 6:173-187 (1996).\r\n\r\nCacabelos, R., Rodr\u00edguez, B., Carrera, C., Beyer, K., Lao, J.I., Sellers, M.A. APOE-related dementia symptoms: Frequency and progression. Ann. Psyciat., 6:189-205 (1996).\r\n\r\nLao, J.I., Beyer, K., Cacabelos, R. Genetic markers of mental retardation. Ann. Psychiat., 6:207-217 (1996).\r\n\r\nManeiro, E., Lombardi, V.R.M., Cacabelos, R. Cytotoxic effects of beta amyloid, histamine, LPS and serum from Alzheimer\u2019s disease patients on cultured endothelial cells. A preliminary study. Ann. Psychiat., 6:231-239 (1996).\r\n\r\nLombardi, V.R.M., Maneiro, E., Cacabelos, R. Neurologic manifestations linked to AIDS and HIV-l infection. Ann. Psychiat., 6:309-330 (1996).\r\n\r\nManeiro, E., Lombardi, V.R.M., Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Ann. Psychiat., 6:331-365 (1996).\r\n\r\nBeyer, K., Lao, J.I., \u00c1lvarez, X.A., Cacabelos, R. Different implications of APOE-4 in Alzheimer\u2019s disease and vascular dementia in the Spanish population. Alzheimer\u2019s Res., 2:215-220 (1996).\r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Blood levels of histamine, IL-l\uf062, and TNF-\uf061 in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol., 29:237-252 (1996).\r\n\r\nCacabelos, R., Rodr\u00edguez, B., Carrera, C., Caama\u00f1o, J., Beyer, K., Lao, J.I., Sellers, M.A. APOE-Related frequency of cognitive and noncognitive symptoms in dementia. Meth. Find. Exp. Clin. Pharmacol., 18:693-706 (1996).\r\n\r\nLombardi, V.R.M., Maneiro, E., Cacabelos, R. Central nervous system damage during HIV infection. Meth. Find. Exp. Clin. Pharmacol., 18:707-722 (1996).\r\n\r\nCacabelos, R., Caama\u00f1o, J., Vinagre, D., Lao, J.I., Beyer, K., \u00c1lvarez, X.A. Brain mapping and transcranial Doppler ultrasonography in Alzheimer\u2019s disease drug monitoring. In: Alzheimer disease: From Molecular Biology to Therapy. R. Becker, E. Giacobini (Eds.). Birkh\u00e4user, Boston, pp. 469-473 (1996).\r\n\r\n\u00c1lvarez, X.A., Zas, R., Lagares, R., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., Miguel-Hidalgo, J.J., Cacabelos, R. Anapsos: New therapeutic strategies for neurodegeneration and brain aging with neuroimmunotrophic factors. In: Alzheimer disease: From Molecular Biology to Therapy. R. Becker, E. Giacobini (Eds.). Birkh\u00e4user, Boston, pp. 367-372 (1996).\r\n\r\nBeyer, K., Lao-Villad\u00f3niga, J.I., Vecino-Bilbao, B., Cacabelos, R., de la Fuente, R. A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia. J. Neurol. Neurosurg. Psychiat., 62:420-421 (1997).\r\n\r\nMiguel-Hidalgo, J.J., Cacabelos, R. Modeling neuronal degeneration in the rodent hippocampus: An approach for studying degenerative neuropathology in dementia. Meth. Find. Exp. Clin. Pharmacol., 19:133-142 (1997).\r\n\r\nManeiro, E., Lombardi, V.R.M., Lagares, R., Cacabelos, R. An experimental model to study the cytotoxic effects induced by \uf062-amyloid, histamine, LPS and serum from Alzheimer patients on rat cultured endothelial cells. Meth. Find. Exp. Clin. Pharmacol., 19:5-12 (1997).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer: Diagn\u00f3stico molecular y futuro terap\u00e9utico. An. Med. Interna, 14(Supl. 1):72-74 (1997).\r\n\r\n\u00c1lvarez, X.A., Laredo, M., Corzo, D., Fern\u00e1ndez-Novoa, L., Mouzo, R., Perea, E., Daniele, D., Cacabelos, R. Citicoline improves memory performance in elderly subjects. Meth. Find. Exp. Clin. Pharmacol., 19:201-210 (1997).\r\n\r\nBeyer, K., Lao, J.I., \u00c1lvarez, X.A., Cacabelos, R. A general method for DNA polymorphism identification in genetic assessment and molecular diagnosis. Meth. Find. Exp. Clin. Pharmacol., 19:87-91 (1997).\r\n\r\nFern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Sempere, J.M., Miguel-Hidalgo, J.J., D\u00edaz, J., Franco-Maside, A., Cacabelos, R. Effects of anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal degeneration. Meth. Find. Exp. Clin. Pharmacol., 19:99-106 (1997).\r\n\r\n\u00c1lvarez, X.A., Zas, R., Fern\u00e1ndez-Novoa, L., Garc\u00eda, M., Polo, E., Detolle-Sarbach, S., Guez, D., Cacabelos, R. Comparative effects of S9977-2 versus tacrine on passive avoidance learning and psychomotor activity. Hum. Psychopharmacol. Clin. Exp., 12:329-335 (1997).\r\n\r\n\u00c1lvarez, X.A., Franco-Maside, A., Zas, R., Sempere, J.M., D\u00edaz, J., Cacabelos, R. Anapsos reverses interleukin-1\uf062 overexpression and behavioral deficits in nbM-lesioned rats. Meth. Find. Exp. Clin. Pharmacol., 19:299-309 (1997).\r\n\r\nSellers, M.A., P\u00e9rez, L., Cacabelos, R. Evaluaci\u00f3n neuropsicol\u00f3gica de la demencia senil en atenci\u00f3n primaria. Formaci\u00f3n M\u00e9dica Continuada en Atenci\u00f3n Primaria, 4:150-173 (1997).\r\n\r\nCacabelos, R., Rodr\u00edguez, B., Carrera, C., Beyer, K., Lao, J.I., Sellers, M.A. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer\u2019s Dis. Assoc. Dis., 11(Suppl. 4):S27-S37 (1997).\r\n\r\n\u00c1lvarez, X.A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Sempere, J.M., Cacabelos, R. Anapsos: Neuroimmunotrophic treatment in Alzheimer\u2019s disease and neurodegenerative disorders. CNS Drug Rev., 3:181-206 (1997).\r\n\r\nLao, J.I., Beyer, K., Cacabelos, R. La gen\u00e9tica molecular aplicada al diagn\u00f3stico de la enfermedad de Alzheimer. Informaciones Psiqui\u00e1tricas, 147:15-33 (1997).\r\n\r\nFern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., \u00c1lvarez, X.A., Cacabelos, R. Global Deterioration Scale-related brain hemodynamics and histamine levels in Alzheimer\u2019s disease and vascular dementia. Ann. New York Acad. Sci., 826:396-400 (1997).\r\n\r\n\u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Corzo, L., Zas, R., Beyer, K., Lao, J.I., Cacabelos, R. Cerebrovascular changes associated with interleukin-1\uf062 (IL-1\uf062) and histamine levels in Alzheimer\u2019s disease. Ann. New York Acad. Sci., 826:375-378 (1997).\r\n\r\nBeyer, K., Lao, J.I., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Sellers, M.A., Cacabelos, R. APOE-\uf0654 allele frequency in Alzheimer\u2019s disease and vascular dementia in the Spanish population. Ann. New York Acad. Sci., 826:452-455 (1997).\r\n\r\n\u00c1lvarez, X.A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Intrahippocampal injections of the \uf062-amyloid 1-28 fragment induce behavioral deficits in rats. Meth. Find. Exp. Clin. Pharmacol., 19:471-479 (1997).\r\n\r\n\u00c1lvarez, X.A., Vecino, B., Perea, J.E., Daniele, D., Cacabelos, R. Citicoline antagonizes bromazepam-induced amnesia in rats. Hum. Psychopharmacol., 12:547-556 (1997).\r\n\r\nCacabelos, R. Alzheimer\u2019s disease: Present and future. J. Autonomic Pharmacol., 17:282 (1997).\r\n\r\nCacabelos, R. Etiopatogenia del deterioro cognitivo. Factores de riesgo de los trastornos de memoria. Prensa M\u00e9dica Argentina, 85:176-177 (1998).\r\n\r\nCacabelos, R. Tratamiento del deterioro de la memoria y el d\u00e9ficit cognitivo. Prensa M\u00e9dica Argentina, 85:179-180 (1998).\r\n\r\nCacabelos, R. Neuroimmune reactions and inflammatory mechanisms in Alzheimer\u2019s disease: gene-specific responses in therapeutics and prevention. Neurogerontol. Neurogeriat., 2:IX-XII (1998).\r\n\r\nManeiro, E., Lombardi, V., Cacabelos, R. Neuroimmune dysfunction in Alzheimer\u2019s disease. Influence of \uf062-amyloid, interleukin-l\uf062, histamine, and APOE-related sera from patients with Alzheimer\u2019s disease on microglial cells. Neurogerontol. Neurogeriat., 2:77-104 (1998).\r\n\r\nLombardi, V., Cacabelos, R. Apoptosis in neurodegenerative diseases: The neuroimmune network. Neurogerontol. Neurogeriat., 2:105-124 (1998).\r\n\r\n\u00c1lvarez, X.A., Miguel, J.J., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Sempere, J.M., Cacabelos, R. Therapeutic agents with potential amyloid scavenging activity: Neuroimmune-associated mechanisms. Neurogerontol. Neurogeriat., 2:141-163 (1998).\r\n\r\nCacabelos, R., P\u00e9rez del T\u00edo, L., Sellers, A. Caregivers\u2019 perception on dementia-associated social, economic and health problems: Sociodemographic study in the Spanish population. Jap. J. Geriat. Psychiat., 9:133-139 (1998).\r\n\r\nMiguel-Hidalgo, J.J., \u00c1lvarez, A., Cacabelos, R. Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system. Cell Tiss. Res., 293:75-86 (1998).\r\n\r\nMiguel-Hidalgo, J.J., Cacabelos, R. \uf062-Amyloid (l-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol., 95:455-465 (1998).\r\n\r\nMiguel-Hidalgo, J.J., Vecino, B., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, A., Cacabelos, R. Neuroprotective role of S12024 against neurodegeneration in the rat dentate gyrus. Eur. Neuropsychopharmacol., 8:203-208 (1998).\r\n\r\nEuropean Concerted Action on Pick\u2019s Disease (ECAPD) Consortium. \u00c1lvarez, X.A., Baker, S., Binetti, G., Boller, F., Bracco, L., Breteler, M., Brun, A., Cacabelos, R., Cairns, N., Cappa, S., Cipolotti, T., Collinge, J., Englund, E., Forleo, P., F\u00f6rstl, H., Grassi, E., Harvey, R., Hodges, J., Gustafson, L., Kurz, A., Lantos, P., Lauten-Schlager, N., Lebert, F., Muggia, S., Pasquier, F., Passant, V., Ravid, R., Rossor, M., Sorbi, S., Spinnler, H., Stevens, J, van Swieten, J., Warrington, E., Xuereb, J. Provisional clinical and neuroradiological criteria for the diagnosis of Pick\u2019s disease. Eur. J. Neurol., 5:519-520 (1998).\r\n\r\nLombardi, V.R.M., Garcia, M., Cacabelos, R. APOE-induced microglial activation: An in vitro assay to screen sera from Alzheimer\u2019s disease patients and novel therapeutic compounds. Meth. Find. Exp. Clin. Pharmacol., 20:377-386 (1998).\r\n\r\nLombardi, V.R.M., Garc\u00eda, M., Cacabelos, R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J. Neurosc. Res., 54:539-553 (1998).\r\n\r\nCacabelos, R. Bio\u00e9tica asistencial del anciano con enfermedad neurodegenerativa y prevenci\u00f3n gen\u00e9tica de la demencia. Bio\u00e9tica y Ciencias de la Salud, 3:35-40 (1998).\r\n\r\nLao, J.I., Beyer, K., Fern\u00e1ndez-Novoa, L., Cacabelos, R. A novel mutation in the predicted TM2 domain of presenilin 2 gene in Spanish patient with late-onset Alzheimer\u2019s disease. Neurogenetics, 1:293-296 (1998).\r\n\r\nSellers, A., P\u00e9rez, L., Carrera, C., Bustos, J.C., Caama\u00f1o, J.M., Rodr\u00edguez, B., Mouzo, R., P\u00e9rez, P., Lao, J.I., Beyer, K., \u00c1lvarez, X.A., Cacabelos, R. Cognitive and non-cognitive symptoms in senile dementia. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 317-322 (1998).\r\n\r\nSellers, A., P\u00e9rez, L., Rodr\u00edguez, B., Pichel, V.M., Caama\u00f1o, J.M., Laredo, M., Alcaraz, M., \u00c1lvarez, X.A., Cacabelos, R. Dementia-associated sleep disorders. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 323-327 (1998).\r\n\r\n\u00c1lvarez, A., Miguel-Hidalgo, J.J., Fern\u00e1ndez-Novoa, L., D\u00edaz, J., Sempere, J.M., Cacabelos, R. Anapsos improves learning and memory in rats with \uf062A(1-28) deposits into the hippocampus. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 699-703 (1998).\r\n\r\nMiguel-Hidalgo, J.J., \u00c1lvarez, X.A., Cacabelos, R. In vivo neurotoxicity of \uf062-amyloid 1-40 in the rat hippocampus. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 705-709 (1998).\r\n\r\nCorzo, L., Fern\u00e1ndez-Novoa, L., Zas, R., Beyer, K., Lao, J.I., \u00c1lvarez, X.A., Cacabelos, R. Influence of the APOE-genotype on serum ApoE levels in Alzheimer\u2019s disease patients. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 765-771 (1998).\r\n\r\nLao, J.I., Beyer, K., Cacabelos, R. Centromeric disturbances affecting all chromosomes of cultured lymphocytes obtained from Alzheimer\u2019s disease patients. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 793-798.\r\n\r\nMouzo, R., \u00c1lvarez, X.A., Pichel, V.M., Sellers, A., Caama\u00f1o, J.M., Laredo, M., Beyer, K., Lao, J.I., P\u00e9rez, P., Alcaraz, M., R\u00faa, M.C., Corzo, L., Fern\u00e1ndez-Novoa, L., Fern\u00e1ndez, R., Cacabelos, R. APOE genotype-related blood pressure in senile dementia. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 799-803 (1998).\r\n\r\nPichel, V.M., Caama\u00f1o, J.M., Sellers, A., Mouzo, R., \u00c1lvarez, X.A., P\u00e9rez, P., Laredo, M., Cacabelos, R. Changes in cerebral blood flow associated with disease staging and APOE genotyping in patients with senile dementia. In: Progress in Alzheimer\u2019s and Parkinson\u2019s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 811-815 (1998).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer: Bases etiopatog\u00e9nicas. En: Salud Mental y Psiquiatr\u00eda en el Umbral del Nuevo Milenio. Asociaci\u00f3n Psiqui\u00e1trica Peruana y Asociaci\u00f3n Psiqui\u00e1trica de Am\u00e9rica Latina. Lima, Per\u00fa, pp. 111-134 (1998).\r\n\r\nCacabelos, R., Beyer, K., Lao, J.I., Mesa, M.D., Fern\u00e1ndez-Novoa, L. Association of genetic risk factors in Alzheimer\u2019s disease and a novel mutation in the predicted TM2 domain of presenilin-2 in late-onset AD. In: Alzheimer\u2019s Disease and Related Disorders. Iqbal, K., Swaab, D.F., Winblad, B., Wisniewski, H.M. (Eds.). John Wiley & Sons, Chichester, pp. 93-102 (1999).\r\n\r\nLombardi, V.R.M., Cacabelos, R. 19\/20 kDa low molecular weight serum protein pattern: a novel potential biochemical prognostic marker for different types of dementia. Neurosci. Lett., 260:61-64 (1999).\r\n\r\nLombardi, V.R.M., Cacabelos, R. E-SAR-94010: A marine fish extract obtained by advanced biotechnological methods. Drugs Future, 24:167-176 (1999).\r\n\r\nCacabelos, R., Takeda, M., Winblad, B. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer\u2019s disease. Int. J. Geriat. Psychiatry, 14:3-47 (1999).\r\n\r\nLombardi, V.R.M., Windisch, M., Garc\u00eda, M., Cacabelos, R. Effects of cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Meth. Find. Exp. Clin. Pharmacol., 21:331-338 (1999).\r\n\r\nCacabelos, R. The search for new health care models, integrated treatments and prevention for dementia. Ann. Psychiatry, 7:XVII-XX (1999).\r\n\r\nMesa, M.D., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Association of genetic risk factors in Alzheimer\u2019s disease. Ann. Psychiatry, 7:35-45 (1999).\r\n\r\nLaredo, M., \u00c1lvarez, X.A., P\u00e9rez, P., Cacabelos, R. Psychometric evaluation and apolipoprotein E genotyping in senile dementia. Ann. Psychiatry, 7:67-75 (1999).\r\n\r\nP\u00e9rez, P., \u00c1lvarez, X.A., Laredo, M., Pichel, V., Cacabelos, R. Brain electrical activity mapping, disease staging and apolipoprotein E genotyping in senile dementia. Ann. Psychiatry, 7:77-85 (1999).\r\n\r\nPichel, V.M., Caama\u00f1o, J.M., Figueroa, J., Hern\u00e1ndez, A., \u00c1lvarez, X.A., P\u00e9rez, P., Laredo, M., Cacabelos, R. Changes in brain hemodynamic parameters associated with disease staging and apolipoprotein E genotyping in patients with senile dementia. Ann. Psychiatry, 7:87-92 (1999).\r\n\r\nMouzo, R., \u00c1lvarez, X.A., Pichel, V.M., Alcaraz, M., Cacabelos, R. Apolipoprotein E-related blood pressure parameters in senile dementia. Ann. Psychiatry, 7:93-97 (1999).\r\n\r\nCorzo, L., Fern\u00e1ndez-Novoa, L., Zas, R., Laredo, M., Alcaraz, M., \u00c1lvarez, X.A., Cacabelos, R. Apolipoprotein E genotype-related serum apolipoprotein E and lipid levels in Alzheimer\u2019s disease. Ann. Psychiatry, 7:99-107 (1999).\r\n\r\nFern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., Laredo, M., P\u00e9rez, P., Pichel, V., Mesa, M.D., Cacabelos, R. Blood histamine levels, brain hemodynamic parameters and risk factors in Alzheimer\u2019s disease and vascular dementia. Ann. Psychiatry, 7:109-117 (1999).\r\n\r\n\u00c1lvarez, X.A., Sampedro, C., Cacabelos, R. Antiapoptotic effects of CDP-choline in a combined (A\uf0624\/hypoperfusion) animal model of hippocampal neurodegeneration. Ann. Psychiatry, 7:147-156 (1999).\r\n\r\nLombardi, V.R.M., Garc\u00eda, M., Cacabelos, R. Genotype-specific microglial response in cell culture systems for the identification of novel therapeutic compounds in Alzheimer\u2019s disease and neuroimmune disorders. Ann. Psychiatry, 7:157-170 (1999).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Lombardi, V. Alzheimer\u2019s disease: Pharmacoeconomics, glutamate-induced neurodegeneration and preventive strategies. Ann. Psychiatry, 7:195-239 (1999).\r\n\r\nLombardi, V.R.M., Garc\u00eda, M., Cacabelos, R. Evolution of senescence: Cellular aging, apoptosis, immune surveillance and tumor development. Ann. Psychiatry, 7:279-308 (1999).\r\n\r\n\u00c1lvarez, X.A., Mouzo, R., Pichel, V., P\u00e9rez, P., Laredo, M., Fern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J., Lozano, R., Cacabelos, R. Effects of citicoline on cognitive performance, brain bioelectrical activity and brain hemodynamics in Alzheimer\u2019s disease patients: A double-blind placebo-controlled study. Ann. Psychiatry, 7:331-352 (1999).\r\n\r\n\u00c1lvarez, X.A., Sampedro, C., Lozano, R., Cacabelos, R. Citicoline protects hippocampal neurons against apoptosis induced by brain \uf062-amyloid deposits plus cerebral hypoperfusion in rats. Meth. Find. Exp. Clin. Pharmacol., 21:535-540 (1999).\r\n\r\n\u00c1lvarez, X.A., Mouzo, R., Pichel, V., P\u00e9rez, P., Laredo, M., Fern\u00e1ndez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J.J., Lozano, R., Cacabelos, R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer\u2019s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Meth. Find. Exp. Clin. Pharmacol., 21:633-644 (1999).\r\n\r\n\u00c1lvarez, X.A., Sampedro, C., Cacabelos, R. Citicoline reduces neuronal apoptosis in rats with brain hypoperfusion and hippocampal \uf062-amyloid implants. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 239-243 (1999).\r\n\r\n\u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Sampedro, C., Lombardi, V., Windisch, M., Cacabelos, R. Neuroimmunotrophic effects of Cerebrolysin in an animal model of hippocampal degeneration induced by \uf062-amyloid. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 233-237 (1999).\r\n\r\nde Olano, M., Mesa, M.D., Fern\u00e1ndez-Novoa, L., Corzo, L., Blanco, A., Cacabelos, R. Angiotensin-converting enzyme I\/D polymorphism and ansiotensinogen M235T polymorphism in cerebrovascular pathology. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 207-210 (1999).\r\n\r\nLaredo, M., Couceiro, V., Corzo, L., P\u00e9rez, P., Anido, R., \u00c1lvarez, X.A., Cacabelos, R. Sleep disorders in vascular dementia and Alzheimer disease. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 129-133 (1999).\r\n\r\nLombardi, V.R., Garc\u00eda, M., Rey, L., Cacabelos, R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer\u2019s disease individuals. J. Neuroimmunol., 97:163-171 (1999).\r\n\r\nAllison, A.C., Cacabelos, R., Lombardi, V.R.M., \u00c1lvarez, X.A., Vigo, C. Central nervous system effects of Celastrol, a potent antioxidant and antiinflammatory agent. CNS Drug Rev., 6:45-62 (2000).\r\n\r\n\u00c1lvarez, X.A., Lombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Garc\u00eda, M., Sampedro, C., Cagiao, A., Cacabelos, R., Windisch, M. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J. Neural Transm., 59:281-292 (2000).\r\n\r\n\u00c1lvarez, X.A., Lombardi, V.R.M., Corzo, L., P\u00e9rez, P., Pichel, V., Laredo, M., Hern\u00e1ndez, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Windisch, M., Cacabelos, R. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J. Neural Transm., 59:315-328 (2000).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Lombardi, V., Fern\u00e1ndez-Novoa, L., Corzo, L., P\u00e9rez, P., Laredo, M., Pichel, V., Hern\u00e1ndez, A., Varela, M., Figueroa, J., Prous Jr. J., Windisch, M., Vigo, C. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today, 36:415-499 (2000).\r\n\r\nCacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. Drug News Perspect., 13:252-254 (2000).\r\n\r\n\u00c1lvarez, X.A., Pichel, V., P\u00e9rez, P., Laredo, M., Corzo, D., Zas, R., Fern\u00e1ndez-Novoa, L., Sempere, J.M., D\u00edaz, J., Cacabelos, R. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: Effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth. Find. Exp. Clin. Pharmacol., 22:585-594 (2000).\r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Lombardi, V.R.M. A pharmacogenomic approach to Alzheimer\u2019s disease. Acta Neurol. Scand., 102(Suppl. 176):12-19 (2000).\r\n\r\nIsaza, C.A., Henao, J., L\u00f3pez, A.M., Cacabelos, R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 22:695-705 (2000).\r\n\r\nCacabelos, R. Psychogeriatric research: A conceptual introduction to aging and geriatric neuroscience. Psychogeriatrics, 1:158-188 (2001).\r\n\r\nAllison, A.C., Cacabelos, R., Lombardi, V.R.M., \u00c1lvarez, X.A., Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer\u2019s disease. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 25:1341-1357 (2001).\r\n\r\nCacabelos, R., Santamar\u00eda, J.L. Hipertensi\u00f3n y Demencia. Mecanismos etiopatog\u00e9nicos y factores gen\u00e9ticos. Hipertensi\u00f3n Cl\u00ednica, IV\/3:626-659 (2001).\r\n\r\nFern\u00e1ndez-Novoa, L., Cacabelos, R. Histamine function in brain disorders. Behav. Brain Res., 124:213-233 (2001).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Presente terap\u00e9utico y retos futuros (I). Rev. Colomb. Psiquiatr\u00eda, XXX\/3:215-238 (2001).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Presente terap\u00e9utico y retos futuros (II). Rev. Colomb. Psiquiatr\u00eda, XXX\/4:323-350 (2001).\r\n\r\nLombardi, V.R.M., Cagiao, A., Fern\u00e1ndez-Novoa, L., \u00c1lvarez, X.A., Corzo, M.D., Zas, R., Sampedro, C., Cacabelos, R. Short term food supplementation effects of a fish derived extract on the immunological status of pregnant rats and their sucking pups. Nutrition Res., 21:1425-1434 (2001).\r\n\r\nCacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. Min. Rev. Medic. Chem., 2:59-84 (2002).\r\n\r\nCacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 34:357-379 (2002).\r\n\r\nLombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Corzo, D., Zas, R., Cacabelos, R. Enhancement in immune function and growth using E-JUR-94013 supplementation. Meth. Find. Exp. Clin. Pharmacol., 24:573-578 (2002).\r\n\r\nMiguel-Hidalgo, J.J., \u00c1lvarez, X.A., Cacabelos, R., Quack, G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res., 958:210-221 (2002).\r\n\r\nCacabelos, R. The histamine-citokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. In: Mapping the Progress of Alzheimer\u2019s and Parkinson\u2019s Disease. Mizuno, Y., Fisher, A., Hanin, I. (Eds.). Advances in Behavioral Biology, 51:59-64 (2002).\r\n\r\nTakeda, M., Cacabelos, R., Ray, O., F\u00f6rstl, H., Hoon Oh, B. International perspective on the diagnosis and treatment of dementia. Cognition & Dementia, 2:53-63 (2003).\r\n\r\nTakeda, M., Okochi, M., Sugaya, K., De-Maw, C., Hashimoto, R., Kuroda, S., Shinosaka, K., Kudo, T., Tanaka, T., Cacabelos, R. Research strategy for understanding neuronal plasticity and degeneration. Seishin Shinkeigaku Zasshi, 105:43-46 (2003).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Takeda, M. Genetic variation and pharmacogenomics in Alzheimer disease. Psychiat. Neurol. Jap., 105:47-67 (2003).\r\n\r\nLombardi, V.R.M., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Cacabelos, R. In vitro regulation of rat-derived microglia. Neurotox. Res., 5:201-212 (2003).\r\n\r\nLombardi, V.R.M., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Blanco, A., D\u00edaz, J., Cacabelos, R. Extracts from Polypodium ferns upregulate the expression of CD95 in human peripheral blood lymphocytes. Orient. Pharm. Exper. Med., 3:90-99 (2003).\r\n\r\n\u00c1lvarez, X.A., Sampedro, C., P\u00e9rez, P., Laredo, M., Couceiro, V., Hern\u00e1ndez, A., Figueroa, J., Varela, M., Arias, D., Corzo, L., Zas, R., Lombardi, V., Fern\u00e1ndez-Novoa, L., Pichel, V., Cacabelos, R., Windisch, M., Aleixandre, M., Moessler, H. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Intern. Clin. Psychopharmacol., 18:271-278 (2003).\r\n\r\nCacabelos, R. The application of functional genomics to Alzheimer\u2019s disease. Pharmacogenomics, 4:597-621 (2003).\r\n\r\nIsaza, C., Henao, J., L\u00f3pez, A.M., Cacabelos, R. Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 25:423-429 (2003).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Corzo, L., Pichel, V., Kubota, Y. Cerebrovascular risk factors in Alzheimer\u2019s disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res., 25:567-580 (2003).\r\n\r\nLombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Neuroglia and neurotrophic factors (NTFs): potential targets for future therapeutics. Current Topics in Pharmacology, 7:229-246 (2003).\r\n\r\nPichel, V., Etcheverr\u00eda, I., Amado, L., Kubota, Y., Cacabelos, R. Cerebrovascular risk factors and brain hemodynamics in dementia. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 23-27 (2003).\r\n\r\nLombardi, V.R.M., Amado, L., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Flow cytometry analysis of CD28-\/CD8+ suppressor cell precursor and CD45RO+\/CD4+ memory T lymphocytes in the peripheral blood of Alzheimer\u2019s disease patients. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 57-61 (2003).\r\n\r\nCorzo, L., Zas, R., Fern\u00e1ndez-Novoa, L., Cacabelos, R. SERUM nitric oxide in Alzheimer disease. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 63-68 (2003).\r\n\r\nKubota, Y., Pichel, V., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Combination therapy in Alzheimer disease: a pharmacogenomic study. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 87-90 (2003).\r\n\r\nEtcheverr\u00eda, I., Pichel, V., Amado, L., Fern\u00e1ndez-Novoa, L., Lombardi, V., Cacabelos, R. APOE genotype-related brain atrophy in the Spanish population. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 91-96 (2003).\r\n\r\nFern\u00e1ndez-Novoa, L., Lombardi, V.R.M., Seoane, S., Etcheverr\u00eda, I., Corzo, L., Cacabelos, R. The ACE gene in Alzheimer\u2019s disease. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 123-126 (2003).\r\n\r\nLombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Association between APOE-4 allele and increased expression of CD95 on T cells from patients with Alzheimer\u2019s disease. Meth. Find. Exp. Clin. Pharmacol., 26:523-529 (2004).\r\n\r\nCacabelos, R., Corzo, L., Fern\u00e1ndez-Novoa, L., Lombardi, V. Histamine in Alzheimer\u2019s disease pathogenesis: Biochemistry and functional genomics. Meth. Find. Exp. Clin. Pharmacol., 26(Suppl. 2):9-16 (2004).\r\n\r\nCacabelos, R., Vallejo, A.I., Lombardi, V., Fern\u00e1ndez-Novoa, L., Pichel, V. E-SAR-94010 (LipoEsar\u00ae): A pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Rev., 10:200-201 (2004).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Corzo, L., Pichel, V., Lombardi, V., Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exp. Clin. Pharmacol., 26:421-444 (2004).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Corzo, L., Amado, L., Pichel, V., Lombardi, V., Kubota, Y. Phenotypic profiles and functional genomics in Alzheimer\u2019s disease and in dementia with a vascular component. Neurol. Res., 26:459-480 (2004).\r\n\r\nCacabelos, R. Genomic characterization of Alzheimer\u2019s disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 5:1049-1105 (2004).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Pichel, V., Lombardi, V., Kubota, Y., Takeda, M. Pharmacogenomic studies with a combination therapy in Alzheimer\u2019s disease. In: Molecular Neurobiology of Alzheimer\u2019s Disease and Related Disorders. Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Karger, Basel, pp. 94-107 (2004).\r\n\r\nCacabelos, R., Lombardi, V., Fern\u00e1ndez-Novoa, L., Kubota, Y., Corzo, L., Pichel, V., Takeda, M. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Molecular Neurobiology of Alzheimer\u2019s Disease and Related Disorders. Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Karger, Basel, pp. 236-285 (2004).\r\n\r\nIsaza, C., Henao, J., Ram\u00edrez, E., Cuesta, F., Cacabelos, R. Polymorphic variants of the beta-2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 27:237-244 (2005).\r\n\r\nCacabelos, R. Funci\u00f3n cerebrovascular en la enfermedad de Alzheimer (2005) www.sinapsis.org\/.\r\n\r\nLombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Effects of fish-derived lipoprotein extracts on activation markers, Fas expression and apoptosis in peripheral blood lymphocytes. Intern. Immunopharmacol., 5:253-262 (2005).\r\n\r\nCacabelos, R., Kubota, Y., Isaza, C., Henao, J., Fern\u00e1ndez-Novoa, L., Lombardi, V.R.M., Corzo, L., Pichel, V. Functional genomics and pharmacogenetics in Alzheimer\u2019s disease. In: Recent Progress in Alzheimer\u2019s and Parkinson\u2019s Diseases. Hanin, I., Cacabelos, R., Fisher, A. (Eds.). Taylor & Francis, London, pp. 89-102 (2005).\r\n\r\nLombardi, V.R.M., Fern\u00e1ndez-Novoa, L., Etcheverr\u00eda, I., Seoane, S., Cacabelos, R. Regulating factors for microglial activation: implication for Alzheimer\u2019s disease and brain damage. In: Recent Progress in Alzheimer\u2019s and Parkinson\u2019s Diseases. Hanin, I., Cacabelos, R., Fisher, A. (Eds.). Taylor & Francis, London, pp. 171-176 (2005).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Kubota, Y., Takeda, M. Molecular genetics of Alzheimer\u2019s disease and aging. Meth. Find. Exp. Clin. Pharmacol., 27(Suppl. A):1-573 (2005).\r\n\r\nCacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer\u2019s disease. Aging Health, 1:303-348 (2005).\r\n\r\nCacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer\u2019s disease. Expert Opin. Pharmacother., 6:1967-1987 (2005).\r\n\r\nCacabelos, R. Role of nutrition in the prevention of Alzheimer\u2019s disease. Aging Health, 1:359-362 (2005).\r\n\r\n\u00c1lvarez, X.A., Corzo, L., Laredo, M., Sampedro, C., Cacabelos, R., Windisch, M., Moessler, H., Crook, T.H. Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjects. Meth. Find. Exper. Clin. Pharmacol., 27:493-487 (2005).\r\n\r\nCacabelos, R. Homocysteine and cognition: from Galenic dogmatism to genetic relativism. Aging Health, 2:783-786 (2006).\r\n\r\nLombardi VRM, Pereira J, Etcheverr\u00eda I, Fern\u00e1ndez-Novoa L, Seoane S, Cacabelos R. Improvement of immune function by means of Conger conger extract in an in vivo model of cold stress. Food and Agricultural Immunology 2006; 17(1-4): 115-127.\r\n\r\n\u00c1lvarez, X.A., Cacabelos, R., Laredo, M., Couceiro, V., Sampedro, C., Varela, M., Corzo, L., Fern\u00e1ndez-Novoa, L., Vargas, M., Aleixandre, M., Linares, C., Granizo, E., Muresanu, D., Moessler, H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer\u2019s disease. Eur. J. Neurol., 13:43-54 (2006).\r\n\r\nCacabelos, R., Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer\u2019s disease. Drugs Future, 31(Suppl. B):5-146 (2006).\r\n\r\nCacabelos, R. Molecular pathology and pharmacogenomics in Alzheimer\u2019s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 29(Supp. A):1-91 (2007).\r\n\r\nTakeda, M., Cacabelos, R. (Eds.). Alzheimer\u2019s disease genomics. Cognition and Dementia, 6(Suppl.):7-113 (2007).\r\n\r\nCacabelos, R. Donepezil in Alzheimer\u2019s disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 3:303-333 (2007).\r\n\r\n\u00c1lvarez, A., Cacabelos, R., Sampedro, C., Garc\u00eda-Fantini, M., Aleixandre, M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-1 in Alzheimer\u2019s disease. Neurobiol. Aging, 28:533-536 (2007).\r\n\r\nCorzo, L., Zas, R., Rodr\u00edguez, S., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Decreased levels of serum nitric oxide in different forms of dementia. Neurosci. Lett., 420:263-267 (2007).\r\n\r\nCacabelos, R (Ed.). Cholinesterase inhibitors in Dementia. Ten years of Donepezil in Alzheimer\u2019s Disease and CNS Disorders (1996-2006): Therapeutic Assessment and Pharmacogenetics. Gen-T\/The EuroEspes Journal, Suppl. 1:1-52 (2007).\r\n\r\nCacabelos, R., Llovo, R., Fraile, C., Fern\u00e1ndez-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer\u2019s disease pharmacogenetics. Cur. Alzheimer Res., 4:479-500 (2007).\r\n\r\nCacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer\u2019s disease. Mol. Diag. Ther., 11:385-405 (2007).\r\n\r\nTakeda, M., Cacabelos, R., Ray, O., F\u00f6rstl, H., Hoon Oh, B. Dementia in the World. Cogn. Dementia, 2:53-63 (2007).\r\n\r\nHarguindey, S., Orive, G., Cacabelos, R., Mel\u00e9ndez Hevia, E., D\u00edaz de Otazu, R., Arranz, J.L., Anitua, E. An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiat. Dis. Treat., 4:1073-1087 (2008).\r\n\r\nCacabelos, R. Application of nutrigenomics to Alzheimer\u2019s disease. AgroFood, 19:37-40 (2008).\r\n\r\nCacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 258(Suppl. 1):28-47 (2008).\r\n\r\nCacabelos, R. Influence of pharmacogenetic factors on Alzheimer\u2019s disease therapeutics. Neurodegenerative Dis., 5:176-178 (2008).\r\n\r\nCacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. Meth Mol. Biol., 448:213-357 (2008).\r\n\r\nCacabelos, R. Pharmacogenomics in Alzheimer\u2019s disease. In: Pharmacogenomics and Personalized Medicine. Cohen, N. (Ed.). pp. 317-368 (2008).\r\n\r\nCacabelos, R. Pleiotropic effects of Apolipoprotein E in dementia: Influence on functional genomics and pharmacogenetics. Adv. Behav. Biol., 57:355-367 (2008).\r\n\r\n\u00c1lvarez, X.A., Sampedro, C., Figueroa, J., Tellado, I., Gonz\u00e1lez, A., Garc\u00eda-Fantini, M., Cacabelos, R., Muresanu, D., Moessler, H. Reductions in qEEG slowing over 1 year and after treatment with cerebrolysin in patients with moderate-severe traumatic brain injury. J. Neural Transm., 115:683-692 (2008).\r\n\r\n\u00c1lvarez, X.A., Sampedro, C., Cacabelos, R., Linares, C., Aleixandre, M., Garc\u00eda-Fantini, M., Moessler, H. Reduced TNF-\u03b1 and increased IGF-I levels in the serum of Alzheimer\u2019s disease patients treated with the neurotrophic agent Cerebrolysin. Int. J. Neuropsychopharmacol., 12:867-872 (2009).\r\n\r\nCacabelos, R. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Vol. IV: Molecular Genetic and Genomic Markers. Ritsner, M.S. (Ed.). Springer, pp. 3-63 (2009).\r\n\r\nCacabelos, R., Mart\u00ednez-Bouza, R., Fern\u00e1ndez-Novoa, L., Carril, J.C., Llovo, R., Tellado, I., Corzo, L., Fraile, C., Cacabelos, N., Bello, A., McKay, A., Bermo, A., Carrera, I., \u00c1lvarez, A., Lombardi, V. Personalized medicine of dementia. Pharmacogenomics of Alzheimer\u2019s disease. Gen-T\/The EuroEspes Journal, 4:18-48 (2009).\r\n\r\nLombardi, V.R.M., Mart\u00ednez, E., Chacon, R., Etcheverr\u00eda, I., Cacabelos, R. Effects of FR-91 on human tumor cell lines. Gen-T\/The EuroEspes Journal, 4:50-60 (2009).\r\n\r\nCacabelos, R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diag., 9:567-611 (2009).\r\n\r\nLombardi, V.R.M., Mart\u00ednez, E., Chac\u00f3n, R., Etcheverr\u00eda, I., Cacabelos, R. Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma. J. Biomed. Biotech., DOI: 10.1155\/2009\/187015 (2009).\r\n\r\nCacabelos, R. Pharmacogenomic protocols in CNS disorders and dementia. Neurodegenerative Dis., 7:167-169 (2010).\r\n\r\nCacabelos, R., Mart\u00ednez-Bouza, R. Genomics and pharmacogenomics of schizophrenia. CNS Neuroscience & Therapeutics. DOI: 10.111_j.1755-5949.2010.00187.\r\n\r\nCacabelos, R., Mart\u00ednez-Bouza, R. Genomics and pharmacogenomics of dementia. CNS Neurosciences & Therapeutics. DOI: 10.111_j.1755-5949.2010.00189.\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Mart\u00ednez-Bouza, R., McKay, A., Carril, J.C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., Alcaraz, M., Rodr\u00edguez, S., Casas, A., Couceiro, V., Alvarez, A. Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. Pharmaceuticals 3:3040-3100 (2010); doi: 10.3390\/ph3103040.\r\n\r\nCacabelos, R., Mart\u00ednez-Bouza, R., Carril, J.C., Fern\u00e1ndez-Novoa, L., Llovo, R., Carrera, I., Corzo, L., Fraile, C., Telladi, I., McKay, A., Bello, A., Cacabelos, N., Lombardi, V. Tarjeta Farmacogen\u00e9tica EuroEspes: La personalizaci\u00f3n del tratamiento farmacol\u00f3gico. Gen-T 5:36-60 (2010).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Mart\u00ednez-Bouza, R., Carril, R., Carrera, I., Fraile, C., Tellado, I., Corzo, L., Lombardi, V. Los genes de la locura. Gen\u00f3mica de la esquizofrenia y los trastornos psic\u00f3ticos. Gen-T 6:34-57 (2010).\r\n\r\nTakeda, M., Mart\u00ednez, R., Kudo, T., Tanaka, T., Okochi, M., Tagami, S., Morihara, T., Hashimoto, R., Cacabelos, R. Apolipoprotein E and central nervous system disorders: Reviews of clinical findings. Psychiat Clin Neurosci 64:592-607 (2010).\r\n\r\nLombardi, V.R.M., Cacabelos, R. Neuron-Glia interactions and neurodegeneration. Psychogeriatria Polska 7(4):115-130 (2010).\r\n\r\nCacabelos, R. Genomics of psychosis. Gen-T (EuroEspes J Int Ed) 3:3 (2011).\r\n\r\nCacabelos, R., Fern\u00e1ndez-Novoa, L., Lombardi, V., Carril, J.C., Corzo, L., Carrera, I., Tellado, I., Mart\u00ednez, R., McKay, A., Takeda, M. Genomics of schizophrenia and psychotic disorders. Gen-T (EuroEspes J Int Ed) 3:6-86 (2011).\r\n\r\nCarril, J.C., Mart\u00ednez-Bouza, R., Fern\u00e1ndez-Novoa, L., Carrera, I., Corzo, L., Fraile, C., Tellado, I., McKay, A., Bello, A., Lombardi, V., Cacabelos, R. The EuroEspes Pharmacogenetic Card. Personalization of pharmacological treatment. Gen-T (EuroEspes J Int Ed) 3:88-118 (2011).\r\n\r\nCarrera, I., Lombardi, V.R.M., Etcheverr\u00eda, I., Mart\u00ednez, E., Chac\u00f3n, R., Cacabelos, R. Prevenci\u00f3n de colitis experimental cr\u00f3nica inducida por dextr\u00e1n sulfato s\u00f3dico (DSS) en ratones tratados con FR-91. Gen-T 7:19-30 (2011).\r\n\r\nCacabelos, R., Mart\u00ednez-Bouza, R., Tellado, I., Alcaraz, M., Nebril, L., Casas, A., Gonz\u00e1lez, Y., L\u00f3pez, L., Couceiro, V., Fraile, C., Rodr\u00edguez, S., Corzo, L., Carril, J.C., Lombardi, V., Carrera, I., Fern\u00e1ndez-Novoa, L. Estados depresivos. Gen-T 7:42-74 (2011).\r\n\r\nCarrera, I., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Lombardi, V., Vigo, C., Cacabelos, R. Desarrollo de la vacuna EuroEspes EB101 contra la enfermedad de Alzheimer. Gen-T 8: 38-52 (2011).\r\n\r\nCacabelos, R. Alzheimer\u2019s disease 2011: Where are we heading. Gen-T 8:54-86 (2011).\r\n\r\nCacabelos, R. Pharmacogenomics of Alzheimer\u2019s disease. Metabolomics 1:3, 1000106e (2011). http:\/\/dx.doi.org\/10.4172\/2153-0769.1000106e.\r\n\r\nAlvarez, X.A., Cacabelos, R., Sampedro, C., Couceiro, V., Aleixandre, M., Vargas, M., Linares, C., Granizo, E., Garc\u00eda-Fantini, M., Baurecht, W., Doppler, E., Moessler, H. Combination treatment in Alzheimer\u2019s disease: Results of a randomized, controlled trial with cerebrolysin and donepezil. Cur Alzheimer Res 8:583-591 (2011).\r\n\r\nAlvarez, X.A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., Doppler, E., Moessler, H. Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer\u2019s disease: results of a randomized, doubled-blind, controlled trial investigating three dosages of cerebrolysin. Eur J Neurol 18:59-68 (2011).\r\n\r\nCacabelos, R., Hashimoto, R., Takeda, M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiat Clin Neurosci 65:3-19 (2011).\r\n\r\nCacabelos, R., Mart\u00ednez-Bouza, R., Carril, J.C., Fern\u00e1ndez-Novoa, L., Lombardi, V., Carrera, I., Corzo, L., McKay, A. Genomics and pharmacogenomics of brain disorders. Current Pharmaceutical Biotechnology 13:674-725 (2012).\r\n\r\nLombardi, V.R.M., Etcheverr\u00eda, I., Carrera, I., Cacabelos, R., Chac\u00f3n, A. Prevention of chronic experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91. J. Biomed. Biotech., (2012). Doi:10.1155\/2012\/826178.\r\n\r\nCacabelos, R., Mart\u00ednez, R., Fern\u00e1ndez-Novoa, L., Carril, J.C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., Takeda, M. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Intern. J. Alzheimer Dis., (2012). Doi:10.1155\/2012\/518901.\r\n\r\nCarrera I., Etcheverr\u00eda, I., Fern\u00e1ndez-Novoa, L., Lombardi, V., Cacabelos, R., Vigo, C. Vaccine development to treat Alzheimer\u2019s disease neuropathology in APP\/PS1 transgenic mice. Intern. J. Alzheimer Dis., (2012). Doi:10.1155\/2012\/376138.\r\n\r\nCanuet, L., Tellado, I., Couceiro, V., Fraile, C., Fern\u00e1ndez-Novoa, L., Ishii, R., Takeda, M., Cacabelos, R. Resting-state network disruption and APOE genotype in Alzheimer\u2019s disease: A lagged functional connectivity study. PLoS ONE (2012) 7(9): e46289. Doi:10.1371\/journal.pone.0046289.\r\n\r\nCacabelos, R. Pharmacogenomics of central nervous system (CNS) drugs. Drug Development Research, 73:461-476 (2012).\r\n\r\nCacabelos, R. The metabolomics paradigm of pharmacogenomics in complex disorders. Metabolomics (2012), 2:5. http\/\/dx.doi.org\/10.4172\/2153-0769.1000e119.\r\n\r\nCacabelos, R., Cacabelos, P., Aliev, G. Genomics and pharmacogenomics of antipsychotic drugs. Open J. Psychiatry 3:46-139 (2013). Doi:10.4236\/ojpsych.2013.31008.\r\n\r\nRomero, A., Cacabelos, R., Oset-Gasque, M.J., Samadi, A., Marco-Contelles, J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer\u2019s disease. Bioorganic & Medicinal Chemistry Lett., (2013). Doi: http:\/\/dx.doi.org\/10.1016\/j.bmcl.2013.02.017.\r\n\r\nCarrera, I., Cacabelos, R. Novel immunotherapeutic procedures for prevention of Alzheimer\u2019s disease. Drug Des., 2013, 2:2. http:\/\/dx.doi.org\/10.4172\/2169-0138.1000107.\r\n\r\nAliev, G., Obrenovich, M.E., Tabrez, S., Jabir, N.R., Reddy, V.P., Li, Y., Burnstock, G., Cacabelos, R., Kamal, M.A. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxidative Medicine and Cellular Longevity (2013). http:\/\/dx.doi.org\/10.1155\/2013\/962984.\r\n\r\nAliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer. Drug Des., (2013), 2:1. http:\/\/dx.doi.org\/10.4172\/2169-0138.1000103.\r\n\r\nCarrera, I., Etcheverr\u00eda, I., Li, Y., Fern\u00e1ndez-Novoa, L., Lombardi, V., Vigo, C., Palacios, H.H., Benberin, V., Cacabelos, R., Aliev, G. Immunocytochemical characterization of Alzheimer disease hallmarks in APP\/PS1 transgenic mice treated with a new anti-amyloid-\u03b2 vaccine. BioMed Research International (2013). http:\/\/dx.doi.org\/10.1155\/2013\/709145.\r\n\r\nTorrellas, C., Fraile, C., Carril, J.C., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Importancia de la farmacogen\u00e9tica en el tratamiento de la hypertension arterial. Gen-T (EuroEspes J.), 9:15-30 (2013).\r\n\r\nCorzo, L., Rodr\u00edguez, S., Lombardi, V., Alejo, R., Cacabelos, R. Propiedades biol\u00f3gicas de Mineraxin. Gen-T (EuroEspes J.), 9:31-40 (2013).\r\n\r\nRomero, A., Cacabelos, R., Marco-Contelles, J. Derivados de tacrina contra la enfermedad de Alzheimer. Gen-T (EuroEspes J.), 9:57-64 (2013).\r\n\r\nCanuet, L., Tellado, I., Couceiro, V., Fraile, C., Fern\u00e1ndez-Novoa, L., Ishii, R., Takeda, M., Cacabelos, R. Influencia del genotipo APOE sobre la actividad cerebral en la enfermedad de Alzheimer. Gen-T (EuroEspes J.), 9:65-74 (2013).\r\n\r\nFern\u00e1ndez-Novoa, L., Corzo, L., Seoane, S., Cacabelos, R. Histamina:una mol\u00e9cula polifac\u00e9tica. Gen-T (EuroEspes J.), 9:75-86 (2013).\r\n\r\nCacabelos, R. Primera Gu\u00eda Mundial de Farmacogen\u00f3mica. Del genoma humano a los retos futuros de la medicina gen\u00f3mica. Gen-T (EuroEspes J.), 9:89-114 (2013).\r\n\r\nCarril, J.C., Seoane, S., Cacabelos, R. Utilidad de la familia de enzimas CYP3A4 como marcadores de inter\u00e9s en farmacogen\u00e9tica. Gen-T (EuroEspes J.), 9:115-124 (2013).\r\n\r\nTellado, I., Canuet, L., Cacabelos, R. Farmacogen\u00f3mica de los agentes transportadores SLC. Gen-T (EuroEspes J.), 9:125-142 (2013).\r\n\r\nLombardi, V.R.M., Cacabelos, R. Nuevas dianas terap\u00e9uticas en la lucha contra el cancer. Gen-T (EuroEspes J.), 9:143-154 (2013).\r\n\r\nAliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA, Benberin VV, Bachurin SO. Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease. Curr Med Chem. 2013 Dec 27. [Epub ahead of print].\r\n\r\nCacabelos R, Cacabelos P, Torrellas C, Carrera I. Inmunoterapia en la enfermedad de Alzheimer: Vacunas y farmacogen\u00f3mica. Cuadernos de Autoinmunidad 2014; 7(1):42-54.\r\n\r\nCacabelos R, L\u00f3pez-Mu\u00f1oz F. The ABCB1 transporter in Alzheimer\u2019s disease. Clin Exp Pharmacol 2014; 4: e128. Doi:10.4172\/2161-1459.1000e128.\r\n\r\nTorrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenetics in the management of hypertension. J Pharmacogenomics Pharmacoproteomics 2014; 5: 126. Doi:10.4172\/2153-0645.1000126.\r\n\r\nSiest G, Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. Pharmacogenomics: from cell to clinic (Part 1). Pharmacogenomics. 2014 Apr;15(5):593-9. doi: 10.2217\/pgs.14.35.\r\n\r\nSiest G, Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. Conference scene: pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics. 2014 Apr;15(6):739-44. doi: 10.2217\/pgs.14.36.\r\n\r\nCacabelos R. The pathogenic component of the APOE-TOMM40 region in Alzheimer\u2019s disease: Its implications in Metabolomics and Pharmacogenomics. Metabolomics 2014; 4: 1000e129. Doi:10.4172\/2153-0769.1000e129.\r\n\r\nCacabelos R. Metabolomics of epigenetic drugs: precautionary measures. Metabolomics 2014; 4: e126. Doi:10.4172\/2153-0769.1000e126.\r\n\r\nCacabelos R, Torrellas C, L\u00f3pez-Mu\u00f1oz F. Epigenomics of Alzheimer\u2019s disease. J Exp Med 2014; 6(3):75-82. http:\/\/dx.doi.org\/10.1016\/j.jecm.2014.03.010.\r\n\r\nCacabelos R1, Torrellas C. Epigenetic drug discovery for Alzheimer's disease. Expert Opin Drug Discov. 2014 Sep;9(9):1059-86. doi: 10.1517\/17460441.2014.930124. Epub 2014 Jul 3.\r\nSee comment in PubMed Commons below\r\nCacabelos R1, Cacabelos P, Torrellas C, Tellado I, Carril JC. Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323-556. doi: 10.1007\/978-1-4939-0956-8_13.\r\n\r\nCacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res. 2014 Sep;75(6):348-65. doi: 10.1002\/ddr.21219.\r\n\r\nCacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, Corzo D, Carril JC, Roses AD. APOE-TOMM40 in the Pharmacogenomics of demetia. J Pharmacogenomics Pharmacoproteomics 2014; 5: 135. Doi:10.4172\/2153-0645.1000135.\r\n\r\nCherif O, Allouche F, Chabchoub F, Chioua M, Soriano E, Y\u00e1\u00f1ez E, Cacabelos R, Romero A, L\u00f3pez MG, Marco-Contelles J. Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer\u2019s Disease. Future Med Chem 2014; 6(17):1883-1891.\r\n\r\nAliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM,Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA, Benberin VV, Bachurin SO. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Current Medicinal Chemistry 2014; 21:2208-2217.\r\n\r\nCarrera I, Etcheverr\u00eda I, Fern\u00e1ndez-Novoa L, Lombardi VRM, Lakshmana MK, Cacabelos R, Vigo C. A comparative evaluation of a novel vaccine in APP\/PS1 mouse models of Alzheimer\u2019s Disease. BioMed Research International 2015; ID 807146. Dx.doi.org\/10.1155\/2015\/807146.\r\n\r\nChioua M, P\u00e9rez M, Bautista-Aguilera OM, Y\u00e1\u00f1ez M, L\u00f3pez MG, Romero A, Cacabelos R, Puig de la Bellacasa R, Brogi S, Butini S, Borrell JI, Marco-Contelles J. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer\u2019s disease. Mini-Reviews in Medicinal Chemistry 2015; 15:648-658.\r\n\r\nCacabelos R, Torrellas C, Carrera I. Opportunities in Pharmacogenomics for the treatment of Alzheimer\u2019s Disease. Future Neurology 2015; 10(3):229-252.\r\n\r\nCacabelos R. New insights into the pathogenesis and pharmacogenomics of attention deficit hyperactivity disorder. Metabolomics 2015, 5:146. Doi:10.4172\/2153-0769.1000146.\r\n\r\nCacabelos R.Pharmacoepigenomics and the metabolomics of drug efficacy and safety. Metabolomics 5:e140. Doi:10.4172\/2153-0760.10000e140.\r\n\r\nCacabelos R, Goldgaber D, Roses AD, Vostrov A, Matsuki H, Torrellas C, Cacabelos P, Corzo D, Carril JC, Fern\u00e1ndez-Novoa L, Carrera I. Gene interactions in the Pharmacogenomics of Alzheimer\u2019s Disease. Sciforschen Genetics and Gene Therapy 2015; 1(1): http:\/\/dx.doi.org\/10.16966\/sggt.102.\r\n\r\nPerianes-Cachero A, Canellas S, Aguado-Llera D, Frago LM, Toledo-Lobo MV, Carrera I, Cacabelos R, Chowen JA,Argente J, Arilla-Ferreiro E, Barrios V. Reduction in A\u03b2-induced cell death in the hippocampus of 17\u03b2-estradiol-treated female rats is associated with an increase in IGF-1 signaling and somatostatinergic tone. J Neurochem 2015 (Oct 7) doi:10.1111\/jnc.13381.\r\n\r\nCacabelos R, Torrellas C. Pharmacogenomics of antidepressants. HSOA Journal ofPsychiatry, Depression& Anxiety 2015; 1:001.\r\n\r\nCacabelos R. Impact of genomic medicine on the future of Neuropsychopharmacology. J Neuropsychopharmacol Mental Health 2015, 1:1. Http:\/\/dx.doi.org\/10.4172\/jnpmh.1000e101.\r\n\r\nCacabelos R. Epigenetic biomarkers in cancer. Clin Med Biochemistry 2015, 1:1. http:\/\/dx-doi.org\/10.4172\/cmbm.1000e101.\r\n\r\nCacabelos R. Metabolomics of drug resistance in cancer: The Epigenetic Component. Metabolomics 2015;5:4. http:\/\/dx-doi-org\/10.4172-0769.1000e141.\r\n\r\nCacabelos R, Torrellas C. Epigenetics of aging and Alzheimer\u2019s disease: Implications for pharmacogenomics and drug response. International Journal of Molecular Sciences 2015; 16:30483-30543; doi:10.3390\/ijms161226236.\r\n\r\nCacabelos R. Proteoepigenomic biomarkers of brain disorders. Metabolomics 2015; 5: e143.\r\ndoi:10.4172\/2153-0769.1000e143.\r\n\r\nTorrellas C, Risso A, Carril JC, Cacabelos R. Optimizaci\u00f3n del uso deantidepresivos con estrategias farmacogen\u00e9ticas. Gen-T 2015; 10:17-26.\r\n\r\nRamos E, Marco Contelles J, Cacabelos R, Romero A. Potencial terap\u00e9utico de la melatonina en combinaci\u00f3n con otros f\u00e1rmacos frente a la neurodegeneraci\u00f3n. Gen-T 2015; 10:43-52.\r\n\r\nDel Coso J, Lara B, Salinero JJ, Areces F, Gallo-Salazar C, Ruiz-Vicente D, Cacabelos R. La importancia del sodio para el rendimiento y la salud del deportista. La fisiolog\u00eda del ejercicio y la gen\u00e9tica como elementos clave para el dise\u00f1o de las futuras bebidas deportivas y los suplementos nutricionales. Gen-T 2015; 10:63-71.\r\n\r\nCarril JC, Cacabelos R. La Tarjeta Farmacogen\u00e9tica Inteligente. Desarrollo de la nueva Tarjeta Farmacogen\u00e9tica EuroEspes para el tratamiento farmacol\u00f3gico personalizado. Gen-T 2015; 10:72-114.\r\n\r\nTellado I, Carril JC, Couceiro V, Fraile C, Torrellas C, Cacabelos R. Impacto del genotipo AGT sobre la actividad cerebral en la demencia vascular. Gen-T 2015; 10:137-142.\r\n\r\nAliev G1, Cacabelos R, Prakash Reddy V. Editorial: Metabolic Disorders, Drug Development, Drug Design and Biomarkers. Curr Pharm Des. 2015 Dec 27. [Epub ahead of print]\r\n\r\nDel Coso J1, Lara B1, Salinero JJ1, Areces F1, Ruiz-Vicente D1, Gallo-Salazar C1, Abi\u00e1n-Vic\u00e9n J1, Cacabelos R2. CFTR genotype-related body water and electrolyte balance during a marathon. Scand J Med Sci Sports. 2015 Aug 17. doi: 10.1111\/sms.12542. [Epub ahead of print\r\n\r\nCacabelos R. Proteomic biomarkers in Alzheimer\u2019s disease. Diagn Pathol Open 2016; 1:1. http:\/\/dx.doi.org\/10.4172\/DPO.1000103.\r\n\r\nCacabelos R. Nutriepigenomics: Mending ideas in nutrition, health and disease. J Nutr Sci 2016; 6:1. http:\/\/doi.org\/10.4172\/2155-9600.100e124.\r\n\r\nCacabelos R1,2, Teijido O1,3, Carril JC1,4. Can cloud-based tools accelerate Alzheimer's disease drug discovery? Expert Opin Drug Discov. 2016 Mar;11(3):215-23. doi: 10.1517\/17460441.2016.1141892. Epub 2016 Feb 3.\r\n\r\nCacabelos R, Reddy VP, Aliev G1. Editorial: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications. CNS Neurol Disord Drug Targets. 2016;15(2):126.\r\n\r\nCacabelos R1, Torrellas C, Carrera I, Cacabelos P, Corzo L, Fern\u00e1ndez-Novoa L, Tellado I, Carril JC, Aliev G. Novel Therapeutic Strategies for Dementia. CNS Neurol Disord Drug Targets. 2016;15(2):141-241.\r\n\r\nCacabelos R. ADHD: Challenges for a better future. Gen-T International 2016; 4:3-5.\r\n\r\nCacabelos R, Torrellas C, Tellado I, Cacabelos P. Genomics, pathogenesis, treatment and Pharmacogenomics of attention-deficit\/hyperactivity disorder. Gen-T International 2016; 4:8-134.\r\n\r\nCacabelos R, Torrellas C, Fern\u00e1ndez-Novoa L, Aliev G. Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Curr Pharm Des. 2016;22(7):819-48.\r\n\r\nCarrera I1, Fernandez-Novoa L, Aliev G, Vigo C, Cacabelos R. Validating Immunotherapy in Alzheimer's Disease: The EB101 Vaccine. Curr Pharm Des. 2016;22(7):849-58.\r\n\r\nCacabelos R. Trial-and-Error versus Personalized Treatment in Depression: The Power of Pharmacogenomics. J Psychiatry Depress Anxiety 2016; 2:004.\r\n\r\nCacabelos R. Histamine: The Missing Link in the Pathogenesis of Some Brain Disorders. Journal of Clinical and Experimental Neuroimmunology 2016; 1:1. http:\/\/dx.doi.org\/10.4172\/jceni.1000103.\r\n\r\nCacabelos R. Epigenetics of Brain Disorders: The Paradigm of Alzheimer\u2019s disease. J Alzheimers Dis Parkinsonism 2016; 6:229. Doi: 10.4172\/2161-0460.1000220.\r\n\r\nCacabelos R. The complexity of Alzheimer\u2019s disease pharmacogenomics and metabolomics in drug development. Metabolomics 2016; 2:6. http:\/\/dx-doi.org\/10.4172\/2153-0769.1000e145.\r\n\r\n

Cap\u00edtulos de Libros y Monograf\u00edas<\/h2>\r\n\r\nCacabelos, R. Effect of social and individual factors on the inner organization and efficiency of a multidisciplinary Group. In: Naka, S. Ed. Proc. 10th World Cong. Soc. Psychiatry, Inter Group Corp., Osaka, pp. 140 (1984).\r\n\r\nWada, H., Watanabe, T., Yamatodani, A., Cacabelos, R., Takeda, N., Itoi, N., Shiosaka, S., Tohyama, M., Kiyono, S., Seo, M., Nagai, K., Nakagawa, H. Distribution of the histaminergic neuron system and its physiological function in the rat brain. In: Proc. 13th Symp. Pharmacol. Act. Mechan., Kyoto, pp. 39-44 (1984). \r\n\r\nCacabelos, R. Histamina cerebral. JANO Med. Hum., 636:40-42 (1984). \r\n\r\nWada, H., Cacabelos, R. Introducci\u00f3n a la histamina cerebral. JANO Med. Hum., 636:43-54 (1984). \r\n\r\nCacabelos, R. Papel de la histamina en el sistema neuroendocrino. JANO Med. Hum., 638:46-61 (1984). \r\n\r\nCacabelos, R. Neurotransmisi\u00f3n histamin\u00e9rgica. JANO Med. Hum., 638:31-45 (1984). \r\n\r\nCacabelos, R., Yamatodani, A., Watanabe, T., Hariguchi, S., Nishimura, T., Wada, H. Acciones centrales de la histamina. JANO Med. Hum., 638:62-85 (1984). \r\n\r\nWada, H., Watanabe, T., Yamatodani, A., Maeyama, K., Itoi, N., Cacabelos, R., Seo, M., Kiyono, S., Nagai, K., Kanagawa, H. Physiological functions of histamine in the brain. In: Ganellin, C.R., Schwartz, J.C. (Eds.). Pergamon Press, Oxford, pp. 225-235 (1985). \r\n\r\nNishimura, T., Niigawa, H., Cacabelos, R., Tada, K., Hariguchi, S. Changes in histamine and neuropeptides in dementia. In: Iizuka, R. (Ed.) Koseisho, Tokyo, pp. 97-106 (1986). \r\n\r\nCacabelos, R., Niigawa, H., Ikemura, Y. Neuroendocrine correlates in senile dementia of the Alzheimer type. In: Sinha, K.K. (Ed.). Neurological Society of India, Catholic Press, Ranchi, 2:231-247 (1986). \r\n\r\nCacabelos, R., Niigawa, H., Otero, F., Fern\u00e1ndez, M., Couto, D.F., Nishimura, T., Rodr\u00edguez, A. Disfunci\u00f3n neuropeptid\u00e9rgica en la enfermedad de Alzheimer: Estrategias neuroqu\u00edmicas con fines diagn\u00f3stico-terap\u00e9uticos. En: Seva D\u00edaz, A. (Ed.). Actas XIII R. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 341-348 (1988). \r\n\r\nCacabelos, R. Actividad neurobiol\u00f3gica del GRF: Marcador diagn\u00f3stico en demencia senil y retraso mental. En: Tresguerres, J.F., Casanueva, F., S\u00e1nchez Franco, F., V\u00e1zquez, J.A. (Eds.). Posibilidades diagn\u00f3sticas del GRF(1- 29)NH2. Editorial Garsi, S.A., Madrid, pp. 99-122 (1989). \r\n\r\nCacabelos, R. Acciones de los neurop\u00e9ptidos sobre el sistema nervioso central. En: Tresguerres, J.F. (Ed.). Fisiolog\u00eda endocrina, Endema, S.A., Madrid, pp. 571-649 (1989). \r\n\r\nCacabelos, R. Marcadores diagn\u00f3sticos na demencia senil. Proc. I Xornada sobre Demencia Senil. Xunta de Galicia, Santiago de Compostela, pp. 47-63 (1989). \r\n\r\nCacabelos, R. Alternativas terap\u00e9uticas na demencia senil. Proc I Xornada sobre Demencia Senil. Xunta de Galicia, Santiago de Compostela, pp. 85-101 (1989). \r\n\r\nCacabelos, R. Demencia senil. Desafio biom\u00e9dico y sociosanitario. Monograf\u00edas M\u00e9dicas JANO, 3:255-266 (1989). \r\n\r\nCacabelos, R., Couto, D.F., Otero, F., Albarr\u00e1n, M., P\u00e9rez, A., Fern\u00e1ndez, M., \u00c1lvarez, X.A. Demencia senil. Etiopatogenia. Monografias M\u00e9dicas JANO, 3:279-283 (1989). \r\n\r\nCacabelos, R., Couto, D.F. Demencia senil. Neurobiolog\u00eda. Monografias M\u00e9dicas JANO, 3:285-295 (1989). \r\n\r\nCacabelos, R., Rodr\u00edguez, A. Demencia senil. Cl\u00ednica. Monografias M\u00e9dicas JANO, 3:339-344 (1989).\r\n\r\nCacabelos, R. Demencia senil. Marcadores diagn\u00f3sticos. Monografias M\u00e9dicas JANO, 3:347-354 (1989). \r\n\r\nOtero, F., Fern\u00e1ndez, M., Cacabelos, R. Demencia senil. Marcadores diagn\u00f3sticos perif\u00e9ricos. Monografias M\u00e9dicas JANO, 3:383-386 (1989). \r\n\r\nAlbarr\u00e1n, M., P\u00e9rez, A., \u00c1lvarez, X.A., Ortiz, T., Rodr\u00edguez, A., Cacabelos, R. Marcadores neuropsicol\u00f3gicos en la enfermedad de Alzheimer. Monograf\u00edas M\u00e9dicas JANO, 3:357-363 (1989). \r\n\r\nCacabelos, R., Otero, F., Fern\u00e1ndez, M., P\u00e9rez, A., Albarr\u00e1n, M., \u00c1lvarez, X.A., Couto, D.F., Niigawa, H., Nishimura, T., Rodr\u00edguez, A. Demencia senil. Alternativas terap\u00e9uticas. Monograf\u00edas M\u00e9dicas JANO, 3:403-414 (1989). \r\n\r\nCacabelos, R., Otero, F., Fern\u00e1ndez, M., \u00c1lvarez, X.A., Albarr\u00e1n, M.A., P\u00e9rez, A., Borr\u00e1s, C.G., Rodr\u00edguez, A. Growth hormone-releasing factor [GRF(1-29)NH2]: Marcador diagn\u00f3stico en trastornos neuropsiqui\u00e1tricos. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 28-37 (1989). \r\n\r\nAlbarr\u00e1n, M.A., P\u00e9rez, A., Cacabelos, R. Influencia del growth hormone-releasing factor (GRF) sobre hormona de crecimiento (GH) en pacientes con retraso mental (RM). Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 38-43 (1989). \r\n\r\nLorenzo Lago, A,, Cacabelos, R., Pardi\u00f1as, M.C., Salazar Bernard, I., Rodr\u00edguez L\u00f3pez, A. Marcadores biol\u00f3gicos en el alcoholismo: Transferrina y GRF. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 43-46 (1989).\r\n\r\nCacabelos, R., Niigawa, H., Nishimura, T. Eficacia terap\u00e9utica del growth hormone-releasing factor (GRF) en demencia senil: Estudios en un modelo animal de enfermedad de Alzheimer y resultados cl\u00ednicos preliminares. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 88-94 (1989). \r\n\r\nP\u00e9rez, A., Otero, F., \u00c1lvarez, X.A., Fern\u00e1ndez, M., Albarr\u00e1n, M.A., Cacabelos, R. Estudio bioqu\u00edmico de fluidos corporales en pacientes con demencia senil tipo Alzheimer y demencia multiinfarto. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 95-102 (1989). \r\n\r\nFern\u00e1ndez, M., Otero, F., \u00c1lvarez, X.A., P\u00e9rez, A., Albarr\u00e1n, M.A., Niigawa, H., Nishimura, T., Cacabelos, R. Respuesta de GH a GRF en pacientes con demencia senil tipo Alzheimer. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 103-108 (1989). \r\n\r\nOtero, F., Fern\u00e1ndez, M., P\u00e9rez, A., Albarr\u00e1n, M., \u00c1lvarez, X.A., Ver\u00edsimo, J., Serrano, F., P\u00e9rez, T., Di\u00e9guez, C., Fraiz, J., Lois, J.L., Borr\u00e1s, C.G., Rodr\u00edguez, A., Cacabelos, R. Eficacia diagn\u00f3stica del test de GRF en trastornos psiqui\u00e1tricos. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 602-608 (1989).\r\n\r\n\u00c1lvarez, X.A., Fern\u00e1ndez, M., Otero, F., Albarr\u00e1n, M.A., P\u00e9rez, A., Couto, D.F., Ver\u00edsimo, J., Otero, T., P\u00e9rez, T., Serrano, F., Di\u00e9guez, C., Borr\u00e1s, C.G., Salazar, I., Lorenzo, A., Rodr\u00edguez, A., Cacabelos, R. Growth hormone-releasing factor (GRF): Marcador diagn\u00f3stico en neuropatolog\u00eda alcoh\u00f3lica. Actas 2\u00ba Cong. Soc. Esp. Psiquiat. Biol., Ar\u00e1n Ed., Madrid, pp. 662-668 (1989). \r\n\r\nCacabelos, R., P\u00e9rez, A., Fern\u00e1ndez, M., Otero, F., \u00c1lvarez, X.A., Albarr\u00e1n, M. Neuroendocrine markers in Alzheimer\u2019s disease: New prospects for diagnosis and treatment. In: Recent advances in basic and clinical neuroendocrinology. Casanueva, F.F., Di\u00e9guez, C. (Eds.). Elsevier Science Publishers, Amsterdam, pp. 383-391 (1989). \r\n\r\nCacabelos, R. Neuroendocrinolog\u00eda en la enfermedad de Alzheimer. En: Marcadores biol\u00f3gicos y perspectivas terap\u00e9uticas en la enfermedad de Alzheimer. Acar\u00edn, N., Alom, J. (Eds.). MCR Ed., Barcelona, pp. 55-68 (1989). \r\n\r\nCacabelos, R., Otero, F., Fern\u00e1ndez, M., Fari\u00f1as, F., \u00c1lvarez, X.A. Marcadores neuroqu\u00edmicos para el diagn\u00f3stico diferencial entre depresi\u00f3n involutiva y demencia senil. En: Las depresiones en el anciano. PTD-Espa\u00f1a. Espaxs, S.A., Barcelona, pp. 53-91 (1990). \r\n\r\nRodr\u00edguez. A., Cacabelos, R., Mateos, R. Estrategias epidemiol\u00f3gicas en el estudio de la enfermedad de Alzheimer. En: Aspectos actuales del envejecimiento normal y patol\u00f3gico. Hayflick, L., Barcia, D., Miquel, J. (Eds.). ELA, Ar\u00e1n Ed., Madrid, pp. 105-112 (1990). \r\n\r\nCacabelos, R. Marcadores neuroqu\u00edmicos en la enfermedad de Alzheimer. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 39-59 (1990).\r\n\r\nRodr\u00edguez, A., Mateos, R., Cacabelos, R., Mazaira, J. Diagn\u00f3stico evolutivo de los cuadros demenciales. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 262-276 (1990). \r\n\r\nAlbarr\u00e1n, M.A., Salazar, I., P\u00e9rez, I., Rodr\u00edguez, A., Cacabelos, R. Hiporrespuesta de GH a GRF en toxic\u00f3manos. Actas X1V Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 466-472 (1990). \r\n\r\nP\u00e9rez, A., Fern\u00e1ndez, M., Cornes, J.M., Albarr\u00e1n, M.A., Cacabelos, R. Respuesta de GH a GRI: (Growth hormone releasing factor) en pacientes con demencia multiinfarto (DMI). Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 473-480 (1990). \r\n\r\nFern\u00e1ndez, M., Di\u00e9guez, C., Cornes, J.M., Cacabelos, R. Respuesta de GH a GRF en trastornos depresivos. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 481-486 (1990). \r\n\r\nOtero, F., Tortajada, I., Alonso, J., Blanco, J., Tabernero, J., Agra, S., Cornes, J.M., Di\u00e9guez, C., Cacabelos, R. Test de GRF: Potencial marcador diagn\u00f3stico en esquizofrenia. Actas XIV Reun. Nac. Soc. Esp. Psiquiat. Biol., D\u00edez Manrique, J.F., V\u00e1zquez Barquero, J.L. (Eds.). Ar\u00e1n Ed., Madrid, pp. 487-490 (1990). \r\n\r\nCacabelos, R. Bases neuroqu\u00edmicas y psicofarmacol\u00f3gicas de la drogadicci\u00f3n. En: Drogodependencias y Sociedad. Fundaci\u00f3n Caixa Galicia, pp. 119-145 (1990). \r\n\r\nCacabelos, R. Histaminergic regulation of the neuroendocrine system. En: Histaminergic Neurons: Morphology and Functions. Ch.14. Watanabe, T., Wada, H. (Eds.). CRC, Florida, pp. 241-270 (1991).\r\n\r\nCacabelos, R., Rubia, F.J. Perspectivas neurobiol\u00f3gicas en hiperquinesia infantil. En: Neurotransmisi\u00f3n y plasticidad sin\u00e1ptica. Esquerda, J.E., Gallego, R., Gual, A., Ram\u00edrez, G., Rubia, F. Spaxs, Barcelona, pp. 261-291 (1991). \r\n\r\nCacabelos, R., Franco-Maside, A., \u00c1lvarez, X.A. Neurobiolog\u00eda de la histamina cerebral. En: Biopatolog\u00eda de los sistemas histamin\u00e9rgicos cerebrales. Varela de Seijas, E. Duphar Pharmaceutica Ed., Madrid, pp. 11-48 (1991). \r\n\r\nRubia, F.J., Mart\u00edn-Loeches, M., Gil, P., Exp\u00f3sito, F.J., Miguel, F., Cacabelos, R. Mapas de actividad el\u00e9ctrica cerebral en la demencia senil de tipo Alzheimer y en la demencia cerebrovascular durante tareas cognoscitivas. En: Bases neuroqu\u00edmicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar Ibabe, M.C. (Eds.). Univ. Granada, pp. 113-131 (1991). \r\n\r\nMart\u00edn-Loeches, M., Gil, P., Miguel, F., Exp\u00f3sito, F.J., Cacabelos, R., Rubia, F.J. Potenciales evocados tard\u00edos en la enfermedad de Alzheimer. En: Bases neuroqu\u00edmicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar lbabe, M.C. (Eds.). Univ. Granada, pp. 133-148 (1991).\r\n\r\nCacabelos, R., Rubia, F.J. Alteraciones neuroqu\u00edmicas en la enfermedad de Alzheimer. En: Bases neuroquimicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar Ibabe, M.C. (Eds.). Univ. Granada, pp. 289-312 (1991). \r\n\r\nCacabelos, R. Nuevas estrategias terap\u00e9uticas en la enfermedad de Alzheimer: psicofarmacolog\u00eda molecular de los agentes nootropos y potencial utilidad de los factores neurotr\u00f3ficos. En; Proc. II Reun. Nac. Soc. Esp. Gerontopsiquiat. Psicogeriat., Bobes Garc\u00eda, J., Ar\u00e1n Ed., Madrid, pp. 57-78 (1991). \r\n\r\nCacabelos, R. Avances en la enfermedad de Alzheimer. En: Gerontolog\u00eda 1992. Jim\u00e9nez Herrero, F. (Ed.). CEA Ed., Madrid, pp. 69-82 (1991). \r\n\r\nCacabelos, R., \u00c1lvarez, X.A. Funci\u00f3n neuroinmune en trastornos mentales. Actas XV Reun. Soc. Esp. Psiq. Biol., C\u00f3rdoba, 1-3.XI.91. ELA, Madrid, 1:7-14 (1991).\r\n\r\nCacabelos, R., Franco-Maside, A., \u00c1lvarez, X.A. Influence of the somatotropinergic system on mental function and psychomotor activity: Environmental factors, development, cognition, and neuropsychiatric disorders. In: Human Growth: Basic and Clinical Aspects. Hern\u00e1ndez, M., Argente, J. (Eds.). Elsevier, Amsterdam, pp. 161-172 (1992). \r\n\r\nCacabelos, R. Brain histamine: Psychoneuroimmune regulator in physiological and pathological conditions. In: Proc. 1st Int. Congr. Vitamins and Biofactors in Life Sciences. Kobayashi, T., Ed. Center For Academic Publications, Japan, pp. 573-576 (1992). \r\n\r\nCacabelos, R. Neurobiolog\u00eda molecular de la enfermedad de Alzheimer: Prospecciones terap\u00e9uticas. En: Actas I Simposio de Psicobiolog\u00eda. P\u00e1saro, E. Ed. Serv. Public. Univ. Coru\u00f1a, pp. 27-51 (1992). \r\n\r\nCacabelos, R. Neurobiolog\u00eda del GRF: Aspectos b\u00e1sicos y aplicaciones cl\u00ednicas. En: P\u00e9ptidos reguladores gastrointestinales. Bl\u00e1zquez, E., Tamarit, J. (Eds.). Fundaci\u00f3n Areces, Madrid, pp. 185-204 (1992). \r\nCacabelos, R., Frey, H., Nishimura, T., Winblad, B. Educational pathways for neurogerontology and psychogeriatrics. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 7-9 (1993).\r\n\r\nCacabelos, R. Neurobiology of aging. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 33-38 (1993). \r\n\r\nG\u00f3mez, M.J., Cacabelos, R. Neuropsychological markers in psychogeriatrics. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T. Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 67-69 (1993). \r\n\r\nFranco-Maside, A., Cacabelos, R. Brain mapping in psychogeriatrics. In: I lnternational Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.) EuroEspes Foundation, La Coru\u00f1a, pp. 71-76 (l993). \r\n\r\nCaama\u00f1o, J., Cacabelos, R. Transcranial Doppler sonography in psychogeriatrics. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 77-82 (1993). \r\n\r\n\u00c1lvarez, X.A., Cacabelos, R. Effects of S-9977-2 on learning, behavior, and serum and brain interleukin-1\uf062 levels in rats. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 203- 206 (1993). \r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Effects of Anapsos on behavior and brain cytokines in rats. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 211-214 (1993). \r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Novo, B., G\u00f3mez, M.J., Zas, R., Rettori, M.C., Kamoun, A., Polo, E., Garc\u00eda, M., Cacabelos, R. Effects of S-9977-2 on behavior and brain interleukin-1\uf062. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 219 (1993). \r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Zas, R., Novo, B., Cacabelos, R. Effects of anapsos on behavior and brain cytokines. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 220 (1993). \r\n\r\n\u00c1lvarez, X.A., Franco, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J., Novo, B., G\u00f3mez, M.J., Zas, R., Cacabelos, R. Age-dependent variations in serum interleukin-1\uf062 and tumor necrosis factor alpha levels in humans. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 221 (1993).\r\n\r\nCaama\u00f1o, J., Franco, A., G\u00f3mez, M.J., Novo, B., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Acute effects of CDP-Choline on middle cerebral artery blood flow velocities in Alzheimer\u2019s disease: A transcranial Doppler study. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 222 (1993).\r\n\r\nCaama\u00f1o, J., Franco, A., G\u00f3mez, M.J., Novo, B., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Cacabelos, R. Cerebrovascular effects of CDP-choline in patients with Alzheimer\u2019s disease: A transcranial Doppler study. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 223 (1993).\r\n\r\nFranco-Maside, A., Caama\u00f1o, J., G\u00f3mez, M.J., \u00c1lvarez, X.A., Fern\u00e1ndez-Novoa, L., Novo, H., Cacabelos, R. CDP-Choline-induced brain mapping changes in patients with Alzheimer\u2019s disease. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 224 (1993). \r\n\r\nFranco-Maside, A., Caama\u00f1o, J., Cacabelos, R. Brain electrical activity mapping correlates with cerebral blood flow velocity in Alzheimer\u2019s disease. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 225 (1993). \r\n\r\nG\u00f3mez, M.J., Cacabelos, R. Relationship between word recall and location in a ten-word list of the Alzheimer\u2019s Disease Assessment Scale. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 227 (1993). \r\n\r\nG\u00f3mez, M.J., \u00c1lvarez, X.A., Cacabelos, R. Dementia mood assessment scale in elderly controls and in patients with depression and\/or cognitive impairment. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coru\u00f1a, pp. 228 (1993). \r\n\r\nCacabelos, R., \u00c1lvarez, X.A., Franco-Maside, A., Fern\u00e1ndez-Novoa, L., Caama\u00f1o, J. Influence of CDP-choline on cognition and interleukin-1\uf062 in Alzheimer\u2019s disease and multi-infarct dementia. In: Alzheimer\u2019s disease and related disorders. Nicolini, M., Zatta, P.F., Corain, B. (Eds.). Advances in Biosciences. Vol. 87. Pergamon Press, London, pp. 347-348 (1993). \r\n\r\nCacabelos, R. Etiopatogenia de la enfermedad de Alzheimer. En: Demencia: Un nuevo reto para la asistencia de ancianos. J.C. Caballero Garc\u00eda, Ed. Barcelona, pp. 43-57 (1993). \r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Bases etiopatog\u00e9nicas para nuevas estrategias terap\u00e9uticas. En: Neuroinmunoprotecci\u00f3n en la demencia senil. Estrategias terap\u00e9uticas pleiotr\u00f3picas en la enfermedad de Alzheimer. Grupo ASAC. Alicante, pp. 9-39 (1994). \r\n\r\nCacabelos, R. Diagnosis of Alzheimer\u2019s disease. Definition of AD phenotype\/genotype. The Karolinska Institute Postgraduate Education Series. Alzheimer\u2019s disease: Advances in Research and Clinical Practice. Winblad, B., Nordberg, A. (Eds.). pp. 42-45 (1994). \r\n\r\nCacabelos, R. New strategies for Alzheimer\u2019s disease treatment: Pleiotropic drugs and multifactorial intervention. In: Alzheimer Disease: Therapeutic Strategies. E. Giacobini, R. Becker. (Eds.). Birkhauser, Boston, pp. 493-498 (1994). \r\n\r\nCacabelos, R., Caama\u00f1o, J., G\u00f3mez, M.J., Fern\u00e1ndez-Novoa, L., Franco-Maside, A., \u00c1lvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer\u2019s disease: Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. In: The Neurobiology of Alzheimer\u2019s Disease. Crowdon, J.H., Nitsch R.M., Corkin S., Wurtman R.J. (Eds.). Proc. Eighth Meeting International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Zurich, pp. 471-475 (1995).\r\n\r\n\r\nCacabelos, R. IRIS Ed. Newsletters 4:1 (1995).\r\n\r\nCacabelos, R. Demencia senil. Enfermedad de Alzheimer. Estrategias terap\u00e9uticas. Grupo ASAC (1995). \r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Etiopatogenia y tratamiento actual. Proc. V Congreso Comunidad Valenciana M\u00e9dicos Rurales y Generalistas. Para una mejor Sanidad en la Comunidad. Soc. Espa\u00f1ola de Medicina Rural y Generalista. SEMERGEN, pp. 69-74 (1995). \r\n\r\nG\u00f3mez, M.J., Caama\u00f1o, J., Vinagre, D., Cacabelos, R. Evaluaci\u00f3n neuropsicol\u00f3gica de la demencia senil. 7\u00ba Curso de Geriatr\u00eda \u201cCiudad de San Sebasti\u00e1n\u201d. Fundaci\u00f3n Matia, pp. 65-91 (1995).\r\n\r\nCaama\u00f1o, J., Vinagre, D., G\u00f3mez, M.J., Franco, A., Cacabelos, R. Demencia: Diagn\u00f3stico diferencial. 7\u00ba Curso de Geriatr\u00eda \u201cCiudad de San Sebasti\u00e1n\u201d. Fundaci\u00f3n Matia, pp. 92-119 (1995).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. 7\u00ba Curso de Geriatr\u00eda \u201cCiudad de San Sebasti\u00e1n\u201d. Fundaci\u00f3n Matia, pp. 153-171 (1995). \r\nCacabelos, R. Enfermedad de Alzheimer: Experiencia Cl\u00ednica con Citicolina. Baliarda, Buenos Aires, 1995. \r\n\r\nCacabelos, R. Demencia senil. Enciclopedia Iberoamericana de Psiquiatr\u00eda. Macropedia. Vol II:359-381 (1995). \r\nCacabelos, R. Enfermedad de Alzheimer: Factores etiopatog\u00e9nicos y evaluaci\u00f3n gen\u00e9tica. Programa de Formaci\u00f3n permanente. Federaci\u00f3n Farmac\u00e9utica, Valencia, A\u00f1o II, Tomo 10:1-40.\r\nCacabelos, R. Claridad mental y autonom\u00eda de comportamiento. Aprender a envejecer sano y activo. IMSERSO. Instituto de Ciencias del Hombre. Madrid, pp. 27-29 (1996). \r\n\r\nCacabelos, R. Bases moleculares del envejecimiento cerebral. En: Temas de Gerontolog\u00eda II. Universidad de Granada\/Ministerio de Trabajo y Asuntos Sociales, pp. 29-41 (1997).\r\nCacabelos, R. Bases biol\u00f3gicas del envejecimiento cerebral. En: Gerontolog\u00eda Social. R. Fern\u00e1ndez-Ballesteros, Pir\u00e1mide Ed., Madrid, pp. 105-151 (2000).\r\n\r\nCano Guti\u00e9rrez, C.A., Cacabelos, R., G\u00f3mez Restrepo, C., Jacquier, M., Lopera, F., Manssur Calder\u00f3n, R.A., Mantallana Eslava, D.L., Monta\u00f1\u00e9s R\u00edos, P., Rom\u00e1n, G., T\u00e9llez Vargas, J.E. Consenso Colombiano de Enfermedad de Alzheimer. Noosfera Ed., Santa Fe de Bogot\u00e1, 2001.\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Perspectivas de futuro. En: Libro Blanco sobre la Enfermedad de Alzheimer y Trastornos Afines. R. Fern\u00e1ndez-Ballesteros, J. D\u00edez Nicol\u00e1s (Eds.). Obra Social Caja Madrid, Editorial M\u00e9dica Panamericana, Madrid, pp. 449-522 (2001).\r\n\r\nCacabelos, R. The histamine-citokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. En: Mapping the Progress of Alzheimer\u2019s and Parkinson\u2019s Disease. Mizuno, Y., Fisher, A., Hanin, I. (Eds.). Advances in Behavioral Biology, 51:59-64 (2002).\r\n\r\nCacabelos, R. Prevenci\u00f3n de Riesgo Cerebral en Altos Ejecutivos. En: Emprendedores con Valores. El directivo ante el nuevo encuentro Europa-Am\u00e9rica. Confederaci\u00f3n Espa\u00f1ola de Directivos y Ejecutivos-CEDE (2002).\r\nCacabelos R (Ed). Preface. The Path to Pharmacogenomics. In: World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012: v-vi.\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. A2M (alpha-2-macroglobulin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:811-812.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. ABCA1 (ATP-binding cassette, sub-family A (ABC1), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:812-824.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. ABCB1 (ATP-binding cassette, sub-family B (MDR\/TAP), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:824-928.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCB11 (ATP-binding cassette, sub-family B (MDR\/TAP), member 11). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:928-930.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC1 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:930-944.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC2 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:944-962.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC3 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:963-965.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC4 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:965-971.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC6 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:971-979.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC8 (ATP-binding cassette, sub-family C (CFTR\/MRP), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:979-985.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCG1 (ATP-binding cassette, sub-family G (WHITE), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:985-996.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCG2 (ATP-binding cassette, sub-family G (WHITE), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:996-1024.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ABL1 (c-abl oncogene 1, non-receptor tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1025-1026.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACACA (acetyl-coA carboxylase alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1026-1027.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACE (angiotensin I converting enzyme (peptidyl-dipeptidase A) 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1027-1034.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACE2 (angiotensin I converting enzyme (peptidyl-dipeptidase A) 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1034-1036.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACHE (acetylcholinesterase (Yt blood group)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1036-1041.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACOX1 (acyl-CoA oxidase 1, palmitoyl). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1041-1042.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL1 (acyl-CoA synthetase long-chain family member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1042-1043.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL3 (acyl-CoA synthetase long-chain family member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1043-1044.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL4 (acyl-CoA synthetase long-chain family member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1044-1045.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL5 (acyl-CoA synthetase long-chain family member 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1045-1046.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL6 (acyl-CoA synthetase long-chain family member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1046.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACVRL1 (activin A receptor type II-like 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1046-1047.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADA (adenosine deaminase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1047-1049.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADCY9 (adenylate cyclase 9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1049-1050.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADD1 (adducin 1 (alpha)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1050-1052.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1A (alcohol dehydrogenase 1A (class 1), alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1052-1053.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1B (alcohol dehydrogenase 1B (class 1), beta polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1053-1054.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1C (alcohol dehydrogenase 1C (class 1), gamma polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1054-1056.\r\n\r\nLombardi V, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADIPOQ (adiponectin, C1Q and collagen domain containing). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1056-1060.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADORA2A (adenosine A2a receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1060-1062.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA1A (adrenergic, alpha-1A-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1062-1064.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA2A (adrenergic, alpha-2A-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1064-1067.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA2C (adrenergic, alpha-2C-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1067-1069.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB1 (adrenergic, beta-1-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1069-1073.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB2 (adrenergic, beta-2-, receptor, surface). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1073-1080.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB3 (adrenergic, beta-3-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1080-1082.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acetyltransferase, beta)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1082-1083.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGT (angiotensinogen (serpin peptidase inhibitor, clade A, member 8)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1083-1088.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGTR1 (angiotensin II receptor, type 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1088-1092.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGXT (alanine-glyoxylate aminotransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1092-1093.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AHR (aryl hydrocarbon receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1093-1098.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AKR1C4 (aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1098-1099.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALAD (aminolevulinate dehydratase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1099-1100.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH1A1 (aldehyde dehydrogenase 1 family, member A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1100-1103.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH2 (aldehyde dehydrogenase 2 family (mitochondrial)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1103-1106.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH3A1 (aldehyde dehydrogenase 3 family, member A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1106-1108.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALOX5 (arachidonate 5-lipoxygenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1108-1111.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AOX1 (aldehyde oxidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1111.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APC (adenomatous polyposis coli). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1112-1115.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOA1 (apolipoprotein A-I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1115-1116.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOA5 (apolipoprotein A-V). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1116-1118.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOB (apolipoprotein B (including Ag(x) antigen)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1118-1119.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOC3 (apolipoprotein C-III). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1119-1120.\r\n\r\nCarril JC, Carrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOD (apolipoprotein D). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1120-1121.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. APOE (apolipoprotein E). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1121-1161.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Lombardi V, Takeda M, Cacabelos R. APP (amyloid beta (A4) precursor protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1161-1183.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AR (androgen receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1183-1189.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ARG1 (arginase, liver). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1189-1190.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AS3MT (arsenic (+3 oxidation state) methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1190-1191.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase\/IMP cyclohydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1191-1192.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ATP7A (ATPase, Cu2+ transporting, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1192-1193.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCAR1 (breast cancer anti-estrogen resistance 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1194.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCHE (butyrylcholinesterase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1194-1196.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCR (breakpoint cluster region). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1196-1197.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BDKRB2 (bradykinin receptor B2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1197.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BDNF (brain-derived neurotrophic factor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1198-1200.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BLK (B lymphoid tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1200-1201.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BLMH (bleomycin hydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1201-1202.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BMPR2 (bone morphogenetic protein receptor, type II (serine\/threonine kinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1202-1203.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRAF (v-raf murine sarcoma viral oncogene homolog B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1203-1204.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRCA1 (breast cancer 1, early onset). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1204-1208.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRCA2 (breast cancer 2, early onset). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1208-1209.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CACNG2 (calcium channel, voltage-dependent, gamma subunit 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1210.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CALU (calumenin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1210-1211.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CASR (calcium-sensing receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1211-1212.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CAT (catalase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1212-1217.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBR1 (carbonyl reductase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1217-1218.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBR3 (carbonyl reductase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1218-1219.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBS (cystathionine beta-synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1219-1220.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CCND1 (cyclin D1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1220-1223.\r\n\r\nLombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CCR5 (chemokine (C-C motif) receptor 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1223-1229.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDA (cytidine deaminase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1229.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK1 (cyclin-dependent kinase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1229-1232.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK2 (cyclin-dependent kinase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1232-1234.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK4 (cyclin-dependent kinase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1234-1236.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK6 (cyclin-dependent kinase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1236-1238.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDKN2A (cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1238-1241.\r\n\r\nLombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CES1 (carboxylesterase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1241-1242.\r\n\r\nLombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CES2 (carboxylesterase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1242-1243.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CETP (cholesteryl ester transfer protein, plasma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1243-1244.\r\n\r\nLombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CFH (complement factor H). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1244-1245.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CFTR (cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1245-1248.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHAT (choline O-acetyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1248-1249.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHDH (choline dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1249.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM1 (cholinergic receptor, muscarinic 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1249-1250.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM2 (cholinergic receptor, muscarinic 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1250-1251.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM3 (cholinergic receptor, muscarinic 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1251-1252.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA1 (cholinergic receptor, nicotinic, alpha 1 (muscle)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1252.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA4 (cholinergic receptor, nicotinic, alpha 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1253-1254.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA5 (cholinergic receptor, nicotinic, alpha 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1254-1255.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNB2 (cholinergic receptor, nicotinic, beta 2 (neuronal)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1255-1256.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHST3 (carbohydrate (chondroitin 6) sulfotransferase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1256-1257.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CNR1 (cannabinoid receptor 1 (brain)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1257-1259.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. COL1A1 (collagen, type I, alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1259-1262.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. COMT (catechol-O-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1262-1264.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CREB1 (cAMP responsive element binding protein 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1264-1265.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRHR1 (corticotropin releasing hormone receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1265-1267.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRHR2 (corticotropin releasing hormone receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1267.\r\n\r\nFern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRP (C-reactive protein, pentraxin-related). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1267-1270.\r\n\r\nLombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CSF1R (colony stimulating factor 1 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1270-1272.\r\n\r\nCarrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CSNK1E (casein kinase 1, epsilon). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1272-1273.\r\n\r\nLombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1273-1274.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1275-1297.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1A2 (cytochrome P450, family 1, subfamily A, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1297-1334.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1335-1347.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1347-1356.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2B6 (cytochrome P450, family 2, subfamily B, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1356-1368.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C8 (cytochrome P450, family 2, subfamily C, polypeptide 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1368-1377.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1377-1401.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C18 (cytochrome P450, family 2, subfamily C, polypeptide 18). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1401-1404.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1404-1423.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Tellado I, Takeda M. CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1423-1589.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2E1 (cytochrome P450, family 2, subfamily E, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1589-1613.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2J2 (cytochrome P450, family 2, subfamily J, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1613-1622.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1622-1901.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1901-1902.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP4B1 (cytochrome P450, family 4, subfamily B, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1902-1906.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP4F2 (cytochrome P450, family 4, subfamily F, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1906-1911.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP7A1 (cytochrome P450, family 7, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1911-1932.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP11B2 (cytochrome P450, family 11, subfamily B, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1932-1943.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP19A1 (cytochrome P450, family 19, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1943-1979.\r\n\r\nCacabelos R, Fern\u00e1ndez-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP27A1 (cytochrome P450, family 27, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1979-1986.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DCK (deoxycytidine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1987-1988.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1988-1989.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DHODH (dihydroorotate dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1989-1990.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DIO2 (deiodinase, iodothyronine, type II). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1990-1992.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPP4 (dipeptidyl-peptidase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1992-1993.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPYD (dihydropyrimidine dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1993-1995.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPYS (dihydropyrimidinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1995-1996.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD1 (dopamine receptor D1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1996-1998.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD2 (dopamine receptor D2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:1998-2002.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD3 (dopamine receptor D3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2002-2004.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD4 (dopamine receptor D4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2004-2006.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD5 (dopamine receptor D5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2006-2008.\r\n\r\nCarrera I, Fern\u00e1ndez-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DTNBP1 (dystrobrevin binding protein 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2008-2010.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EDN1 (endothelin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2011-2013.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EDNRA (endothelin receptor type A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2013-2015.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EGFR (epidermal growth factor receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2015-2019.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EPHX1 (epoxide hydrolase 1, microsomal (xenobiotic)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2020-2022.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERAP1 (endoplasmic reticulum aminopeptidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2022-2023.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro\/glioblastoma derived oncogene homolog (avian)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2023-2026.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERBB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2026-2028.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC1 (excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2028-2029.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC2 (excision repair cross-complementing rodent repair deficiency, complementation group 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2029-2032.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC6 (excision repair cross-complementing rodent repair deficiency, complementation group 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2032-2034.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ESR1 (estrogen receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2034-2042.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ESR2 (estrogen receptor 2 (ER beta)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2042-2046.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F2 (coagulation factor II (thrombin)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2047-2049.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F5 (coagulation factor V (proaccelerin, labile factor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2049-2050.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F7 (coagulation factor VII (serum prothrombin conversion accelerator)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2050-2051.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FABP1 (fatty acid binding protein 1, liver). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2052-2053.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FABP2 (fatty acid binding protein 2, intestinal). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2053-2054.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCER2 (Fc fragment of IgE, low affinity II, receptor for (CD23)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2054-2055.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCGR2A (Fc fragment of IgG, low affinity IIa, receptor (CD32)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2055-2057.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCGR3A (Fc fragment of IgG, low affinity IIIa, receptor (CD16a)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2057-2059.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FGB (fibrinogen beta chain). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2059-2061.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FKBP5 (FK506 binding protein 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2061-2062.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FLT3 (fms-related tyrosine kinase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2062-2064.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO1 (flavin containing monooxygenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2064-2066.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO2 (flavin containing monooxygenase 2 (non-functional)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2066-2067.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO3 (flavin containing monooxygenase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2067-2068.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMR1 (fragile X mental retardation 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2068-2069.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FOS (FBJ murine osteosarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2069-2074.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FSHR (follicle stimulating hormone receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2074-2075.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. G6PD (glucose-6-phosphate dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2076-2078.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GABRA6 (gamma-aminobutyric acid (GABA) A receptor, alpha 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2078-2079.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GCH1 (GTP cyclohydrolase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2079-2082.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GGCX (gamma-glutamyl carboxylase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2082-2083.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GGH (gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2083-2085.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GH1 (growth hormone 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2085-2086.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GHR (growth hormone receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2086-2088.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GNAS (GNAS complex locus). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2089-2091.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GNB3 (guanine nucleotide binding protein (G protein), beta polypeptide 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2091-2093.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIA3 (glutamate receptor, ionotrophic, AMPA 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2093-2095.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIK2 (glutamate receptor, ionotropic, kainate 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2095-2096.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIK4 (glutamate receptor, ionotropic, kainate 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2096-2097.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRINA (glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2097.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRK5 (protein-coupled receptor kinase 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2097-2098.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRM3 (glutamate receptor, metabotropic 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2098-2099.\r\n\r\nCarrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSK3B (glycogen synthase kinase 3 beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2099-2101.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSS (glutathione synthetase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2102-2104.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTA1 (glutathione S-transferase alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2104-2106.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTK1 (glutathione S-transferase kappa 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2106-2107.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTM1 (glutathione S-transferase mu 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2107-2111.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTO1 (glutathione S-transferase omega 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2111-2113.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTO2 (glutathione S-transferase omega 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2113.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTP1 (glutathione S-transferase pi 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2113-2118.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTT1 (glutathione S-transferase theta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2118-2121.\r\n\r\nCarril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HBB (hemoglobin, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2122-2125.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HCP5 (HLA complex P5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2125-2126.\r\n\r\nCarril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HFE (hemochromatosis). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2126-2129.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-A (major histocompatibility complex, class I, A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2129-2131.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-B (major histocompatibility complex, class I, B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2131-2135.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-C (major histocompatibility complex, class I, C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2135-2137.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DPB1 (major histocompatibility complex, class II, DP beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2137-2139.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DQA1 (major histocompatibility complex, class II, DQ alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2139-2141.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DRB1 (major histocompatibility complex, class II, DR beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2141-2145.\r\n\r\nCarril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2145-2147.\r\n\r\nCorzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HNF4A (hepatocyte nuclear factor 4, alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2147-2150.\r\n\r\nCorzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HOXB13 (homeobox B13). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2150-2152.\r\n\r\nCorzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HP (haptoglobin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2152-2153.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HRH1 (histamine receptor H1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2153-2155.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HRH2 (histamine receptor H2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2155.\r\n\r\nCorzo L, Fern\u00e1ndez-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HSD17B1 (hydroxysteroid (17-beta) dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2155-2156.\r\n\r\nLombardi V, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HSPA1L (heat shock 70kDa protein 1-like). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2156-2157.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1A (5-hydroxytryptamine (serotonin) receptor 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2157-2159.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1B (5-hydroxytryptamine (serotonin) receptor 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2159-2161.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1D (5-hydroxytryptamine (serotonin) receptor 1D). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2161.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR2A (5-hydroxytryptamine (serotonin) receptor 2A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2161-2164.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR2C (5-hydroxytryptamine (serotonin) receptor 2C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2164-2165.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3A (5-hydroxytryptamine (serotonin) receptor 3A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2165-2168.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3B (5-hydroxytryptamine (serotonin) receptor 3B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2168-2169.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3C (5-hydroxytryptamine (serotonin) receptor 3, family member C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2169.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR6 (5-hydroxytryptamine (serotonin) receptor 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2169-2170.\r\n\r\nCarril JC, Fern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTT (huntingtin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2170-2174.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ICAM1 (intercellular adhesion molecule 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2175-2178.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNA1 (interferon, alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2178-2179.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNB1 (interferon, beta 1, fibroblast). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2179-2181.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNG (interferon, gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2181-2186.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IGF1 (insulin-like growth factor 1 (somatomedin C)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2186-2189.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IGF2 (insulin-like growth factor 2 (somatomedin A)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2189-2190.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL1B (interleukin 1, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2190-2196.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL1RN (interleukin 1 receptor antagonist). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2196-2198.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL2 (interleukin 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2198-2201.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL4 (interleukin 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2201-2204.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL6 (Interleukin 6 (interferon, beta 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2204-2210.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL6R (interleukin 6 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2210-2211.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL8RA (interleukin 8 receptor, alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2211-2212.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL8RB (interleukin 8 receptor, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2212-2213.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL10 (interleukin 10). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2213-2218.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL12B (interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2218-2221.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL17RB (interleukin 17 receptor B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2221-2222.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. IMPDH1 (IMP (inosine monophosphate) dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2222-2223.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. INPP1 (inositol polyphosphate-1-phosphatase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2223.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IRF1 (interferon regulatory factor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2223-2224.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ITGA2 (integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2224-2225.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ITGB3 (integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2225-2227.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ITPA (inosine triphosphatase (nucleoside triphosphate pyrophosphatase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2227.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNE1 (potassium voltage-gated channel, Isk-related family, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2228-2229.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNE2 (potassium voltage-gated channel, Isk-related family, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2229-2230.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNH2 (potassium voltage-gated channel, subfamily H (eag-related), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2230-2232.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2232-2234.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2234-2236.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. KDR (kinase insert domain receptor (a type III receptor tyrosine kinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2236-2237.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2237-2238.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2239-2241.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. LCK (lymphocyte-specific protein tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2242.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. LCT (lactase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2243.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LDLR (low density lipoprotein receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2243-2246.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LEP (leptin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2246-2248.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LEPR (leptin receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2248-2249.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LIPC (lipase, hepatic). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2249-2250.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LOXL1 (lysyl oxidase-like 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2250-2251.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LPL (lipoprotein lipase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2251-2253.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LRRK2 (leucine-rich repeat kinase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2253-2254.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTA (lymphotoxin alpha (TNF superfamily, member 1)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2254-2256.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTA4H (leukotriene A4 hydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2256.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTC4S (leukotriene C4 synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2256-2257.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAOA (monoamine oxidase A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2258-2259.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAOB (monoamine oxidase B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2260-2261.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MAPK7 (mitogen-activated protein kinase 7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2261.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAPT (microtubule-associated protein tau). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2261-2266.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MC1R (melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2266-2267.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MEN1 (multiple endocrine neoplasia I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2267-2269.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MET (met proto-oncogene (hepatocyte growth factor receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2269-2270.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MGMT (O-6-methylguanine-DNA methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2270-2272.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2272-2274.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MMP2 (matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2274-2276.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MMP3 (matrix metalloproteinase 3 (stromelysin 1, progelatinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2276-2278.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2278-2279.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ATP6 (mitochondrially encoded ATP synthase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2279-2280.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-COI (mitochondrially encoded cytochrome c oxidase I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2280-2281.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND1 (mitochondrially encoded NADH dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2281-2282.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND4 (mitochondrially encoded NADH dehydrogenase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2282-2283.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND6 (mitochondrially encoded NADH dehydrogenase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2283.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-RNR1 (mitochondrially encoded 12S RNA). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2283-2284.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-TK (mitochondrially encoded tRNA lysine). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2284-2285.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-TL1 (mitochondrially encoded tRNA leucine 1 (UUA\/G)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2285.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTHFR (5,10-methylenetetrahydrofolate reductase (NADPH)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2285-2288.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTNR1A (melatonin receptor 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2288-2289.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTNR1B (melatonin receptor 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2289-2290.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTR (5-methyltetrahydrofolate-homocysteine methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2290-2291.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTTP (microsomal triglyceride transfer protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2291-2292.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NAT2 (N-acetyltransferase 2 (arylamine N-acetyltransferase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2293-2296.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NDUFB4 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2296.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NEU2 (sialidase 2 (cytosolic sialidase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2296.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NNMT (nicotinamide N-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2296-2298.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NOS3 (nitric oxide synthase 3 (endothelial cell)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2298-2301.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NOTCH3 (notch 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2301-2302.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NOX1 (NADPH oxidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2302-2303.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NPC1 (Niemann-Pick disease, type C1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2303-2304.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NPPA (natriuretic peptide precursor A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2304-2305.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NPY (neuropeptide Y). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2305-2306.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NQO1 (NAD(P)H dehydrogenase, quinone 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2306-2309.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NR1I2 (nuclear receptor subfamily 1, group I, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2309-2313.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NR1I3 (nuclear receptor subfamily 1, group I, member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2313-2314.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NR3C1 (nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2314-2318.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NRXN1 (neurexin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2318.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NTRK2 (neurotrophic tyrosine kinase, receptor, type 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2318-2320.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. OASL (2'-5'-oligoadenylate synthetase-like). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2321.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. OPRM1 (opioid receptor, mu 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2321-2323.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ORM1 (orosomucoid 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2323.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. P2RY1 (purinergic receptor P2Y, G-protein coupled, 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2324.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. P2RY12 (purinergic receptor P2Y, G-protein coupled, 12). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2324-2325.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PARK2 (parkinson protein 2, E3 ubiquitin protein ligase (parkin)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2325-2326.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDE1C (phosphodiesterase 1C, calmodulin-dependent 70kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2327.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDE5A (phosphodiesterase 5A, cGMP-specific). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2327-2328.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDGFRA (platelet-derived growth factor receptor, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2328-2330.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDGFRB (platelet-derived growth factor receptor, beta polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2330-2331.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PEMT (phosphatidylethanolamine N-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2331-2332.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2332-2333.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. POLG (polymerase (DNA directed), gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2333-2335.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PON1 (paraoxonase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2335-2338.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARA (peroxisome proliferator-activated receptor alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2338-2340.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARD (peroxisome proliferator-activated receptor delta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2340-2342.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARG (peroxisome proliferator-activated receptor gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2342-2345.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARGC1A (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2345-2347.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PRDX4 (peroxiredoxin 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2347.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PRNP (prion protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2347-2352.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PROC (protein C (inactivator of coagulation factors Va and VIIIa)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2352-2353.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PSEN1 (presenilin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2353-2357.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PSEN2 (presenilin 2 (Alzheimer disease 4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2357-2359.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER1 (prostaglandin E receptor 1 (subtype EP1), 42kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2359.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER2 (prostaglandin E receptor 2 (subtype EP2), 53kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2359-2360.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER3 (prostaglandin E receptor 3 (subtype EP3)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2360-2361.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER4 (prostaglandin E receptor 4 (subtype EP4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2361-2362.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGES (prostaglandin E synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2362-2363.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGFR (prostaglandin F receptor (FP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2363.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGIR (prostaglandin I2 (prostacyclin) receptor (IP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2363-2364.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGIS (prostaglandin I2 (prostacyclin) synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2364-2365.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGS1 (prostaglandin-endoperoxide synthase 1 (prostaglandin G\/H synthase and cyclooxygenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2365-2367.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGS2 (prostaglandin-endoperoxide synthase 2 (prostaglandin G\/H synthase and cyclooxygenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2367-2373.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RB1 (retinoblastoma 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2374-2377.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. REN (renin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2377.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RET (ret proto-oncogene). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2377-2379.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RGS2 (regulator of G-protein signaling 2, 24kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2379-2380.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RGS4 (regulator of G-protein signalling 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2380-2381.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RRAS2 (related RAS viral (r-ras) oncogene homolog 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2381-2382.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RRM1 (ribonucleotide reductase M1 polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2382.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RYR1 (ryanodine receptor 1 (skeletal)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2382-2383.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCARB1 (scavenger receptor class B, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2384-2385.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN1A (sodium channel, voltage-gated, type I, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2385-2386.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN1B (sodium channel, voltage-gated, type I, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2386.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN2A (sodium channel, voltage-gated, type II, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2386-2387\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN3A (sodium channel, voltage-gated, type III, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2387.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN4A (sodium channel, voltage-gated, type IV, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2387-2388.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN5A (sodium channel, voltage-gated, type V, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2388-2390.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN9A (sodium channel, voltage-gated, type IX, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2390-2391.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCNN1G (sodium channel, nonvoltage-gated 1, gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2391-2392.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC5A5 (solute carrier family 5 (sodium iodide symporter), member 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2392-2393.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC5A8 (solute carrier family 5 (iodide transporter), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2393-2394.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A2 (solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2394-2395.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A3 (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2395-2397.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A4 (solute carrier family 6 (neurotransmitter transporter, serotonin), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2397-2399.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC10A1 (solute carrier family 10 (sodium\/bile acid cotransporter family), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2399-2400.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC10A2 (solute carrier family 10 (sodium\/bile acid cotransporter family), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2400-2401.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC11A1 (solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2401-2402.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC12A3 (solute carrier family 12 (sodium\/chloride transporters), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2402.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC14A2 (solute carrier family 14 (urea transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2402-3.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC15A1 (solute carrier family 15 (oligopeptide transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2403-2404.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC15A2 (solute carrier family 15 (H+\/peptide transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2404.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC19A1 (solute carrier family 19 (folate transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2404-2405.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A1 (solute carrier family 22 (organic cation transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2406.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A2 (solute carrier family 22 (organic cation transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2406-2407.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A4 (solute carrier family 22 (organic cation\/ergothioneine transporter), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2407-2408.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A6 (solute carrier family 22 (organic anion transporter), member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2408-2409.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A7 (solute carrier family 22 (organic anion transporter), member 7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2409-2410.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A8 (solute carrier family 22 (organic anion transporter), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2410-2411.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A16 (solute carrier family 22 (organic cation\/carnitine transporter), member 16). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2411-2412.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC23A2 (solute carrier family 23 (nucleobase transporters), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2412.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC28A1 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2412-2413.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC28A2 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2413.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1A2 (solute carrier organic anion transporter family, member 1A2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2413-2414.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1B1 (solute carrier organic anion transporter family, member 1B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2414-2416.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1B3 (solute carrier organic anion transporter family, member 1B3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2416.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1C1 (solute carrier organic anion transporter family, member 1C1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2416-2417.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO2B1 (solute carrier organic anion transporter family, member 2B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2417-2418.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SNAP25 (synaptosomal-associated protein, 25kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2418.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SNCA (synuclein, alpha (non A4 component of amyloid precursor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2418-2420.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SOD2 (superoxide dismutase 2, mitochondrial). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2420-2424.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SOD3 (superoxide dismutase 3, extracellular). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2424-2425.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SPG7 (spastic paraplegia 7 (pure and complicated autosomal recessive)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2425.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SRD5A2 (steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2425-2427.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SSTR2 (somatostatin receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2427.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SSTR5 (somatostatin receptor 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2427-2428.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. STAT3 (signal transducer and activator of transcription 3 (acute-phase response factor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2428-2431.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A1 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2431-2432.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A2 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2432-2433.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A3 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2433-2435.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1C2 (sulfotransferase family, cytosolic, 1C, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2435.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1E1 (sulfotransferase family 1E, estrogen-preferring, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2435-2436.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TACR2 (tachykinin receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2437.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TAP1 (transporter 1, ATP-binding cassette, sub-family B (MDR\/TAP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2437-2438.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBX21 (T-box 21). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2438-2439.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBXA2R (thromboxane A2 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2439-2440.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBXAS1 (thromboxane A synthase 1(platelet)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2440.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TERT (telomerase reverse transcriptase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2440-2442.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TGFB1 (transforming growth factor, beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2442-2448.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TGFBR1 (transforming growth factor, beta receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2448-2449.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. THBD (thrombomodulin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2449-2450.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TIMP3 (TIMP metallopeptidase inhibitor 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2450-2451.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TLR4 (toll-like receptor 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2451-2453.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNF (tumor necrosis factor (TNF superfamily, member 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2453-2464.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNFRSF1A (tumor necrosis factor receptor superfamily, member 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2464-2465.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNFRSF1B (tumor necrosis factor receptor subfamily, member 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2465-2467.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TOP1 (topoisomerase (DNA) I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2467-2468.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TP53 (tumor protein p53). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2468-2474.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TPH1 (tryptophan hydroxylase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2474-2475.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TPH2 (tryptophan hydroxylase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2475-2476.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TPMT (thiopurine S-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2477.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TPRV1 (transient receptor potential cation channel, subfamily V, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2478-2479.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TYMS (thymidylate synthetase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2479-2481.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UCP2 (uncoupling protein 2 (mitochondrial, proton carrier)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2482-2483.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2483-2490.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A3 (UDP glucuronosyltransferase 1 family, polypeptide A3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2490-2493.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A4 (UDP glucuronosyltransferase 1 family, polypeptide A4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2493-2495.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A6 (UDP glucuronosyltransferase 1 family, polypeptide A6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2495-2497.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A7 (UDP glucuronosyltransferase 1 family, polypeptide A7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2497-2500.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A9 (UDP glucuronosyltransferase 1 family, polypeptide A9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2500-2502.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A10 (UDP glucuronosyltransferase 1 family, polypeptide A10). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2502-2506.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT2B7 (UDP glucuronosyltransferase 2 family, polypeptide B7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2506-2509.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT2B15 (UDP glucuronosyltransferase 2 family, polypeptide B15). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2509-2510.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. USF2 (upstream transcription factor 2, c-fos interacting). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2510-2511.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. USP5 (ubiquitin specific peptidase 5 (isopeptidase T)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2511.\r\n\r\nLombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VCAM1 (vascular cell adhesion molecule 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2512-2513.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VDR (vitamin D (1,25- dihydroxyvitamin D3) receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2513-2516.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VEGFA (vascular endothelial growth factor A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2516-2520.\r\n\r\nFern\u00e1ndez-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VGF (VGF nerve growth factor inducible). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2520.\r\n\r\nCarril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VKORC1 (vitamin K epoxide reductase complex, subunit 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2520-2521.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. WNK1 (WNK lysine deficient protein kinase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2522-2523.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. WNT5B (Wingless-type MMTV integration site family, member 5B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2523.\r\n\r\nTellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XDH (xanthyne deydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2524-2525.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XPA (xeroderma pigmentosum, complementation group A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2525-2526.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2526-2528.\r\n\r\nCorzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ZFAND6 (zinc finger, AN1-type, domain 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coru\u00f1a, 2012:2529.\r\n\r\nAliev, G., Reddy, V.P., Cacabelos, R. Role of electron microscopy-immunocytochemistry and in situ hybridization in the study of oxidative stress-induced mitochondrial abnormalities and the pathobiology of neurodegeneration and cancer. In: Current Microscopy Contributions to Advances in Science and Technology. M\u00e9ndez-Vilas, A. (Ed). pp. 366-385 (2012). \r\n\r\nAliev G, Horecky J, Vancova O, Ashraf GM, Hassan I, Bragin V,Bragin I, Shevtsova E, Klochkov SG, Kosenso EA, Cacabelos R, Bachurin SO, Benberin VV, Kaminsky YG. The three-vessel occlusion as a model of vascular dementia \u2013 Oxidative stress and mitocondrial failure as an indicator of brain hypoperfusion. In: Systems Biology of Free Radicals and Antioxidants. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2023-2032. Doi: 10.1007\/978-3-642-30018-9.\r\n\r\nAliev G, Ashraf GM, Horecky J, Vancova O, Gvozdjakova A, Kucharska J, Palacios HH, Li Y, Perveen A, Khan TA, Bragin V, Bragin I, Shetsova E, Klochkov SG, Kosenko EA, Cacabelos R, Kaminsky YG, Sudakov KV, Benberin VV, Bachurin SO. Potential preventive effects of Coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion. In: Systems Biology of Free Radicals and Antioxidants. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2033-2048. Doi: 10.1007\/978-3-642-30018-9.\r\n\r\nAliev G, Li Y, Palacios HH, Obrenovich ME, Bragin V, Bragin I, Shevtsova E, Klochkov SG, Kosensko EA, Cacabelos R, Kaminsky YG, Bachurin SO, Benberin VV. Oxidative stress-induced mitocondrial damage as a hallmark for drug development in the context of the neurodegeneration, cardiovascular, and cerebrovascular diseases. In: Systems Biology of Free Radicals and Antioxidants. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2083-2126. Doi: 10.1007\/978-3-642-30018-9.\r\n\r\nAliev G, Li Y, Palacios HH, Obrenovich ME, Bragin V, Bragin I, Shevtsova E, Klochkov SG, Kosensko EA, Kaminsky YG, Bachurin SO, Cacabelos R. Atherosclerotic lesions and mitocondrial DNA deletions as a primary hallmark of the brain microcirculation \u2013 Implication in the pathogenesis of Alzheimer\u2019s disease. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2127-2145. Doi: 10.1007\/978-3-642-30018-9.\r\n\r\nAliev G, Burzynski G, Ashraf GM, Jabir NR, Cacabelos R, Benberin VV, Burzynski SR. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. Laher I (Ed.). Springer-Verlag, Berlin Heidelberg; 2014; pp.2325-2147. Doi: 10.1007\/978-3-642-30018-9.\r\n\r\nCacabelos R, Cacabelos P, Torrellas C. Personalized medicine of Alzheimer\u2019s disease. In: Handbook of Pharmacogenomics and Stratified Medicine. Padmanabhan S (Ed). Elsevier, Amsterdam, 2014: pp. 563-615.\r\n\r\nCacabelos R. Scientific leadership and mental health service to the community. In: Department of Psychiatry Osaka University Medical School. A 120-year history of growth and development. Takeda M (Ed). 2014; pp. 253-258.\r\nCacabelos R. The first version of the EuroEspes Pharmacogenetic Card. In: Cacabelos R (Ed). Research Reports 2006-2010. Vol. 4, pp. 1-2, EuroEspes Publishing Co., Coru\u00f1a (2015).\r\nCacabelos R. The First Guide of PharmacoGenomics, the EuroPharmaGenics (EPG) Database, and the first Chair of Genomic Medicine in Spain. In: Cacabelos R (Ed). Research Reports 2011-2014. Vol. 5, pp. 1-2. EuroEspes Publishing Co., Coru\u00f1a (2015).\r\nCacabelos R. Designing the future. In: Cacabelos R (Ed). Camilo Jos\u00e9 Cela University Health Science Reports 2013; pp. 1-2, CJC University Press, Madrid (2015). \r\n\r\nCacabelos R. Quality vs Quantity. Scientific Development to serve public welfare. In: Cacabelos R (Ed). Camilo Jos\u00e9 Cela University Health Science Reports 2014, pp. 1-2, CJC University Press, Madrid (2015).\r\n\r\nCacabelos R, Torrellas C, Cacabelos P, Villanueva MJ, Pi\u00f1eiro S, Solveira. Pharmacogenetics of neurodegenerative disorders. In: Preventive and Predictive Genetics: Towards Personalized Medicine. Grech & Grossman Eds. Springer, 2015:173-240.\r\n\r\nCacabelos R, Torrellas C, Tellado I, Cacabelos P, L\u00f3pez-Mu\u00f1oz F. Genomics, therapeutics and Pharmacogenomics of attention-deficit\/hyperactivity disorder. In: Attention Deficit Hyperactivity Disorder (ADHD). L\u00f3pez-Mu\u00f1oz F, \u00c1lamo C (Eds). Nova Science Publishers, 2015:65-256.\r\n\r\nCacabelos R, Torrellas C, L\u00f3pez-Mu\u00f1oz F. Pharmacogenomics of antidepressants drugs. In: Srinivasa V (ed). Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer-India. 2016; dOI 10.1007\/978-81-322-2803-5_35.\r\n\r\n

Art\u00edculos de Divulgaci\u00f3n y Opini\u00f3n<\/h2>\r\n\r\nCacabelos, R. La esfera sociosanitaria japonesa. JANO Med. Hum., 606:15-19 (1984). \r\n\r\nCacabelos, R. Violencia en la escuela y delincuencia juvenil: enfermedades de la juventud japonesa. JANO Med. Hum., 608:15-16 (1984). \r\n\r\nCacabelos, R. Una sociedad enferma de poder. JANO Med. Hum., 609:15-16 (1984). \r\n\r\nCacabelos, R. Alcoholismo: Una irresponsabilidad con apolog\u00eda. JANO Med. Hum., Extra Mayo, pp 7-11 (1984). \r\n\r\nCacabelos, R. El suicidio en Jap\u00f3n. JANO Med, Hum., 619:18-26 (1984). \r\n\r\nCacabelos, R. La lecci\u00f3n de un s\u00edndrome. JANO Med. Hum., 626: l3-16 (1984). \r\n\r\nCacabelos, R. Hiroshima y Nagasaki (I). An\u00e1lisis y consecuencias de la cat\u00e1strofe nuclear 39 a\u00f1os despu\u00e9s. JANO Med. Hum., 630:96-118 (1984). \r\n\r\nCacabelos, R. Salud Mental versus Hombre Integral. JANO Med. Hum., 628:15-21 (1984). \r\n\r\nCacabelos, R. El mundo se interesa por la salud de los lagos. La enfermedad de Minamata. JANO Med. Hum., 637:17-21 (1984). \r\n\r\nCacabelos, R. La desplanificaci\u00f3n familiar internacional y el modelo japon\u00e9s. JANO Med. Hum., 632:16-24 (1984). \r\n\r\nCacabelos, R. Interfer\u00f3n japon\u00e9s. Producci\u00f3n masiva de interfer\u00f3n a partir del gusano de seda por ingenier\u00eda gen\u00e9tica. JANO Med. Hum., Extra Diciembre, pp. 10-14 (1984). \r\n\r\nCacabelos, R. LXI aniversario del gran terremoto de Tokio. JANO Med. Hum., 640:16-20 (1984). \r\n\r\nCacabelos, R. El quebradizo entorno econ\u00f3mico del mundo de las computadoras y su relaci\u00f3n con la medicina. JANO Med. Hum., 644:19-21 (1985). \r\n\r\nCacabelos, R. Nuevas perspectivas en el uso de animales de experimentaci\u00f3n. JANO Med. Hum., 649:25-29 (1985). \r\n\r\nCacabelos, R. El alcohol en el mundo: algo m\u00e1s que un problema psicosocial. JANO Med. Hum., 659:160-168 (1985). \r\n\r\nCacabelos, R. La edad de la as\u00edntota o la enfermedad de los pa\u00edses avanzados. JANO Med. Hum., 660:24-26 (1985). \r\n\r\nCacabelos, R. Jap\u00f3n honra a Rebecca Lancefield. JANO Med. Hum., 662:761-762 (1985).\r\n\r\nCacabelos, R. La ciencia se dio cita en Tsukuba Expo \u00b485. JANO Med. Hum., 663:1007-1017 (1985).\r\n\r\nCacabelos, R. Tabaco japon\u00e9s: entre la ciencia y la alevos\u00eda. JANO Med. Hum., 666: 1763-1766 (1985). \r\n\r\nCacabelos, R. Los priones: Una revoluci\u00f3n en el campo de la biolog\u00eda. JANO Med. Hum., 664:1253-1256 (1985). \r\n\r\nCacabelos, R. Alzheimer y biotecnolog\u00eda: modas en Jap\u00f3n. JANO Med. Hum., 665:1506-1508 (1985). \r\n\r\nCacabelos, R. Medio siglo de terapia convulsionante. JANO Med. Hum., 707:41-50 (1986). \r\n\r\nCacabelos, R. El \u201ctechnostress\u201d invade Jap\u00f3n. JANO Med. Hum., 709:205-207 (1986). \r\n\r\nCacabelos, R. Jap\u00f3n: tercer pa\u00eds del mundo en inversiones cient\u00edficas. JANO Med. Hum., 722:1627-1628 (1986). \r\n\r\nCacabelos, R. Los pueblos se quedan sin gente y sin asistencia sanitaria digna. JANO Med. Hum., 713:645-650 (1986). \r\n\r\nCacabelos, R. La investigaci\u00f3n cient\u00edfica en Jap\u00f3n. JANO Med. Hum., 724:1876-1880 (1986). \r\n\r\nCacabelos, R. Grave crisis en la psiquiatr\u00eda japonesa. JANO Med. Hum., 726:2116-2119 (1986). \r\n\r\nCacabelos, R. OUCEM-86: Un sistema computadorizado para estudiar memoria, conducta y aprendizaje. JANO Med. Hum., 758:28-32 (1987). \r\n\r\nCacabelos, R. Microscop\u00eda electr\u00f3nica. JANO Med. Hum., 760:22-25 (1987). \r\n\r\nCacabelos, R. Perfil de la inteligencia artificial en medicina: una perspectiva internacional. JANO Med. Hum., 770:22-32 (1987). \r\n\r\nCacabelos, R. Condicionantes transculturales y profesionales en el diagn\u00f3stico de procesos psiqui\u00e1tricos menores en China, Jap\u00f3n y los EE.UU. JANO Med. Hum., 763:27-28 (1987). \r\n\r\nCacabelos, R. Incipiente educaci\u00f3n sexual escolar y contracepci\u00f3n farmacol\u00f3gica. JANO Med. Hum., 765:24-27 (1987). \r\n\r\nCacabelos, R. Espa\u00f1oles en Jap\u00f3n: una poblaci\u00f3n de alto riesgo con abundantes problemas sociosanitarios. JANO Med. Hum., 766:17-20 (1987). \r\n\r\nCacabelos, R. Presente y futuro de la neuropsiquiatr\u00eda japonesa. JANO Med. Hum., 777:21-29 (1987). \r\n\r\nCacabelos, R. Las ra\u00edces de la medicina japonesa. JANO Med. Hum., 779:16-21 (1987). \r\n\r\nCacabelos, R. C\u00f3mo fabricar un cient\u00edfico japon\u00e9s. JANO Med. Hum., 786:19-21 (1987). \r\n\r\nCacabelos, R. Estrategia japonesa ante el desafio de una sociedad geri\u00e1trica. JANO Med. Hum., 787: 16-22 (1987). \r\n\r\nCacabelos, R. Comentarios epidemiol\u00f3gicos, etiopatog\u00e9nicos y preventivos sobre el retraso mental. JANO Med. Hum., 788:27- 30 (1987). \r\n\r\nCacabelos, R. El gobierno japon\u00e9s proh\u00edbe la comercializaci\u00f3n y experimentaci\u00f3n humana con growth hormone-releasing factor (GRF). JANO Med. Hum., 788:35-37 (1987). \r\n\r\nCacabelos, R. Leupeptin: \u00bfUna alternativa terap\u00e9utica en lesiones nerviosas? JANO Med. Hum., 789:23-26 (1987). \r\n\r\nCacabelos, R. KOGAIBYO: Enfermedades producidas por contaminaci\u00f3n ambiental. JANO Med. Hum., 790:21-25 (1987). \r\n\r\nCacabelos, R. Recientes estudios sobre amiloidosis hereditaria y polineuropat\u00eda craneal idiop\u00e1tica. JANO Med. Hum., 792:16-21 (1987). \r\n\r\nCacabelos, R. El hemisferio dominante de un narcisismo circunspecto. JANO Med. Hum., 793:25-26 (1987). \r\n\r\nCacabelos, R. Influencia de los desastres naturales sobre la aparici\u00f3n de trastornos psiqui\u00e1tricos en Nagasaki. JANO Med. Hum., 794:16-19 (1987). \r\n\r\nCacabelos, R. Aspectos gen\u00e9ticos de la epilepsia. JANO Med. Hum., 795:18-22 (1987). \r\n\r\nCacabelos, R. Estudios cromos\u00f3micos en enfermos mentales japoneses. JANO Med. Hum., 796:25-26 (1987). \r\n\r\nCacabelos, R. KAMPO: Medicina tradicional japonesa. JANO Med. Hum., 802:17-18 (1988). \r\n\r\nCacabelos, R. Pluralismo m\u00e9dico: una alternativa para paliar deficiencias de la biomedicina moderna. JANO Med. Hum., 806:19-20 (1988). \r\n\r\nCacabelos, R. Las paradojas de la higiene popular japonesa. JANO Med. Hum., 807:18-20 (1988). \r\n\r\nCacabelos, R. El rol m\u00e9dico de la religi\u00f3n japonesa o las reliquias m\u00e1gico-m\u00edticas de una sociedad superindustrializada. JANO Med. Hum., 811:25-29 (1988).\r\n\r\nCacabelos, R. Programa de desarrollo de investigaci\u00f3n biom\u00e9dica para el bienestar social: Tecnificaci\u00f3n de la salud y ayuda a los incapacitados. JANO Med. Hum., 813:27-29 (1988). \r\n\r\nCacabelos, R. Factores de riesgo coronario en Jap\u00f3n. JANO Med. Hum., 815:16-19 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Evoluci\u00f3n hist\u00f3rica de la ciencia de los ordenadores. JANO Med. Hum., 815:69-82 (1988). \r\n\r\nCacabelos, R. Correlaci\u00f3n de los factores de riesgo cardiaco en Asia y Europa. JANO Med. Hum., 816:20-24 (1988). \r\n\r\nCacabelos, R. Epidemiolog\u00eda oncol\u00f3gica: \u00bfPrevenci\u00f3n \u00f3 supervivencia posterap\u00e9utica? JANO Med. Hum., 817:16-19 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en Medicina. Organizaci\u00f3n y funcionamiento de los ordenadores; Hardware y Software. JANO Med. Hum., 817:65-72 (1988). \r\n\r\nCacabelos, R. Investigaci\u00f3n oncol\u00f3gica: De la ciencia al negocio. JANO Med. Hum., 818:25-26 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Aplicaciones generales y espec\u00edficas de los ordenadores. JANO Med. Hum., 819:87-101 (1988). \r\n\r\nCacabelos, R. Treinta a\u00f1os de neuroqu\u00edmica japonesa. JANO Med. Hum., 820:33-34 (1988). \r\n\r\nCacabelos, R. Parkinsonismo yatrog\u00e9nico y discinesia tard\u00eda en pacientes japoneses: \u00bfdiferencias \u00e9tnicas con respecto a Occidente? JANO Med. Hum., 821:33 (1988). \r\n\r\nCacabelos, R. Demencia senil: M\u00e1s frecuente en Europa y Am\u00e9rica que en Asia. JANO Med. Hum., 822:15-16 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Inteligencia artificial. JANO Med. Hum., 822:77-95 (1988). \r\n\r\nCacabelos, R. La nueva generaci\u00f3n l\u00e1ser en medicina. JANO Med. Hum., 823:18-20 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Rob\u00f3tica. JANO Med. Hum., 824:71-78 (1988). \r\n\r\nCacabelos, R. La dial\u00e9ctica del tabaquismo o el ejercicio de la libertad. JANO Med. Hum., 825:15-16 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Perspectivas de futuro en ordenadores y telem\u00e1tica. JANO Med. Hum., 826:60-66 (1988), \r\n\r\nCacabelos, R. Enfermedad Moyamoya. JANO Med. Hum., 829:21-22 (1988). \r\n\r\nCacabelos, R. Introducci\u00f3n a los ordenadores en medicina. Contribuci\u00f3n japonesa a la ciencia de los ordenadores. JANO Med. Hum., 831:63-71 (1988). \r\n\r\nCacabelos, R. Farmacolog\u00eda molecular de la terapia anti-SIDA. JANO Med. Hum., 835:25-26 (1988). \r\n\r\nCacabelos, R. Inmunofarmacolog\u00eda: Una expresi\u00f3n biotecnol\u00f3gica vanguardista en medicina. JANO Med. Hum., 836:26-27 (1988). \r\n\r\nCacabelos, R. Degeneraci\u00f3n espinocerebelar: nuevas perspectivas cl\u00ednicoterap\u00e9uticas. JANO Med. Hum., 837:41-43 (1988). \r\n\r\nCacabelos, R. Proyecto TRH: neurobiolog\u00eda molecular e ingreso de los neurop\u00e9ptidos en la farmacopea japonesa. JANO Med. Hum., 838:21-26 (1988). \r\n\r\nCacabelos, R. Esclerosis lateral amiotr\u00f3fica en Jap\u00f3n. JANO Med. Hum., 843:16-20 (1988). \r\n\r\nCacabelos, R. Algunos datos sobre la depresi\u00f3n entre la poblaci\u00f3n japonesa. JANO Med. Hum., 846: 19-21 (1989). \r\n\r\nCacabelos, R. Investigaciones sobre la enfermedad de Creutzfeldt-Jakob. JANO Med. Hum., 848:21-24 (1989). \r\n\r\nCacabelos, R. Demencia senil. JANO Med. Hum., 851:34-43 (1989). \r\n\r\nCacabelos, R. Ciencia, medicina y cooperaci\u00f3n industrial en Jap\u00f3n. Hacia una remodelaci\u00f3n de las estrategias cient\u00edfico-industriales. JANO Med. Hum., 853:21-22 (1989). \r\n\r\nCacabelos, R. La fiabilidad m\u00e9dica y el dilema del paciente en Jap\u00f3n. Los m\u00e9dicos deben ser ejemplo de escrupulosa moralidad social. JANO Med. Hum., 856:21-22 (1989). \r\n\r\nCacabelos, R. La tercera edad en Jap\u00f3n, un problema por resolver. Jano Med. Hum., 857:19-23 (1989). \r\n\r\nCacabelos, R. Propiedades de la lectina y acci\u00f3n antibacteriana de las sarcotoxinas. JANO Med. Hum., 858:27-28 (1989). \r\n\r\nCacabelos, R. Impacto de la inform\u00e1tica en el medio sociocultural y biom\u00e9dico. JANO Med. Hum., 859:17-22 (1989), \r\n\r\nCacabelos, R. SIDA cerebral. JANO Med. Hum., 862:32-43 (1989). \r\n\r\nCacabelos, R. Estrategias para alcanzar un liderazgo cient\u00edfico a nivel mundial. JANO Med. Hum., 865:23-24 (1989). \r\n\r\nCacabelos, R. Nuevas estrategias para el control de la natalidad en China. JANO Med. Hum., 879:21-22 (1989). \r\n\r\nCacabelos, R. La formaci\u00f3n del m\u00e9dico en Jap\u00f3n (I). El M\u00e9dico, 338:DLXXV-DLXXX (1989). \r\n\r\nCacabelos, R. La formaci\u00f3n del m\u00e9dico en Jap\u00f3n (II). El M\u00e9dico, 339:DLXXXI-DLXXXVI (1989). \r\n\r\nCacabelos, R. Salud Mental. Hacia un nuevo concepto de salud integral, prevenci\u00f3n de los trastornos mentales y cobertura social en psiquiatr\u00eda. JANO Med. Hum., 884:77-89 (1989).\r\n\r\nCacabelos, R. Enfermedad mental y psiquiatr\u00eda en Jap\u00f3n. Investigaci\u00f3n M\u00e9dica Permanente. Psiquiatr\u00eda, 4:197-198 (1989). \r\n\r\nCacabelos, R. Contribuci\u00f3n japonesa al desarrollo de la biotecnolog\u00eda. JANO Med. Hum., 892:17-22 (1990). \r\n\r\nCacabelos, R. Jap\u00f3n invierte en alta tecnolog\u00eda para la investigaci\u00f3n biom\u00e9dica. JANO Med. Hum., 894:22-26 (1990). \r\n\r\nCacabelos, R. Envejecimiento poblacional, mercado de salud para la tercera edad. JANO Med Hum., 896:24-27 (1990). \r\n\r\nCacabelos, R. Repercusiones cient\u00edficas del proyecto del genoma humano (PGH). JANO Med. Hum., 897:24-26 (1990). \r\n\r\nCacabelos, R. Problemas \u00e9ticos, sociales y religiosos han paralizado la pr\u00e1ctica de los trasplantes de \u00f3rganos que ven\u00edan practic\u00e1ndose en Jap\u00f3n. JANO Med. Hum., 898:20-21 (1990). \r\n\r\nCacabelos, R. Bases neurobiol\u00f3gicas de la adicci\u00f3n alcoh\u00f3lica. JANO Med. Hum., 900:75-93 (1990). \r\n\r\nCacabelos, R. La industria farmac\u00e9utica de Jap\u00f3n dispone ya de los requisitos esenciales para poder dedicarse a la conquista del mercado exterior. JANO Med. Hum., 901:20-21 (1990). \r\n\r\nCacabelos, R. El aumento de la inversi\u00f3n para la investigaci\u00f3n del c\u00e1ncer revela una vez m\u00e1s que existe gran preocupaci\u00f3n del gobierno y la sociedad japonesas. JANO Med. Hum., 902:23-24 (1990). \r\n\r\nCacabelos, R. Pensando en el futuro de las ciencias m\u00e9dicas, las autoridades del Jap\u00f3n invierten en biotecnolog\u00eda, biolog\u00eda molecular y gen\u00e9tica molecular. JANO Med. Hum., 904:23-24 (1990). \r\n\r\nCacabelos, R. En los \u00faltimos a\u00f1os, la industria farmac\u00e9utica japonesa ha estado viviendo una de las \u00e9pocas econ\u00f3micamente m\u00e1s venturosas de los ochenta. JANO Med. Hum., 905:27-28 (1990). \r\n\r\nCacabelos, R. Depresi\u00f3n senil. JANO Med. Hum., 916:25-40 (1990). \r\n\r\nCacabelos, R. Alzheimer\u2019s disease: Towards an understanding of aetiology and pathogenesis. Med. Clin., 95:399 (1990). \r\n\r\nCacabelos, R. Envejecimiento cerebral. JANO Med. Hum., 927:43-48 (1990). \r\n\r\nCacabelos, R. Jap\u00f3n, dispuesto a demostrar que sus cient\u00edficos son tan creadores como los europeos y americanos. La estrategia actual radica en invertir m\u00e1s en investigaci\u00f3n b\u00e1sica. JANO Med. Hum., 925:22-23 (1990). \r\n\r\nCacabelos, R. La participaci\u00f3n industrial en la investigaci\u00f3n acad\u00e9mica. JANO Med. Hum., 936:26 (1991). \r\n\r\nCacabelos, R. Desarrollo de la psicolog\u00eda y de las ciencias cognitivas en Jap\u00f3n. JANO Med. Hum., 939:23-24 (1991). \r\n\r\nCacabelos, R. Las autoridades niponas dise\u00f1an estrategias en la lucha antidroga. JANO Med. Hum., 938:24-26 (1991). \r\n\r\nCacabelos, R. La medicina tradicional china (Kampo) sigue estando vigente en Jap\u00f3n. JANO Med. Hum., 940:32-33 (1991). \r\n\r\nCacabelos, R. Gen\u00e9tica de la enfermedad de Alzheimer. JANO Med. Hum., 948:44-64 (1991) \r\n\r\nCacabelos, R. Las estrategias de control de calidad en Jap\u00f3n ayudan a abaratar la sanidad, simplificar los esquemas asistenciales y mejorar la salud. JANO Med. Hum., 954:23-24 (1991). \r\n\r\nCacabelos, R. Calidad de vida y bienestar: influencia de la medicina japonesa. JANO Med. Hum., 963:27-28 (1991). \r\n\r\nCacabelos, R. Gesti\u00f3n cient\u00edfica: un embri\u00f3n de buenas intenciones. S\u00edstole, 84:9 (1991). \r\n\r\nCacabelos, R. D\u00e9cadas de tradici\u00f3n, evoluci\u00f3n y progreso en la medicina japonesa. JANO Med. Hum., 970:28-32 (1991). \r\n\r\nCacabelos, R. Una de las preocupaciones de un amplio sector de la sociedad japonesa se centra en buscar salida al sufrimiento de los enfermos terminales. JANO Med. Hum., 972:28-30 (1991). \r\n\r\nCacabelos, R. Estrategias cient\u00edficas ante el siglo XXI. Anuario S\u00edstole. 101 (1992). \r\n\r\nCacabelos, R. En Jap\u00f3n hay en la actualidad 14 millones de personas mayores de 65 a\u00f1os. JANO Med. Hum., 977:21 (1992). \r\n\r\nCacabelos, R. Demencia-SIDA. JANO Med. Hum., 984:31-44 (1992). \r\n\r\nCacabelos, R. Planificaci\u00f3n sanitaria. S\u00edstole, 98:4 (1992). \r\n\r\nCacabelos, R. Tratamiento actual de la enfermedad de Alzheimer. S\u00edstole, 100:51 (1992). \r\n\r\nCacabelos, R. La fase de recesi\u00f3n econ\u00f3mica en la que ha entrado Jap\u00f3n podr\u00eda llegar a originar cambios muy importantes en su pol\u00edtica cient\u00edfica. JANO Med. Hum., 996:35 (1992). \r\n\r\nCacabelos, R. Futuro de la investigaci\u00f3n sobre la enfermedad de Alzheimer. Noticias M\u00e9dicas, 3468:89-90 (1992). \r\n\r\nCacabelos, R. Neurociencias, econom\u00eda y salud. S\u00edstole, 107:4 (1992). \r\n\r\nCacabelos, R. Enfermedad de Alzheimer: El reto de la psicofarmacolog\u00eda molecular. JANO Med. Hum., 1000:161-164 (1992). \r\n\r\nCacabelos, R. La inteligencia artificial en Jap\u00f3n tras el fracaso de la quinta generaci\u00f3n de ordenadores. JANO Med. Hum., 999:34-36 (1992). \r\n\r\nCacabelos, R. Perspectivas de futuro para el Alzheimer. Diario M\u00e9dico, 14 Julio, 1992. \r\n\r\nCacabelos, R. Soluciones a la crisis sanitaria (I). S\u00edstole 120:2 (1992). \r\n\r\nCacabelos, R. Soluciones a la crisis sanitaria (II). S\u00edstole l23:2 (1992). \r\n\r\nCacabelos, R. Soluciones a la crisis sanitaria (III). S\u00edstole 125:2 (1992). \r\n\r\nCacabelos, R. Soluciones a la crisis sanitaria (IV). S\u00edstole 126:2 (1992). \r\n\r\nCacabelos, R. Demencia senil: prioridad sanitaria. El Correo Gallego. Medicina. 20.12.92, pp. 5 (1992). \r\n\r\nCacabelos, R. El reto de las neurociencias. Anuario S\u00edstole, pp. 78-79 (1993). \r\n\r\nCacabelos, R. Sistema de salud japon\u00e9s: un modelo de rentabilidad y eficacia. JANO Med. Hum., 1048:19-20 (1993). \r\n\r\nCacabelos, R. Avances en el tratamiento del mal de Alzheimer. ABC Cultural de la Ciencia, Madrid, 7 Enero, pp. 56 (1994). \r\n\r\nCacabelos, R. Tetrahidroaminoacridina: Una esperanza terap\u00e9utica para la enfermedad de Alzheimer. JANO Med. Hum., 1082:57-60 (1994). \r\n\r\nCacabelos, R. New functional aspects of the suprachiasmatic nucleus of the hypothalamus. Med. Clin. 102:526,531,539 (1994). \r\n\r\nCacabelos, R. Nuevas posibilidades terap\u00e9uticas en la enfermedad de Alzheimer. Diario M\u00e9dico, Junio 6, pp. 12 (1994). \r\n\r\nCacabelos, R. Alzheimer: Nuevas esperanzas para una enfermedad temible. ABC Cultural. ABC de la Ciencia. Julio 1, pp. 52-53 (1994). \r\n\r\nCacabelos, R. Neurofarmacolog\u00eda molecular de la enfermedad de Alzheimer. Primeras generaciones de f\u00e1rmacos anti-demencia. Direcci\u00f3n Farmac\u00e9utica 5:48-54 (1994). \r\n\r\nCacabelos, R. Alzheimer: Aspectos m\u00e9dicos y sociofamiliares. Punto de Encuentro, 9:20-23 (1995). \r\n\r\nCacabelos, R. Enfermedad de Alzheimer: Muerte celular y riesgo gen\u00e9tico. Diario M\u00e9dico, 20 Sept., pp. 15 (1996). \r\n\r\nCacabelos, R. El reto de la enfermedad de Alzheimer. ABC Cultural. ABC de la Ciencia. (27.9.1996), 256:62 (1996). \r\n\r\nCacabelos, R. Pr\u00f3logo a \u201cEnfermedad de Alzheimer. Aspectos psicosociales\u201d. Autor: J.A. Fl\u00f3rez Lozano. EDIKAMed, Barcelona, 1996. \r\n\t \r\nAdeva Candenas, J., Fl\u00f3rez-Lozano, J.A., Caballero-Garc\u00eda, J.C., Cacabelos, R., Garc\u00eda Garc\u00eda, M.C., Mart\u00ednez Lage, J.M., Ma\u00fajo Iglesias, B.A. Las demencias en el presente y en el futuro. JANO LII\/1203:929\/33 (1997). \r\n\r\nCacabelos, R. Demencia senil: El reto del siglo XXI. JANO LII\/1203:930-936\/34-40 (1997). \r\n\r\nCacabelos, R. Un juicio a la bioingenier\u00eda. ABC de la Ciencia. 279:55 (1997). \r\n\r\nCacabelos, R. El Alzheimer, prioridad sociosanitaria para el siglo XXI. El Diario Monta\u00f1\u00e9s, pp. 4 (9.5.1997) \r\n\r\nCacabelos, R. Cerebro y conciencia. Recensiones bibliogr\u00e1ficas. Med. Cl\u00edn., 109:288 (1997). \r\n\r\nCacabelos, R. Premio a la perseverancia innovadora. La Vanguardia, pp. 27 (7.10.1997). \r\n\r\nCacabelos, R. Pr\u00f3logo a \u201cManual de cuidados b\u00e1sicos de una enfermedad familiar (Enfermedad de Alzheimer)\u201d. Autor: Miguel Mu\u00f1oz-Cruzado y Barba. Drug Farma, Madrid, 1998. \r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Reto y compromiso. DKV Previasa Magazine. 2:13-17 (1998). \r\n\r\nCacabelos, R. Educaci\u00f3n, madurez cerebral y prevenci\u00f3n del fracaso escolar. Programa ADI, CIBE, La Coru\u00f1a (2000).\r\n\r\nCacabelos, R. Operaci\u00f3n Genoma. Europa pagar\u00e1 un alto precio por quedarse atr\u00e1s. Muy Interesante 229:28 (2000).\r\n\r\nCacabelos, R. La geograf\u00eda del pri\u00f3n. El Cultural, 7\/2:56-57 (2001).\r\n\r\nCacabelos, R. Medicina Predictiva y Genoma. ByN Dominical II\/57:70 (2001).\r\n\r\nCacabelos, R. Salud mental y prevenci\u00f3n de riesgo cerebral en altos ejecutivos. ECO 130:71 (2002).\r\n\r\nCacabelos, R. Plan de prevenci\u00f3n gen\u00e9tica de la enfermedad de Alzheimer. ECO 131:50 (2002).\r\n\r\nCacabelos, R. Progreso biotecnol\u00f3gico. ECO 132:60 (2002).\r\n\r\nCacabelos, R. Impacto del Genoma Humano en la Econom\u00eda Mundial. ECO 133:50 (2002).\r\n\r\nCacabelos, R. Econom\u00eda y Salud. ECO 135:44 (2002).\r\n\r\nCacabelos, R. Saber o no saber: Esa es la diferencia. ECO 136:44 (2002).\r\n\r\nCacabelos, R. Criterios de Excelencia. ECO 137:78 (2002).\r\n\r\nCacabelos, R. Pensando en Jap\u00f3n. ECO 138:52 (2002).\r\n\r\nCacabelos, R. Salvemos el mar. ECO 139:52 (2002).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Retos para el futuro. Alzheimer en Asturias. N\u00ba 2, Julio-Diciembre (2002).\r\n\r\nCacabelos, R. Educaci\u00f3n y Fugas\u2026de Cerebros. ECO 140:70 (2003).\r\n\r\nCacabelos, R. Patolog\u00eda vascular y demencia: asociaci\u00f3n de alto riesgo. Consejos de tu Farmac\u00e9utico 35:16-17 (2002).\r\n\r\nCacabelos, R. Gen\u00e9tica de los trastornos mentales. Consejos de tu Farmac\u00e9utico 36:20-21 (2002).\r\n\r\nCacabelos, R. Enfermedad de Alzheimer. Retos para el futuro. J\u00fabilo 47:24-27 (2003).\r\n\r\nCacabelos, R. Progreso biotecnol\u00f3gico en Espa\u00f1a. Ejecutivos 134: 46-47 (2003).\r\n\r\nCacabelos, R. La Medicina Gen\u00f3mica del Futuro. Bolet\u00edn das Ciencias, 62:67-69 (2006).\r\n\r\nCacabelos, R. Funci\u00f3n cerebrovascular en la enfermedad de Alzheimer. Sinapsis. www.sinapsis.org (2006).\r\n\r\nCacabelos, R. Exposici\u00f3n Fotogr\u00e1fica: Por la Galicia Natural. Fundaci\u00f3n Ebiotec y Ayuntamiento de A Coru\u00f1a (2006).\r\n\r\nCacabelos, R. Specula orbis. Gen-T\/The EuroEspes Journal, 1:3 (2007). \r\n\r\nCacabelos, R. Medicina gen\u00f3mica y enfermedad de Alzheimer. Gen-T\/The EuroEspes Journal, 1:30-38 (2007).\r\n\r\nCacabelos, R. Stultia mentis. Gen-T\/The EuroEspes Journal, 2:3 (2007).\r\n\r\nCacabelos, R. Gen\u00e9tica del dolor de cabeza. El enigma de la herencia en las migra\u00f1as. Gen-T\/The EuroEspes Journal, 2:32-44 (2007).\r\n\r\nCacabelos, R. La gen\u00e9tica familiar es el primer factor de riesgo para padecer Alzheimer. Acofar, 469: 16-18 (2007).\r\n\r\nCacabelos, R. La Uni\u00f3n Europea se abraza a la Farmacogen\u00f3mica. El Global, 10-16 Sept. (2007).\r\n\r\nCacabelos, R. Los retos de la medicina gen\u00f3mica y el paradigma de la farmacogen\u00e9tica. Rev. Esp. Econom\u00eda Salud, 7:5-6 (2008). \r\n\r\nCacabelos, R. Medicina personalizada versus medicina numeralizada. Gen-T\/The EuroEspes Journal, 3:3 (2008).\r\n\r\nCacabelos, R. Los genios de la locura. Evoluci\u00f3n del conocimiento sobre la enfermedad mental. Gen-T\/The EuroEspes Journal, 3:28-45 (2008).\r\n\r\nDe la Torre, J., Cacabelos, R. Patolog\u00eda cardio-cerebrovascular en la enfermedad de Alzheimer. Gen-T\/The EuroEspes Journal, 3:56-65 (2008).\r\n\r\nHarguindey, S., Orive, G., Anitua, E., Arranz, J.L., Cacabelos, R., D\u00edaz de Otazu, R., Mel\u00e9ndez Hevia, E. Hacia un enfoque integrado de las enfermedades neurodegenerativas. Gen-T\/The EuroEspes Journal, 3:82-89 (2008).\r\n\r\nCacabelos, R. The abyssal waters of personalized medicine. Gen-T\/The EuroEspes Journal, International Edition, 2:5-7 (2008).\r\n\r\nCacabelos, R. Paso a la cultura del conocimiento. Gen-T\/The EuroEspes Journal, 4:3 (2009). \r\n\r\nTerr\u00f3n, F., Kiener, P.A., Ortiz, P., Cacabelos, R., Hug, P. Biotecnolog\u00eda. En: Ponencias VI Congreso de Directivos CEDE. Liderando en positivo. Pamplona, 29-30 Oct. Sodena. Sociedad de Desarrollo de Navara, pp. 279-312 (2010).\r\n\r\nCacabelos, R. La crisis de la salud social. Gen-T 5:3 (2010).\r\n\r\nCacabelos, R. Consejos a un hijo (adolescente). Gen-T 5:97-98 (2010).\r\n\r\nCacabelos, R. Reforma sanitaria. Gen-T 6:3 (2010).\r\n\r\nCacabelos, R. Consejos a un colega (m\u00e9dico). Gen-T 6:97-98 (2010).\r\n\r\nCacabelos, R. Pepinos, par\u00e1sitos e intoxicaciones. Gen-T 7:3 (2011).\r\n\r\nCacabelos, R. Consejos a un Presidente. Gen-T 7:96-98 (2011).\r\n\r\nCacabelos, R. El Alzheimer comienza 30 a\u00f1os antes de manifestarse. El Correo Gallego. http:\/\/www.elcorreogallego.es\/popImprimir.php?idWeb=1&idNoticia=702652.\r\n\r\nCacabelos, R. Historias de la aldea, un poco de paz navide\u00f1a (\u2026 y feliz traspaso de incompetencias). Gen-T 8:3 (2011).\r\n\r\nCacabelos, R. La biblia de la gen\u00f3mica. Gen-T 9:3-5 (2013).\r\n\r\nCacabelos, R. \u00c9tica de progreso en tiempo de crisis. Alterius non sit qui sus ese potest. Gen-T 9:177-178 (2013).\r\n\r\nCacabelos R. Priorizar las inversiones y una buena gesti\u00f3n ser\u00e1n clave para salir de la crisis. El Correo Gallego. 31 Diciembre,pp. 28-29, 2014.\r\n\r\nCacabelos R. El mundo de Jonathan Livingston Harguindey. El Correo Gallego, 4 Enero, pp. 6, 2015.\r\n\r\nCacabelos R. The challenges of Pharmacogenomics and Personalized medicine in an aged population. Adjacent Government 7. http:\/\/edition.pagesuite-professional.co.uk. Page 368. 2015. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.\r\n\r\nCacabelos R. Genomic Medicine: the reconceptualization of Health and Disease. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.http:\/\/www.adjacentgovernment.co.uk\/category\/ebooks\/\r\n\r\nCacabelos R. Drug development for Alzheimer\u2019s disease. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.http:\/\/edition.pagesuite-professional.co.uk\/launch.aspx?eid=793abb3f-e692-439f-9236-554269c9e570\r\n \r\nCacabelos R. Alzh\u00e9imer: prevenci\u00f3n contra el riesgo y tratamiento personalizado contra el da\u00f1o. El Faro de Vigo, 18 Septiembre, pp. 17, 2015.\r\n\r\nCacabelos R. Cuando perdemos la memoria. El Correo Gallego, 20 Septiembre, pp. 7, 2015\r\n\r\nCacabelos R. El martillo del Herrero. El Correo Gallego, 27 Septiembre, pp. 7, 2015.\r\n\r\nCacabelos R. Soluciones al gasto por enfermedad. http:\/\/diario.eleconomista.es\/1\/578734-eleconomista-sanidad-01-octubre-2015.\r\n\r\nCacabelos R. El papel es nuestra vida. El Correo Gallego, 11 Octubre, pp. 6, 2015.\r\n\r\nCacabelos R. \u00c9gloga a mi presidente (I). El Correo Gallego, 22 Octubre, pp. 16, 2015.\r\n\r\nCacabelos R. \u00c9gloga a mi presidente (II). El Correo Gallego, 23 Octubre, pp. 18, 2015.\r\n\r\nCacabelos R. Medicina gen\u00f3mica de los trastornos mentales. La nueva revoluci\u00f3n conceptual en psiquiatr\u00eda. http:\/\/www.psiquiatria.com\/psiq_general_y_otras_areas\/genetica\/medicina-genomica-de-los-trastornos-mentales-la-nueva-revolucion-conceptual-en-psiquiatria\/\r\n\r\nCacabelos R. Investigaci\u00f3n Biom\u00e9dica y Medicina Personalizada. La Cultura del Conocimiento. El Correo Gallego. Especial Medicina. 16 Dic. Pp. 3-5 (2015).\r\n\r\nCacabelos R. Desvar\u00edos en el lupanar pol\u00edtico. Gen-T 2015; 10:3.\r\n\r\nCacabelos R. Al profesor universitario. Gen-T 2015; 10:199-200.\r\n\r\nCacabelos R. Misuse of pharmacotherapy: Danger on the horizon. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.\r\n\r\nCacabelos R. Epigenetics: The missing link at the frontier of health and disease. http:\/\/www.adjacentgovernment.co.uk\/category\/nhs-health-social-care-news\/.","_et_gb_content_width":"","footnotes":""},"class_list":["post-179","page","type-page","status-publish","hentry"],"yoast_head":"\nPublicaciones - Rc<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publicaciones - Rc\" \/>\n<meta property=\"og:description\" content=\"Publicaciones Art\u00edculos y Trabajos Cient\u00edficos Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Nishimura, T. Histamine within the hypothalamo-hypophyseal system after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:342-344. Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Tada, K., Takeda, M., Nishimura, T., Takagi, T., Sugita, T., Tanizawa, O. On the chronological changes in hypothalamic […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/\" \/>\n<meta property=\"og:site_name\" content=\"Rc\" \/>\n<meta property=\"article:modified_time\" content=\"2016-06-02T10:06:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"177 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/\",\"url\":\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/\",\"name\":\"Publicaciones - Rc\",\"isPartOf\":{\"@id\":\"https:\/\/ramoncacabelos.org\/web\/#website\"},\"datePublished\":\"2016-05-24T15:59:37+00:00\",\"dateModified\":\"2016-06-02T10:06:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ramoncacabelos.org\/web\/publicaciones\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/ramoncacabelos.org\/web\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ramoncacabelos.org\/web\/#website\",\"url\":\"https:\/\/ramoncacabelos.org\/web\/\",\"name\":\"Dr Ram\u00f3n Cacabelos\",\"description\":\"Ram\u00f3n Cacabelos\",\"publisher\":{\"@id\":\"https:\/\/ramoncacabelos.org\/web\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ramoncacabelos.org\/web\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ramoncacabelos.org\/web\/#organization\",\"name\":\"Dr Ram\u00f3n Cacabelos\",\"url\":\"https:\/\/ramoncacabelos.org\/web\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/ramoncacabelos.org\/web\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ramoncacabelos.org\/web\/wp-content\/uploads\/2026\/01\/cacabelos-1-768x556-1.jpg\",\"contentUrl\":\"https:\/\/ramoncacabelos.org\/web\/wp-content\/uploads\/2026\/01\/cacabelos-1-768x556-1.jpg\",\"width\":768,\"height\":556,\"caption\":\"Dr Ram\u00f3n Cacabelos\"},\"image\":{\"@id\":\"https:\/\/ramoncacabelos.org\/web\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publicaciones - Rc","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/","og_locale":"es_ES","og_type":"article","og_title":"Publicaciones - Rc","og_description":"Publicaciones Art\u00edculos y Trabajos Cient\u00edficos Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Nishimura, T. Histamine within the hypothalamo-hypophyseal system after bilateral adrenalectomy. Bull. Jpn. Neurochem. Soc., 1983; 22:342-344. Cacabelos, R., Yamatodani, A., Wada, H., Hariguchi, S., Tada, K., Takeda, M., Nishimura, T., Takagi, T., Sugita, T., Tanizawa, O. On the chronological changes in hypothalamic […]","og_url":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/","og_site_name":"Rc","article_modified_time":"2016-06-02T10:06:52+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"177 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/","url":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/","name":"Publicaciones - Rc","isPartOf":{"@id":"https:\/\/ramoncacabelos.org\/web\/#website"},"datePublished":"2016-05-24T15:59:37+00:00","dateModified":"2016-06-02T10:06:52+00:00","breadcrumb":{"@id":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ramoncacabelos.org\/web\/publicaciones\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ramoncacabelos.org\/web\/publicaciones\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ramoncacabelos.org\/web\/"},{"@type":"ListItem","position":2,"name":"Publicaciones"}]},{"@type":"WebSite","@id":"https:\/\/ramoncacabelos.org\/web\/#website","url":"https:\/\/ramoncacabelos.org\/web\/","name":"Dr Ram\u00f3n Cacabelos","description":"Ram\u00f3n Cacabelos","publisher":{"@id":"https:\/\/ramoncacabelos.org\/web\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ramoncacabelos.org\/web\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ramoncacabelos.org\/web\/#organization","name":"Dr Ram\u00f3n Cacabelos","url":"https:\/\/ramoncacabelos.org\/web\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ramoncacabelos.org\/web\/#\/schema\/logo\/image\/","url":"https:\/\/ramoncacabelos.org\/web\/wp-content\/uploads\/2026\/01\/cacabelos-1-768x556-1.jpg","contentUrl":"https:\/\/ramoncacabelos.org\/web\/wp-content\/uploads\/2026\/01\/cacabelos-1-768x556-1.jpg","width":768,"height":556,"caption":"Dr Ram\u00f3n Cacabelos"},"image":{"@id":"https:\/\/ramoncacabelos.org\/web\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/pages\/179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/comments?post=179"}],"version-history":[{"count":4,"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/pages\/179\/revisions"}],"predecessor-version":[{"id":350,"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/pages\/179\/revisions\/350"}],"wp:attachment":[{"href":"https:\/\/ramoncacabelos.org\/web\/wp-json\/wp\/v2\/media?parent=179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}